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Abstract 
 Worldwide, cancer is still one of the major leading causes of death. In particular, 
breast cancer is the one presenting the highest incidence rates in women. Therefore, new 
approaches for breast cancer treatment based on the development of promising anticancer 
agents that can efficiently improve patient survival are of utmost relevance. 
 In the present work, several modified biogenic polyamines and their newly synthesised 
Pt(II) and Pd(II) complexes were studied regarding their conformational behaviour by 
vibrational spectroscopy (infrared and Raman). Since Pt(II) and Pd(II) complexes have shown 
good anticancer activity, an accurate knowledge of the structural profile of these compounds 
is essential for understanding the molecular basis of their cytotoxic activity. The all-trans 
geometry was found to be favoured for all the alkylated polyamines, in their totally 
protonated state. In the other hand, their polynuclear complexes presented a stable geometry 
very similar to that previously obtained for the analogous chelates with spermidine and 
spermine, comprising two or three cisplatin-like (MCl2(NH3)2) moieties. 
The in vitro cytotoxic activity of these compounds was then evaluated in established 
human breast cancer cell lines (JIMT-1, L56Br-C1, MCF-7 and MDA-MB-231) and in one 
normal-like immortalised breast cell line (MCF-10A) as model systems. The MCF-10A cells 
were found to be least affected by the tested compounds, while significant growth inhibition 
and apoptotic cell death was observed for some of the cancer cell lines, L56Br-C1 being the 
most sensitive to this type of treatment.  
 Norspermidine (NSpd) and its Pd(II) complex were generally shown to have a stronger 
antiproliferative effect, as compared to its Pt(II) analogue. Also they were found to reduce the 
cellular activity of the growth-related enzyme ornithine decarboxylase to a lower level than 
the Pt(II) complex, in most of the cell lines examined. Moreover, treatment with NSpd or Pd-
NSpd decreased colony formation, i.e. the malignancy of the breast cancer cells, to a much 
larger extent than the Pt(II) counterpart. None of these agents appeared to act as a genotoxin 
at a 25 µM concentration. 
 Regarding the spermine analogues, palladination of N
1
,N
11
-bis(ethyl)norspermine 
(BENSpm) led to enhanced cytotoxicity, in contrast to platination of N
1
-cyclo-propylmethyl-
N
11
-ethylnorspermine (CPENSpm), that reduced cytotoxicity, which may be explained by 
differences in the cellular uptake of the chelates. BENSpm and Pd-BENSpm treatment 
reduced the putative cancer stem cell population CD44
+
CD24
- 
(evaluated by flow cytometry). 
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Furthermore, Pd-BENSpm was the most efficient compound of those investigated regarding 
induction of DNA damage and decrease in colony formation. Pt-CPENSpm and Pd-Spm, in 
the other hand, were shown to be the least toxic compounds of all tested. Pd-Spm efficiently 
reduced the cellular glutathione levels, which probably was a consequence of its metabolic 
inactivation by conjugation to this endogenous thiol. 
 Overall, the results show that the polynuclear Pd(II)-polyamine complexes display a 
stronger anticancer effect than their Pt(II) homologues, which renders them promising new 
metal-based therapeutic agents against breast cancer, coupling increased efficiency to a 
slightly lower toxicity. 
 
 
Keywords: breast cancer; modified biogenic polyamines; Pt(II)/Pd(II) polynuclear complexes; 
anticancer agents; vibrational spectroscopy; cytotoxicity; cell cycle; apoptosis; DNA damage; 
stem cells; glutathione.  
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Resumo 
 O cancro continua a ser uma das principais causas de morte em todo o mundo. O 
cancro de mama, em particular, é um dos que apresenta a maior taxa de incidência em 
mulheres. Desta forma, novas abordagens para o tratamento do cancro de mama baseadas no 
desenvolvimento de compostos anticancerígenos promissores que permitam uma eficiente 
melhoria na sobrevivência do paciente, são de extrema importância.  
 No presente trabalho, várias poliaminas biogénicas modificadas e correspondentes 
complexos de platina (Pt(II)) e paládio (Pd(II)) foram estudados relativamente ao seu 
comportamento conformacional, através de espectroscopia vibracional (infravermelho e 
Raman). Uma vez que os complexos de Pt(II) e Pd(II) têm demonstrado uma boa actividade 
anticancerígena, um conhecimento rigoroso do perfil estrutural destes compostos é essencial 
para compreendermos a base molecular da sua atividade citotóxica. A geometria all-trans foi 
reconhecida como sendo a mais favorável para todas as poliaminas alquiladas, em condições 
totalmente protonadas. Po outro lado, os respetivos complexos polinucleares apresentaram 
uma geometria estável muito semelhante àquela previamente obtida para os quelatos análogos 
com espermidina e espermina, contendo duas ou três unidades análogas da cisplatina 
(MCl2(NH3)2). 
A atividade antineoplásica destes compostos in vitro foi avaliada em linhas celulares 
humanas de cancro de mama (JIMT-1, L56Br-C1, MCF-7 e MDA-MB-231), assim como 
numa linha imortalizada não-neoplásica (MCF-10A), como sistema modelo. As células MCF-
10A mostraram ser menos afetadas pelos compostos testados, no entanto uma inibição 
significativa do crescimento e uma indução de morte celular (por apoptose) foram detetadas 
em algumas das linhas cancerígenas estudadas. As células L56Br-C1 foram as mais sensíveis 
a este tipo de tratamento. 
A norespermidina (NSpd) e o seu complexo de Pd(II) apresentaram um efeito 
antiproliferativo mais forte relativamente ao análogo de Pt(II). Verificou-se ainda que estes 
compostos reduziam a atividade celular da enzima ornitina descarboxilase na maioria das 
linhas celulares analisadas, para doses inferiores relativamente às do complexo de Pt(II). 
Além disso, o tratamento com NSpd ou com Pd-NSpd diminuíram a formação de colónias, 
i.e. a malignidade das células de cancro de mama, com maior eficiência do que o homólogo 
de Pt(II). Nenhum destes compostos aparentou atuar como uma genotoxina (na concentração 
de 25 µM). 
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Relativamente aos análogos da espermina, a paladinação do N
1
,N
11
-
bis(etil)norespermina (BENSpm) levou a um aumento da citotoxicidade, em contraste com a 
platinação do N
1
-metilciclopropil-N
11
-etilnorespermina (CPENSpm) que reduziu a 
citotoxicidade, o que pode ser explicado por diferenças na entrada celular dos dois quelatos. O 
BENSpm e o Pd-BENSpm apresentaram um efeito redutor face à população de células 
estaminais cancerígenas CD44
+
CD24
-
 (avaliada por citometria de fluxo). O Pd-BENSpm foi o 
composto mais eficiente de todos os investigados relativamente à indução de danos no ADN e 
redução na formação de colónias. O Pt-CPENSpm e o Pd-Spm, por sua vez, mostraram ser os 
compostos menos tóxicos de todos os testados. O Pd-Spm diminuiu eficientemente os níveis 
intracelulares de glutationa, o que provavelmente foi uma consequência da sua inativação 
metabólica por conjugação a este tiol endógeno. 
 Os resultados obtidos mostram que os complexos polinucleares de poliaminas com 
Pd(II) possuem uma atividade anticancerígena mais elevada do que os seus homólogos de 
Pt(II), podendo assim serem considerados promissores agentes terapêuticos inorgânicos 
contra o cancro de mama, acoplando uma maior eficiência a uma toxicidade mais reduzida. 
 
 
Palavras-chave: cancro de mama; poliaminas biogénicas modificadas; complexos 
polinucleares de Pt(II)/Pd(II); agentes anticancerígenos; espectroscopia vibracional; 
citotoxicidade; ciclo celular; apoptose; danos no ADN; células estaminais; glutationa.  
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1.  Introduction 
 1.1.   Cancer 
       1.1.1.    History of Cancer 
  The name cancer was first applied and described by the Greek physician Hippocrates 
(460–370 BC), also entitled the “Father of Medicine”. This word was derived from 
“karkinos”, the Greek word for crab, as cancer, with its irradiating blood vessels, can 
resemble a crab with its claws. At that time, Hippocrates assumed that one of the human 
fluids was black bile and that cancer developed by an excess of this fluid in any location of 
the human body, causing an inflammation and then cancer [1]. However, it was only in the 
19
th
 century that cancer was classified as a disease of cells [2]. Since then, this has been an 
extensively studied area of medicinal chemistry and pharmacology and the search for new 
approaches for the early detection and diagnosis of this severe pathology became imperative. 
In 1911, Carrel and Burrows established the technique of cell culture, widely used nowadays 
for the development of new anticancer agents [3]. 
 
       1.1.2.    Epidemiology and Definition of Cancer 
 Worldwide, cancer is one of the major leading causes of death. Actually, cancer is the 
second leading cause of death, being only exceeded by cardiovascular diseases [4]. An initial 
short term predictive study performed for the entire European Union estimated that in the year 
of 2012 approximately 717000 men and 566000 women would die of cancer [5]. Similarly, in 
the United States about 302000 men and 275500 women were also expected to die of cancer 
in 2012 [6], which represents an enormous burden on society (both sociologically and 
economically). In 2008, approximately 7.6 million of people died from cancer worldwide, 
which represents about 13% of all deaths. Estimations for the number of deaths in the whole 
world have been projected, with the data showing a big rise: approximately 13.1 million of 
people are expected to die of cancer in 2030 [7]. 
  Cancer comprises a very complex and diverse class of disorders characterised by an 
uncontrolled growth of abnormal cells in the body. It can affect all parts of the human body 
and is usually classified according to the tissue from which the cancerous cells originate, as 
well as the normal cell type they resemble the most [8]. 
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  Tumours are formed in the body by abnormal growth and division of cells, forming a 
clump of cells that are not affected by surrounding normal cells. Tumours can be benign (non-
cancerous and non-invasive) or malignant (cancerous and invasive) [8]. In the latter case, 
quickly growing cancerous cells have the ability to move throughout the body using the blood 
and lymph flows, leading to the invasion and destruction of healthy tissues in distant organs, 
in a process named metastasis. 
  Therefore, cancer can be defined as a malignant tumour originating from permanently 
growing cells. Unlike normal cells, cancer cells do not follow an orderly path of growth, 
division and death. Actually, they often cannot execute programmed cell death (apoptosis) 
and, instead, continue to grow and divide [9].  
  Extensive experimental evidence has shown that the biology of cancer is very complex 
and diverse, comprising over 100 distinct types determined, for instance, by their histology 
and hormone dependency. Tumour subtypes can be found within specific organs, and cancers 
from the same subtype can exhibit a great variability and heterogeneity [8,10].    
 
       1.1.3.    Histological Classification of Cancer 
  Based on its histological type (type of tissue in which the cancer cell has its origin), 
cancer can be classified into seven distinct groups (one of the many possible histological 
cancer classifications) [11,12]: 
 
 Carcinoma: tumour originating from epithelial cells. Since epithelial tissues are the 
most abundant in the body, carcinomas are responsible for approximately 80–90% of 
cancers, in organs such as breast, lung, pancreas, colon and prostate; 
 
 Sarcoma: tumour originating from connective and supportive tissues (muscles, 
bones, cartilage and fat); 
 
 Myeloma: tumour originating from plasma cells. These plasmocytes (generated in 
the bone marrow) are white blood cells responsible for antibody production; 
 
 Leukemia: tumour originating from hematopoietic cells. This type of cancer mainly 
affects the bone marrow (where blood cells are produced) and often accumulates in 
the bloodstream. In these conditions, the bone marrow produces excessive immature 
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white blood cells that fail to perform their normal functions, often leading to an 
infection; 
 
 Lymphoma: tumour originating from lymphatic cells. This type of cancer begins and 
develops in the nodes or glands of the lymphatic system and immune system tissues; 
 
 Central Nervous System Cancers: tumour originating from the tissues of the brain 
and spinal cord. 
 
       1.1.4.    Hallmarks of Cancer 
  Cancer development proceeds via a series of premalignant stages in which a 
succession of genetic alterations drives the progressive conversion of normal human cells into 
highly malignant cells [13]. Cancer cells have defects in regulatory circuits that control 
normal cell proliferation and homeostasis [14]. 
  Earlier studies have shown that most, if not all, human cancers share six common main 
physiological cellular alterations, acquired during tumour development, that allow malignant 
growth and metastatic dissemination. These distinct and complementary acquired traits or 
capabilities include (Fig. 1) [2]: 
 
 Sustained proliferative signalling – cancer cells can induce and sustain positively 
acting growth stimulatory signals; 
 
 Evading growth suppressors – cancer cells evade processes that depend on the action 
of tumour suppressor genes to negatively regulate cell growth and proliferation; 
 
 Activation of invasion and metastasis – ability of cancer epithelial cells (carcinoma 
cells) to invade surrounding tissue and blood vessels and disseminate in the human 
body giving rise to metastasis; 
 
 Enabling replicative immortality – ability of cancer cells to indefinite proliferate 
without evidence of either senescence (irreversible entrance into a non-proliferative 
but viable status) or crisis/apoptosis; 
 
 Induction of angiogenesis – during tumour progression, the tumour-associated 
neovasculature is stimulated –– angiogenesis. This process allows the normally 
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quiescent vasculature to develop new vessels that support the expansion of the cancer 
growth and, therefore, has to be continuously activated; 
 
 Resistance to cell death – cancer cells have a number of strategies that limit or evade 
programmed cell death (by apoptosis).  
 
 
 
Figure 1: Schematic representation of the six hallmarks of cancer. 
 
 Acquisition of these six modifications is feasible by two so-called enabling or 
consequential characteristics of malignant tumours that contribute to the multistep 
carcinogenesis: the development of genomic instability and a consequent accumulation of 
mutations in cancer cells [2,9], and the development of inflammation in innate cells of the 
immune system. Both characteristics are recognised to promote tumour progression [2].  
 In the last decade, two additional and important traits of malignant cells that support 
tumour progression have been reported, although they are not yet fully validated. These two 
emerging hallmarks of cancer include: reprogramming the cellular energy metabolism (to 
allow continuous cell proliferation) and evading destruction by the immune system (mainly 
involving T and B lymphocytes, macrophages and natural killer cells) [2].  
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             1.1.5.    Cancer – A Genetic Disease 
 Cancer is usually considered a genetic disease, due to the involvement of dynamic 
changes in the genome that are responsible for its progression [9,14,15]. In cancer, the 
uncontrollable cell growth arises from the occurrence of errors/mutations in the cellular DNA, 
resulting in damages in the genes involved in cell division [16]. There are four critical types 
of genes responsible for the cell division process: oncogenes (stimulate cell proliferation), 
tumour suppressor genes (limit cell growth), suicide genes (control apoptosis and activate cell 
death if something goes wrong), and DNA repair genes (recognise and repair cellular DNA 
damage). Tumours can be produced by a change or combination of changes in any of these 
genes [17], being often linked to a genomic instability and variability along with the 
generation of multiple mutations [15]. 
 
 1.2.   Breast Cancer 
       1.2.1    Epidemiology 
  Although there has been a significant improvement in prognosis and survival, breast 
cancer is still one of the most widely malignant tumour forms among women [18,19]. Breast 
cancer can also occur in men, with an incidence approximately 100 times lower, but with a 
similar statistical survival rate [20,21]. 
  A recent breast cancer research study performed by the Institute for Health Metrics 
and Evaluation and the University of Queensland (Australia) showed that globally, breast 
cancer incidence increased from approximately 641000 cases in 1980 to 1643000 cases in 
2010. In 2010, roughly 425000 women died from breast cancer in developing countries, 
68000 of these being within the age range 15 to 49 [22]. In the European Union, breast cancer 
is the major cause of female cancer death (representing 16% of all cancers), with about 88000 
women having died from this disease in 2012 [5]. 
  The incidence of breast cancer is normally higher in developed countries as compared 
to less developed ones, with more than half of the incident cases worldwide being diagnosed 
in Europe and North America [23]. This might be due to an enhanced life expectancy, an 
increase in obesity, a rise in alcohol consumption, the lack of physical exercise, delayed 
childbirth and less breast feeding, or later menopause in women [18,24]. However, most of 
breast cancer-related deaths occur in low and middle income countries, where the majority of 
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the patients are diagnosed in very late stages of the disease, essentially due to economical 
reasons, as well as to a lack of awareness of early signs and symptoms, and to the difficulty to 
get access to health care services [23]. 
 
       1.2.2.    Types of Breast Cancer 
  Breast cancer is any type of malignant growth in the breast tissue, mainly in the ducts 
(connecting the lobules to the nipples) and lobules (group of glands responsible for milk 
production). The ductal carcinomas comprise 85–90% of all cases and the lobular carcinomas 
comprise 8% of all cases. In addition, breast cancer can be either classified as in situ (cells are 
confined to the region where they originated) or invasive (cells have invaded the surrounding 
breast tissue including the lymph and blood systems) [21,25]. In invasive forms, cells from 
the primary tumour can travel through the lymph or blood vessels to any place in the human 
body, giving rise to a secondary cancer of the same type as the primary one. The majority of 
breast cancers are invasive (or infiltrating) and their therapy success is deeply influenced by 
the stage of the disease when diagnosed. 
  In order to choose the most suitable treatment, it is of utmost importance to identify 
the histology and stage of the tumour. Staging is the process of finding out how widespread a 
cancer is at the time of diagnosis. One of the most widely accepted classifications for staging 
breast cancer is the TNM stage classification [26,27], that is based on three essential 
characteristics: the size of the tumour (T), the lymph node involvement (N) and the distant 
tumour metastasis (M). However, currently, this classification has been revised and improved 
to allow a better determination of breast cancer prognosis [28,29]. 
  Breast cancer development can be identified as hereditary. While 90–95% of breast 
cancer cases are considered spontaneous, the remaining 5–10% are hereditary because of 
inherited mutations, mainly in the well-known breast cancer genes BRCA1 and BRCA2. 
Mutations in these genes account for approximately 80% of all hereditary breast cancer 
[21,25,30]. 
     
       1.2.3.    Tumour Classification Based on Receptor Expression 
  Breast cancer treatment is initially governed by the expression status of the most 
widely studied markers in breast tissue: estrogen receptor (ER), progesterone receptor (PR) 
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and human epidermal growth factor receptor 2 (HER2) [31-33]. Breast cancers that are ER- 
and/or PR-positive are correlated with the most favourable prognosis, since expression of 
these markers usually results in response to hormonal therapy [32]. On the other hand, breast 
cancers that overexpress HER2, lack ER and PR expression or triple-negative breast cancers 
(ER-, PR- and HER2-negative) are associated with a less favourable prognosis and higher risk 
of death [31,32]. 
 
       1.2.4.    Tumour Classification Determined by Gene Expression Data 
  The genome broad expression patterns of tumours are suggested to represent their 
biology, with the multiplicity in patterns reflecting biological diversity. Thus, relating the 
gene expression profile to clinical outcomes is a crucial issue in understanding this diversity. 
The analysis of the gene expression patterns suggests a division of breast carcinomas into five 
distinct subgroups with different prognosis: luminal-like subtypes A (in general ER- and PR-
positive) and B, HER2-overexpressing (ErbB2+), basal-like (usually triple negative) and 
normal-like [32-36]. These subtypes also differ markedly in prognosis and in the therapeutic 
targets they express. The difference in gene expression patterns among these groups is likely 
to represent distinct tumour phenotypes, thereby influencing response to treatment and overall 
survival. The basal-like tumour subclass, for instance, has been correlated with a more 
aggressive cancer outcome [37]. 
 
       1.2.5.    Treatment Options 
  Depending on the profile and development stage of breast cancer, several therapeutic 
strategies can be applied. The main options used nowadays in the clinic are: 
 
 Local treatment: 
 
 Surgery: the most common treatment for breast cancer and, most of the times, it is the 
first one to be used. It consists in the removal of the tissue containing the cancer cells 
as well as of the surrounding tissue, in order to stop further spreading and to reduce 
the risk of cancer relapse. 
 
 Radiotherapy: uses carefully measured and controlled high-energy radiation (usually 
X-rays) to destroy the cancer cells or shrink the tumours, with the advantage of 
 Tânia M. Silva 
___________________________________________________________________________ 
 
10 
 
affecting only the cells in the part of the body containing the cancer. It may be used 
after surgery to destroy breast cancer cells that remain in the chest area by damaging 
their DNA.  
 
 Systemic treatment: 
 
 Chemotherapy: consists in the intravenous or oral administration of anticancer agents 
(either of natural origin or synthetic), with a view to kill or stop proliferation of cancer 
cells. It can be used before or after surgery. Combination of drugs with synergetic 
effects may also be applied (cocktails). This is a systemic treatment, as the whole 
organism is exposed to the drugs. 
 
 Hormone therapy: applied to hormone-dependent breast cancers that contain 
hormone receptors within the cells (ER- and/or PR-positive). The purpose is to block 
these receptors or to reduce hormone production in the body, thereby stopping or 
slowing the growth of cancer cells that require these natural hormones. 
 
 Targeted therapy: consists in the intravenous or oral administration of drugs or other 
substances (often named missile drugs), that target specific characteristics of the 
cancer cells, which are responsible for tumour growth by using specifically designed 
carrier and targeting agents (e.g. magic bullet [38]). This kind of strategy is designed 
to have a higher specificity and lower toxicity (e.g. less damage to normal cells) [39]. 
It can be applied, for instance, to women with a higher level of HER2 expression in 
the tumour [39,40]. 
  
  In conclusion, breast cancer is a heterogeneous disease with distinct morphologies, 
metastatic behaviour and therapeutic response. Despite the availability of several different 
approaches for its treatment, the mortality rate is still too high in patients displaying 
metastases (metastatic breast cancer, which is triple negative). Therefore, the search for new 
options and the cytotoxicity evaluation of novel potential anticancer agents that can efficiently 
prevent, detect and treat breast cancer (particularly its metastatic forms) are major goals in 
breast cancer research.  
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       1.2.6.    Breast Cancer Stem Cells 
 Breast cancer cells in a tumour are not the same, i.e. different phenotypes can be found 
within the breast cancer cells that form the tumour. 
 Al-Hajj and co-workers [41] were the first to identify and prospectively discriminate a 
minority subpopulation of cells in a human solid breast cancer that had the total capacity of 
forming tumours in vivo, while the remaining bulk of cancer cells from the tumour could not 
[41-43]. This tumourigenic population had the ability to extensively proliferate, divide and 
maintain the same phenotype, but also to differentiate into all other phenotypes found in the 
tumour [44]. This population was recognised as cancer stem cells (CSCs) and was identified 
based on its cell surface phenotype: CD44
+
/CD24
-/low/
epithelial-specific antigen (ESA)
+ 
phenotype, which is most common in the breast cancer basal-like type (triple negative) [44-
47]. Thus, the cellular heterogeneity of human breast cancer has been characterised based on 
the combined expression of two cell surface markers: CD44 and CD24. While CD44 
expression was positively associated with stem cell-like properties, the CD24 expression was 
linked to differentiated epithelial characteristics [37]. 
 The characteristic of the CSC is that it can divide and produce new CSCs and that it 
also can differentiate into all the other phenotypes found in the cancer [44,45]. The CSC 
model has been recognised as the promoter of tumour development and maintenance [44,47-
49]. CSCs appear to survive conventional treatment and support tumour regrowth, while the 
bulk cells (that display other phenotypes) die, therefore leading to treatment failure [47]. For 
this reason, one of the major concerns in breast cancer research is to identify the minority 
population of CSCs and eradicate them from cancer patients, as they are the basis for 
treatment failure and tumour regrowth.    
 Human breast cancer cell lines contain these subpopulations with stem-like features 
[50]. Experimental evidence has shown that cells with a CD44
+
/CD24
- 
phenotype in breast 
cancer cell lines had an enhanced tumour formation ability in vivo [46]. Additionally, some 
studies showed that the CD44
+
/CD24
- 
phenotype population is linked to an increased 
expression of pro-invasive genes, as well as to the ability to form distant metastasis [51], 
therefore becoming a suitable candidate for breast cancer therapy. 
      In conclusion, targeting CSC is currently one of the most promising means to 
efficiently treat breast cancer. Therefore, the search for new anticancer agents that can 
efficiently affect or reduce the breast CSCs, thereby enhancing the effect of cancer treatment, 
is crucial.  
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 1.3   Polyamines 
       1.3.1    Polyamines as Essential Molecules 
  The polyamine family has a very long history and its crucial role in a vast array of 
biochemical functions has been recognised over the years. In 1678, the Dutch tradesman and 
scientist Antonie Van Leeuwenhoek, also known as the “Father of Microbiology” and 
inventor of the microscope, became the pioneer in the research and discovery of the 
polyamines, when he isolated some “three-sided” crystals from human semen [52-55]. Much 
later, these crystals were correctly identified as spermine phosphate by Ladenburg and Abel. 
Spermidine was discovered, in tissue, almost forty years later. Putrescine was isolated from 
tissues after bacterial decomposition and it is largely responsible for the foul odour of 
putrefying flesh [52,53,55,56]. The polyamines putrescine, spermidine and spermine (Fig. 2) 
are ubiquitous substances virtually present in significant amounts in most prokaryotic and all 
eukaryotic cells [54,57,58]. They are low molecular weight and flexible multivalent 
polycations, with spatially distributed charges. At physiological pH, these molecules are 
positively charged, fully protonated at their primary and secondary amino groups [53,55,57]. 
Therefore, at physiological pH, putrescine has two, spermidine three and spermine four 
positive charges. Due to their cationic nature, polyamines interact electrostatically with 
negatively charged molecules, such as nucleic acids, proteins and phospholipids [53]. Cells 
depend on polyamines for growth and they can produce them internally or obtain them from 
exogenous sources (e.g. food or intestinal bacteria) [56,57,59]. Exogenously acquired 
polyamines enter cells by active energy requiring uptake across the plasma membrane. Once 
inside the cells, they will probably be distributed to all cellular compartments, due to their 
high solubility [60].  
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Figure 2: Structural representation of the biogenic polyamines putrescine, spermidine and spermine 
under physiological conditions. 
 
       1.3.2    Polyamine Function and Homeostasis 
  The polyamines are critical for a variety of fundamental cellular processes like 
proliferation, differentiation and apoptosis [53,61-64]. The effects on these processes are 
presumably caused by various specific molecular interactions such as involvement in:  
 
 DNA replication and repair [65] 
 
 DNA conformation by allowing the transition of the conformation B-DNA to Z-DNA 
[53,60,66]  
 
 DNA condensation by neutralising the negative charges on the phosphate backbone 
[65,66] 
 
 RNA synthesis and processing [63,65] 
 
 Gene transcription and translation [53,55,62] 
 
C N H
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+
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 Protein synthesis [55,63,65] 
 
 Stabilisation of membranes and cytoskeletal structures [63,67]; 
 
 Cellular protection by binding cations like Cu and Fe and thus acting as strong metal 
chelators [60] 
 
 Modulation of the membrane polarity and rigidity by forming complexes with 
phospholipids and proteins [53,60] 
 
 Lipid peroxidation prevention, by acting as antioxidants [53,60] 
 
 Regulation of ion channels [63,68] 
 
  It has been reported that polyamine function depends on their electrical charge, with 
their binding energy increasing from putrescine to spermine. Spermine appears to be the most 
active biogenic polyamine in several biological processes, whereas putrescine was found to be 
the least active one [69,70]. This can be explained because spermine is displaying the greatest 
charge, is the longest polyamine and has the highest flexibility [53].  
  The polyamine levels are elevated in proliferating cells and low in non-proliferating 
cells. In eukaryotes, due to the crucial roles of the polyamines in essential cellular functions, 
there is a strict regulatory control of the intracellular polyamine levels by multiple 
mechanisms involving biosynthesis, catabolism, uptake and excretion [63,64,71,72]. These 
mechanisms are then required for normal cellular polyamine homeostasis. Both polyamine 
uptake and biosynthesis are increased during cellular responses to proliferative stimuli. 
Conversely, polyamine degradation and excretion are induced upon a rise in the polyamine 
content, along with the inhibition of polyamine biosynthesis and uptake [73]. The polyamine 
pool is limited, at the lower limit, by its importance for cellular proliferation and at the upper 
limit by its cytotoxicity, which may induce cell death [53,71].  
 
       1.3.3    Polyamine Metabolism 
  The complete polyamine metabolism involves seven enzyme-catalysed reactions (Fig. 
3) that keep the intracellular polyamine content in agreement with the cellular requirements 
[55].  
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  In mammalian cells, the first step of the polyamine biosynthetic pathway consists of 
the conversion of arginine to ornithine through the action of arginase. Ornithine is available 
for polyamine production not only by the action of arginase within the cells, but can also be 
obtained from the circulating plasma [55,64]. Thereafter, ornithine is decarboxylated by the 
rate-limiting enzyme ornithine decarboxylase (ODC) to produce putrescine. Then, two 
aminopropyl groups, provided by decarboxylated S-adenosylmethionine (dcAdoMet), are 
successively added to putrescine to form spermidine and to spermidine to form spermine. 
Putrescine is converted to spermidine by the aminopropyltransferase spermidine synthase, 
while spermidine is converted to spermine by a second closely related but distinct 
aminopropyltransferase, spermine synthase. Both the aminopropyltransferases are stable and 
constitutively expressed [53]. The aminopropyl moiety is derived originally from the amino 
acid methionine, which together with ATP forms S-adenosylmethionine (AdoMet) in a 
reaction catalysed by methionine adenosyltransferase. AdoMet is then decarboxylated by S-
adenosylmethionine decarboxylase (AdoMetDC), resulting in dcAdoMet, the aminopropyl 
donor [53,64,68,72,74,75]. The by-product formed after the spermidine and spermine 
synthase reactions is 5′-methylthioadenosine, which is recycled back to adenosine for further 
use by a phosphorylase [64,76]. 
  Although the reactions involving the aminopropyltransferases are essentially 
irreversible, spermidine and spermine can be recycled into putrescine and spermidine, 
respectively, through a reverse metabolic pathway [64,70]. The first step of the 
interconversion pathway consists of the acetylation of the primary nitrogen of the 
aminopropyl group of spermine and spermidine into N
1
-acetylspermine or N
1
-
acetylspermidine, respectively, catalysed by the rate-limiting enzyme spermidine/spermine 
N
1
-acetyltransferase (SSAT). The acetyl group is provided by acetyl-CoA. Then, the resultant 
acetyl derivatives N
1
-acetylspermine and N
1
-acetylspermidine can be either excreted from the 
cells or oxidised by the flavin adenine dinucleotide-dependent acetylpolyamine oxidase 
(APAO) to form 3-acetamidopropanal (3-AAP) and hydrogen peroxide (H2O2), together with 
either spermidine and putrescine, respectively [53,70,72,74,75]. Nevertheless, spermine can 
be directly converted into spermidine, without the need for the acetylation step, through the 
action of the spermine oxidase (SMO). The oxidative products of SMO activity are 
spermidine, the reactive oxygen species H2O2 and 3-AAP [76,77].  
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Figure 3: Schematic representation of the polyamine metabolic pathways. 
 
  It is im portant to high light that polyamine levels ar e carefully controlled by th e 
combination of three key enzym es: while biosynthesis is regulated by ODC and AdoMetDC, 
the catabolism is regulated by SSAT [74]. The activities of the biosynthetic enzymes are low 
in non-proliferating cells, but increase as the cells enter the cell cycle in response to various 
growth stimuli [78].  
  The major features of these rate-limiting enzymes are shown in Table 1. 
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Table 1: Main characteristics of the metabolic enzymes ODC, AdoMetDC and SSAT. 
Enzymes Important characteristics 
ODC 
 
 Mammalian ODC was first discovered in 1968 [55] 
 Pyridoxal 5’-phosphate dependent enzyme [53,55,70] 
 Cytosolic protein [75] 
 Short half-life protein [53,55,70-72,75] 
 Highly regulated in eukaryotic cells at transcriptional, translational and 
pos-translational levels [70,75,79,80] 
 ODC activity induced by growth-promoting stimuli including hormones, 
growth factors, tissue regeneration and several drugs [79] 
 ODC overexpression can cause cellular transformation [79] 
 ODC degradation by the 26S proteosome is ubiquitin-independent 
[53,79] 
 ODC feedback regulation by polyamines: down-regulation in the 
presence of polyamine excess [71,72] and up-regulation in the presence 
of low polyamine levels [53,72] 
 
AdoMetDC 
 
 Pyruvoyl-containing and dependent enzyme [72,74,75] 
 Short half-life protein (but longer than that of ODC) [72,75] 
 Activated by an autocatalytic serinolysis reaction that creates the 
pyruvoyl group [81] 
 Well-regulated at transcriptional, translational and protein turnover levels 
[68,70,72,75] 
 AdoMetDC activity stimulated by putrescine [75,81] 
 Acts as a regulatory control point in AdoMet metabolism [55] 
 AdoMetDC degradation requires polyubiquitination [68] 
 AdoMetDC feedback regulation by polyamines: down-regulation in the 
presence of polyamine excess and up-regulation in the presence of low 
polyamine levels [72,75] 
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Table 1: Main characteristics of the metabolic enzymes ODC, AdoMetDC and SSAT. (Continuation) 
SSAT 
 
 Readily inducible enzyme that requires acetyl-CoA as a substrate 
[53,68,70,82] 
 SSAT is a predominantly cytosolic protein, although recently it has been 
also found in the mitochondria [82] 
 Short half-life [53,72,75,80,82,83] 
 Present in very small amounts in the cell [83] 
 Highly-regulated at several levels, including transcription, translation, 
mRNA processing and protein stabilisation [72,80,82] 
 Induced by spermidine and spermine, but not by putrescine [53] 
 Induced by polyamine analogues [53,72,80] and by a large variety of 
stimuli, such as hormones, toxins (H2O2), cytokines and growth factors 
[68,72,75,80,82,83] 
 SSAT activity is induced in the presence of increased polyamine levels 
[75] 
 Changes in SSAT levels have recently been linked to a variety of 
pathological stages, including carcinogenesis [82] 
 
 
       1.3.4.    Polyamine Transport 
  De novo synthesis is the main source of polyamines in the majority of mammalian 
cells. However, in addition to the metabolic pathway, cellular polyamine transport 
mechanisms also largely contribute to the homeostatic regulation of the polyamine levels 
[70,72,84]. Therefore, the significant acquisition of exogenous polyamines from diet and the 
small contribution from the intestinal microbial flora to balance the intracellular polyamine 
content have to be taken into account [53,75,76,84,85]. 
  The polyamine transport system (PTS) comprises the uptake and efflux of polyamines 
into and out of the cell and it is extremely important for the salvage of polyamines [68,72,75]. 
Although the molecular structure of the mammalian PTS still remains to be identified, 
evidence from yeast and bacteria suggest that most cell types exhibit two separate classes of 
PTS: one that is sodium dependent with a preference for putrescine (and probably other 
diamines) but also able to transport spermidine and spermine, and one that is sodium 
independent with a preference for spermidine and spermine, but not putrescine. The PTS is 
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energy-, time-, temperature-, and concentration-dependent and saturable, suggesting it is a 
carrier-mediated transport [53,55,76,85]. However, this system is not highly specific and can 
be responsible for the transport of several different molecules, such as paraquat, 
antiproliferative agents such as methylglyoxal bis(guanylhydrazone) (MGBG), mepacrine and 
polyamine-based compounds, into the cell [68,86]. In general, and since the transporter is not 
specific for putrescine, spermidine or spermine, the affinity of the carrier increases for amines 
which have chain lengths resembling those of spermidine or spermine. It has also been shown 
that the primary nitrogen groups of the polyamines seem to be critical for uptake [87].  
  Recently, two different models for the mammalian PTS have been described: one 
through an endocytic-mediated pathway using cell surface heparin sulfate proteoglycans 
(polyamines bind to heparin sulfate and enter into the cell by endocytosis) and one through a 
membrane transporter that requires an electronegative membrane potential [72,85,86]. 
  Polyamines can also be transported out of the cells by a polyamine efflux system, e.g. 
excretion of the products formed by the SSAT reaction steps in the catabolic pathway. N
1
-
acetylspermidine and putrescine are the major products readily excreted from cells. Besides 
being excreted, putrescine can also be degraded by diamine oxidase [53,68,72,86]. Excretion 
is a selective process and is regulated by the growth status of the cell, being activated when 
cell growth decreases and inhibited by initiation of cell growth (in response to a growth 
stimulus) [53]. 
  The cellular polyamine content plays a key role in the regulation of the polyamine 
transporters by a feedback mechanism. Thus, when cells are depleted of polyamines, 
polyamine transport is up-regulated, whereas in the presence of a polyamine excess, the 
polyamine transporter is down-regulated [72,75].  
  In 1976, Canellakis and his co-workers [88] discovered a unique small protein 
inhibitor of ODC, which was induced upon addition of putrescine. They called this protein 
antizyme (Az), which later was shown to be widely distributed among eukaryotes [89]. Az is 
synthesised by a unique mechanism from two open reading frames via a polyamine-
stimulated ribosomal translational frameshifting [72,79,84,90-92]. Az binds with high affinity 
to transient ODC monomer subunits forming Az-ODC heterodimers, and thereby preventing 
the formation of the enzymatically active ODC homodimer. In mammalian cells, this binding 
of Az to ODC forms the enzymatically inactive Az-ODC complex, which is degraded by the 
26S proteosome [53,70,72,74,79,80,91-93]. The ODC degradation by the 26S proteosome 
occurs in an ATP-dependent but ubiquitin-independent manner [53,91]. 
 Tânia M. Silva 
___________________________________________________________________________ 
 
20 
 
  Several lines of evidence have shown that Az, which is induced by increased 
intracellular polyamine levels, besides regulating the degradation of ODC, inhibits the cellular 
polyamine transport, although the exact mechanism is not known [68,74]. Expression of high 
levels of Az have been linked to growth inhibition by the decrease in ODC, as well as the 
occurrence of a marked down-regulation of polyamine uptake [68,75,93]. Therefore, Az is a 
key regulatory protein in polyamine homeostasis [62]. 
  Mammalian cells also contain another protein very important for cellular polyamine 
homeostasis named antizyme inhibitor (AzI). This is a 49 kDa protein, originally purified 
from rat liver extracts by Hayashi and colleagues [94]. AzI is a protein with a short half-life 
and highly homologous to ODC [72,79,92,93]. Although a number of residues required for 
ODC activity are conserved in AzI, this is a distinct protein that lacks enzymatic activity 
[79,80,93]. AzI binds to Az with a higher affinity than ODC does. [79]. AzI acts as a positive 
regulator of the polyamine pathway by strongly binding to Az and thus rescuing the ODC 
subunits from interaction with Az, thereby preventing Az-mediated ODC degradation by the 
26S proteosome [72,79,80,93]. AzI is also a rapidly degraded protein. Like ODC, the AzI 
degradation is mediated by the 26S proteosome but, in contrast to ODC, AzI is degraded in an 
ubiquitin-dependent manner [72,79,89,92]. Moreover, binding of Az actually stabilises AzI 
by preventing its ubiquitination [79].  
  Several lines of evidence indicate that AzI is also involved in cell proliferation and 
tumour progression. High levels of AzI have been correlated with increases in ODC protein, 
polyamine synthesis and cell proliferation [79,80,93]. It has been reported that AzI 
overexpression gives rise to increased polyamine content, therefore leading to increased 
cellular proliferation and transformation, while down-regulation results in reduced polyamine 
content and inhibition of cell proliferation [79,80,89]. Since AzI is known to stimulate cell 
proliferation, increased antizyme inhibitor levels may directly promote tumourigenesis [93]. 
 
       1.3.5.    Polyamines and Cancer 
  One of the most important goals in cancer research is to study and characterise the 
molecular basis of the uncontrolled proliferation of cancer cells. The association of increased 
polyamine levels with rapid cell proliferation is well established [95]. Deregulation of cellular 
polyamine levels is linked with diverse pathological conditions. It has been demonstrated that 
polyamines are able to affect numerous processes in carcinogenesis, with their synthesis 
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becoming a potential target for antitumour drugs [74,76,96]. Therefore, from a 
pharmacological point of view, the polyamine metabolism has been identified as a target for 
cancer chemotherapy and chemoprevention, mainly due to five major reasons [67,76,80]: 
 
 Polyamines are necessary for cell proliferation; 
 
 Polyamine levels are significantly increased in cancer cells and tissues; 
 
 The ODC gene has been recognised as an oncogene and its activity is also increased in 
cancer cells; 
 
 Inhibition of polyamine biosynthesis with consequent depletion of the intracellular 
polyamine pools may reduce or prevent cellular growth; 
 
 Polyamine metabolism is essential for all cancers. 
 
  In addition, a strong correlation between the growth rate of cancer cells and their 
polyamine levels has been reported, in a way that human cancer cells require more 
polyamines than the equivalent normal cells. Increased polyamine content has also been 
found in the urine from a majority of patients with various types of cancer [76,96], which may 
be useful in the diagnosis of cancer and evaluation of the efficiency of chemotherapy. 
However, since not all cancer patients present an increased content of polyamines in their 
urine, new prognostic markers for cancer screening are required [57,96]. 
  The potential cancer chemopreventive strategies include the inhibition of polyamine 
synthesis or induction of polyamine catabolism. Increased polyamine levels are correlated 
with increased rate of cell proliferation, decreased apoptosis and increased expression of 
genes affecting tumour invasion and metastasis. On the other hand, inhibition of polyamine 
levels is correlated with decreased cell proliferation, increased apoptosis and decreased 
expression of genes affecting tumour invasion and metastasis [57].  
  In breast cancer, a positive association between the polyamine content in the tumour 
and its recurrence has been recognised. In the same way, it has been shown that there is 
frequently a positive relationship between increased polyamine levels and poorer cancer 
prognosis [70]. 
  Cancer, including breast cancer, is usually associated with an increase in biosynthesis, 
decrease in catabolism and rise in the uptake of exogenous polyamines. In order to obtain 
100% inhibition of cancer cell proliferation in vivo, it is essential to affect all these steps in 
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polyamine homeostasis [97]. In this thesis, cell cultures were used to demonstrate the 
involvement of polyamines in the proliferation and development of breast cancer [96].  
 
       1.3.6.    Polyamine Depletion 
  Polyamine homeostasis is often altered in cancer, with cancer cells exhibiting higher 
polyamine levels. Since the polyamine biosynthetic pathway has become a target for 
chemotherapeutic intervention, two approaches can be used to deplete the intracellular 
polyamine pools: the use of inhibitors of the biosynthetic enzymes or the use of synthetic 
polyamine analogues. Agents that cause changes in polyamine metabolism or function can 
become promising compounds in cancer treatment (including breast cancer), either alone or in 
combination with other agents [98]. 
 
  1.3.6.1.    Polyamine Biosynthesis Inhibitors 
  Induction of polyamine synthesis, usually leading to the accumulation of intracellular 
polyamine levels, plays a very important role in cancer biology, including breast cancer. 
  In terms of therapeutic intervention, most of the research has focused on the 
biosynthetic enzymes ODC and AdoMetDC, but especially on ODC [99]. Inhibition of these 
enzymes would be expected to decrease the polyamine levels. Since ODC activity was 
increased in cancer cells, this enzyme became a promising target for possible prevention of 
tumour growth [76]. In addition, higher levels of polyamines and ODC activity have been 
detected in human breast cancer cells, compared to normal and benign breast cells, therefore 
increasing the evidences that the polyamine pathway plays an essential role in breast cancer 
development [74]. ODC inhibitors have been shown to deplete putrescine and spermidine 
contents, while the spermine content is not affected [99-101]. However, although less is 
known about the role played in cancer of the other rate-limiting biosynthetic enzyme 
(AdoMetDC), this enzyme is also an evident target [76]. AdoMetDC inhibitors have been 
shown to deplete spermidine and spermine pools, but not the putrescine pool [99-101]. 
  Over the last decades, there has been an intense research on the use of polyamine 
biosynthesis inhibitors to efficiently deplete the intracellular polyamine levels. Therefore, a 
number of single enzyme inhibitors were specifically designed and synthesised with the hope 
of finding a new and effective anticancer drug [53,76,99]. 
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 One of the first efficient and rationally designed inhibitors was α-
difluoromethylornithine (DFMO) (Fig. 4). DFMO was synthesised by scientists at the Merrel 
Dow Research Institute [102]. It is an irreversible, suicide inhibitor of ODC [99,101,102]. 
DFMO binds to the active site of ODC and is enzymatically decarboxylated, which activates 
the inhibitor. Although initially this was thought to be a very promising agent, it was found to 
be poorly efficient as a single agent for inhibition of tumour growth and progression, thereby 
failing to cure cancer patients [70,101,103]. This selective ODC inhibition stopped 
proliferation in several cells lines, but it was not enough to inhibit tumour growth [100]. In 
phase II studies of several cancers (breast, colon and small-cell lung cancers), DFMO did not 
show antitumour activity and its addition to conventional therapy in solid tumours had no 
significant inhibitory effect in cancer progression [103,104]. This lack of efficiency can be 
explained by the availability of polyamines from the intestinal microbial flora and by the 
activation of an up-regulation in polyamine transport caused by biosynthesis inhibition, 
thereby allowing the uptake of exogenous polyamines (from bacteria as well as from the food) 
[99,101,102]. Therefore, compounds that prevent polyamine transport can increase the 
antiproliferative activity of DFMO. In addition, inhibition of ODC is maintained only with 
high doses of DFMO. DFMO uptake occurs slowly by facilitated diffusion, while its 
excretion from the body occurs rapidly [53].  
  Currently, DFMO is being evaluated and used as a chemopreventive agent in low non-
toxic doses [102] against several types of cancer, including colorectal, prostate, non-
melanoma, neuroblastoma and breast cancer [57,99,103,104]. Moreover, DFMO is highly 
efficient as an antiparasitic agent in the treatment of African sleeping sickness [99,100,103]. 
  In an effort to overcome the disappointing results obtained with DFMO as a single 
agent in chemotherapeutic intervention, DFMO was combined with a number of other 
cytotoxic agents [70,101].  
  In conclusion, the results obtained with DFMO in cell culture clearly demonstrate that 
prevention of polyamine biosynthesis may be a possible strategy for inhibiting cancer cell 
proliferation. However, for this strategy to be effective also in vivo the following conditions 
need to be considered [101]: 
 
 Polyamine depletion may need to encompass all three polyamines;  
 
 Polyamine depletion may be hampered by compensatory mechanisms in polyamine 
biosynthesis. 
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 Polyamine depletion may be hampered by a compensatory increase of polyamine 
uptake. 
 
 
  
Figure 4: Structural representation of the polyamine biosynthetic inhibitor DFMO. 
 
 Other polyamine biosynthetic inhibitors that have been synthesised include the 
AdoMetDC inhibitors: 4-amidinoindan-1-one-2’-amidinohydrazone (CGP48664, also known 
as SAM486A) [78,99] and MGBG [66,99]. 
  Taking all of this into account, it may be concluded that the polyamine pathway, with 
its crucial role in cell proliferation, is still a worthy target for the development of new 
antiproliferative agents [101]. 
 
  1.3.6.2.    Polyamine Analogues 
  In the cancer field, apart from the use of inhibitors of polyamine metabolism, new 
studies on the potential use of synthetic polyamine analogues to achieve more efficient 
polyamine depletion are of utmost relevance. 
  The first generation of polyamine analogues (symmetrically substituted analogues) as 
an alternative approach to interfere with the polyamine biosynthesis were first developed by 
Porter, Bergeron and colleagues in the 80’s [101,105]. Since then, several groups have 
synthesised polyamine derivatives, the unsymmetrically substituted ones (second generation) 
having been developed by Dr. Woster’s group [53,101]. A third generation of polyamine 
analogues was developed by the SLIL Biomedical Corporation and covers conformationally 
restricted analogues, cyclic analogues and oligoamine analogues [53,101]. 
  Worldwide, several research groups and companies have synthesised and are currently 
synthesising different polyamine analogues. These analogues are compounds structurally 
N H OC F
DFMO
1. Introduction 
___________________________________________________________________________ 
25 
 
similar to the biogenic polyamines that negatively regulate ODC and AdoMetDC without, 
however, being able to functionally substitute the natural polyamines [53,101]. These 
analogues are efficiently taken up by the PTS and, once intracellular, they will accumulate to 
high concentrations in the cell. Consequently, increased cellular level of the polyamine 
analogues activates the feedback control, down-regulates biosynthesis and up-regulates 
catabolism of the natural polyamines [106,107]. Since the modified polyamines cannot 
functionally substitute for the biogenic ones, several different cellular processes are disrupted, 
leading to growth inhibition, and sometimes cell death (by apoptosis) is induced (Trojan horse 
effect) [101,107,108].  
  A large number of polyamine analogues are able to induce a total and rapid depletion 
of the three biogenic polyamines in the cells due to the combined homeostatic responses, 
which include induction of SSAT and PAO (catabolism activation), feedback inhibition of 
polyamine biosynthesis and activation of the export from the cell [75]. Polyamine analogues 
also compete for uptake with the natural polyamines [101]. These features, together with the 
relatively non-toxic response in normal tissues, have contributed to the use of polyamine 
analogues as single therapeutic agents. 
  Since rapidly proliferating cells (including cancer cells) have a higher requirement for 
polyamines than normal cells, agents that are effective in rapidly depleting cells of their 
polyamine pools can be used in cancer treatment [108]. In addition, polyamine analogues may 
be particularly attractive to use in cancers that are resistant to other forms of 
chemotherapeutic treatment.  
  According to their function, the analogues can be divided into two groups [53,106]: 
 
 Polyamine mimetic: a polyamine analogue that enters into the cell and mimics the 
function of the biogenic polyamines, usually without causing depletion of the 
intracellular polyamine pools, but causing a reduction in cell growth. 
 
 Polyamine anti-metabolite: a polyamine analogue that enters into the cell and 
depletes the intracellular polyamine pools by activation of polyamine catabolism and 
export (along with the biosynthetic down-regulation). This results in growth 
inhibition. These agents can be useful used as anticancer drugs. 
  
  The major polyamine analogues synthesised up to this date have been modified 
spermidine and spermine, by alkylation at specific sites. These analogues may be 
symmetrically- or unsymmetrically-alkylated derivatives of polyamines, varying in the length 
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of the intermediate carbon chains [101,103,106]. Some symmetrically substituted polyamine 
analogues include N
1
,N
11
-bis(ethyl)norspermine (BENSpm), N
1
,N
8
-bis(ethyl)spermidine 
(BES), N
1
,N
12
-bis(ethyl)spermine (BESpm) and N
1
,N
14
-bis(ethyl)homospermine (BEHSpm). 
Some unsymmetrically substituted polyamine analogues include N
1
-cyclo-propylmethyl-N
11
-
ethylnorspermine (CPENSpm), N
1
-ethyl-N
11
-((cycloheptyl)methyl)-4,8-diazaundecane 
(CHENSpm) and N
1
-ethyl-N
11
- ((isopropyl)methyl)-4,8-diazaundecane (IPENSpm). 
  The polyamine analogues used in this study were BESpm, BENSpm, CPENSpm and 
norspermidine (NSpd) (Fig. 5) and their most important characteristics are described in Table 
2. 
 
 
 
Figure 5: Structural representation of the polyamine analogues BESpm, BENSpm, CPENSpm and 
NSpd under physiological conditions. 
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Table 2: Main features of the polyamine analogues BES, BENSpm, CPENSpm and NSpd. 
Polyamine analogues Important features 
BESpm 
 
 Spermine analogue 
 First generation of polyamine analogues 
 Uses the PTS to be readily transported into mammalian cells 
[103] 
 Down-regulates ODC and AdoMetDC and induces SSAT 
[74,103,109,110] 
 Induces cell death by apoptosis in leukaemia, lung and 
melanoma cancer cell lines [103,111] 
 Significantly inhibits cell growth in breast cancer cell lines 
[110,111] 
 
BENSpm 
 
 Spermine analogue 
 First generation of polyamine analogues 
 Uses the PTS to be readily transported into mammalian cells 
[103] 
 Down-regulates ODC and AdoMetDC and super-induces 
SSAT [74,103,107,109,110] 
 Efficiently depletes the three intracellular polyamines in 
several breast cancer cell lines [107] 
 Growth inhibition and cytocidal effects in some cancer cell 
lines [74,112] 
 Induces cell death by apoptosis in breast, lung and melanoma 
cancer cell lines [107] 
 Effectively inhibits cell proliferation in breast cancer cell lines 
[107,112-114] 
 Antitumour activity in experimental models including breast, 
prostate, melanoma and lung cancer models and has undergone 
phase I and II clinical trials [103,110,114-116] 
 No significant therapeutic effects are shown in breast and lung 
cancer patients due to low efficacy in clinical activity → did 
not pass phase II clinical trials [101,103,114,117]  
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Table 2: Main features of the polyamine analogues BES, BENSpm, CPENSpm and NSpd. 
(Continuation) 
CPENSpm 
 
 Spermine analogue 
 Second generation of polyamine analogues 
 Down-regulates ODC and super-induces SSAT [74,109] 
 Effectively inhibits cell proliferation in breast cancer cell lines 
[107,112-114] 
 Induces cell death by apoptosis in breast, prostate and lung 
cancer cell lines [103,109] 
 Its cytotoxicity it is not exclusively dependent on SSAT 
induction [110] 
 Displays a cell type specific cytotoxicity [109,104] 
 
 
NSpd 
 
 Spermidine analogue 
 Naturally occurring triamine polyamine in some species of 
plants, bacteria and algae [118-120] 
 Antineoplastic activity against some types of tumours in mice 
[121]  
 
 
  Several polyamine analogues and polyamine pathway drugs are presently being tested 
in human cancer patients as potential new chemotherapeutic agents. These compounds are 
being evaluated individually, collectively and in combination with other anticancer drugs or 
traditional chemotherapeutics, since good results were achieved in vitro, namely in breast 
cancer cells [97,113,122].  
  In conclusion, the polyamine analogues are able to target more than one step in the 
polyamine biosynthetic pathway, therefore providing potentially better polyamine depletion 
than, for instance, single enzyme biosynthetic inhibitors. The use of particular analogues will 
then result in greater antiproliferative effects [101]. 
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 1.4.   Cell cycle 
       1.4.1.    Cell Cycle Phases 
  In eukaryotes, the cell cycle process is more complex than in prokaryotes, consisting 
of a highly ordered series of four coordinated and discrete phases (Fig. 6), in which the cell 
duplicates its components (growth phase) and then divides into two new cells (division 
phase). The four consecutive phases that constitute the cell cycle are [9,123-127]: 
 
 Gap 1 (G1): is the first phase of the cell cycle and is initiated after the mitosis phase is 
finished. During G1 phase, the metabolically active and continuously growing cell 
prepares for DNA synthesis by synthesising the required RNA and proteins to make its 
DNA copies. Also in this phase, the cell integrates growth stimulatory and inhibitory 
signals and decides whether to proceed into the next phase, pause, or exit the cell 
cycle. 
 
 Synthesis (S): corresponds to the interval between the two gap phases (G1 and G2, 
respectively). During S phase, DNA synthesis takes place, the DNA is replicated and 
two exact copies of the chromosome are formed (duplication of the genetic material). 
 
 Gap 2 (G2): is initiated after the S phase of the cell cycle is completed. During G2 
phase, cells continue to grow and prepare for the next phase (division) by synthesising 
the required proteins and structural components.  
 
 Mitosis (M): corresponds to the interval between the two gap phases (G2 and G1, 
respectively). During M phase, cell division takes place, after chromosome 
segregation, separation and distribution of the duplicated chromosomes to the 
daughter cells. The two identical daughter cells contain equal amounts of the same 
genetic material as the original parental cell. M phase can be divided into four mitotic 
phases entitled prophase, metaphase, anaphase and telophase. 
 
  However, many eukaryotic cells do not undergo continuous division and, instead, they 
will mature or differentiate in order to execute specific functions in the organism [123]. These 
cells become quiescent (temporarily or permanently out of cell cycle) and no longer divide. 
Resting cells in this quiescent state are in another gap phase of the cell cycle entitled G0. In 
this state, proteins and signalling molecules responsible for cell growth are down-regulated. In 
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order to re -enter the c ell cycle into the G 1 phase and undergo further division into two 
daughter cells, cells can exit th e quiescent state if stim ulated by external growth signals 
(mitogenic stimulation) [74,124,125,127]. Actually th ere are som e cells that rem ain in this 
quiescent state for their entire lifetim e, thereby not experiencing cell division [125]. On the 
other hand, newborn cells can enter this phase to  rest for a while before entering into a new 
the cell cycle [128]. 
  Initially the cell cycle wa s only divided into two phases because these were the on ly 
two that could be distinguished in the microscope:  
 
 Interphase: where nothing seemingly happened but increase in cell size  It includes 
the G0, G1, S and G 2 phases. Eukaryotic cells spend the majority of their lifetime in 
interphase. 
 
 Mitosis: where the cell was observed to divide into two daughter cells  It comprises 
the M phase (cell nuclei division) followed by cytokinesis (cytoplasm division). 
 
 
 
Figure 6: Schematic representation of the cell cycle in eukaryotic cells. 
 
  Usually, the time spent by the cells in each  phase of the cell cycle differs considerably 
(especially for the G 0/G1 phase), depending on the type of cells. However, a typical 
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eukaryotic cell (rapidly proliferating human cell) approximately divides every 24 h, with G1, 
S, G2 and M phases lasting around 11, 8, 4 and 1 h, respectively [123,125]. 
 
       1.4.2.    Checkpoint Controls in the Cell Cycle 
  Of the four cell cycle phases described, the two critical steps are DNA replication and 
cell division [127]. The regulation of the normal cell cycle must certify that the events in each 
phase are completed before proceeding into the next. The loss of control will lead to abnormal 
development and can cause causer.  
  Hence, the cell must pass through a series of checkpoints (known as restriction 
checkpoints) for checking the DNA integrity. These checkpoints controls are activated in 
response to DNA damage or other error signals in the cell and are placed in late G1 and at the 
G2/M interface, in order to prevent proliferation and development of mutated or damaged 
cells [124]. There are also checkpoint control mechanisms within mitosis to guarantee that 
conditions are favourable for cell division to be completed [125]. 
  When DNA is damaged, the progression of the cell cycle through S phase may be 
slowed down or a cell cycle arrest may occur at checkpoints in G1 or G2. The arrest in G1 may 
allow repairing the damaged DNA before the cell enters into the S phase, where the damaged 
DNA otherwise would be replicated [123]. In mammalian cells, the arrest in G1 can be 
mediated by the action of the well-known protein p53. This protein is rapidly induced as a 
response to DNA damage [123]. However, in human cancer cells the p53 gene is often 
mutated, resulting in damaged DNA being replicated and transmitted to the daughter cells, 
instead of being repaired. This will cause instability of the cellular genome and allow cancer 
development [123]. Actually, it has been reported that defects in many genes coding for 
proteins that regulate the cell cycle have been implicated in human cancer [126]. Therefore, 
new researches over the mechanisms that regulate the cell cycle are of utmost importance. 
 
       1.4.3.    Cyclins and Cyclin Dependent Kinases 
  The cell cycle is regulated and driven by different groups of proteins named cyclins 
and cyclin dependent kinases (CDKs), which control the major transitions occurring in the 
cell cycle of eukaryotic cells [126,129,130]. Cyclins are regulatory proteins sequentially 
synthesised and degraded in a cyclic way during the cell cycle progression [131]. CDKs are 
protein kinases constitutively expressed, that positively or negatively regulate the activity of 
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proteins essential for cell cycle progression by phosphorylation [9,129,130]. Specific cyclins 
can be found in each cell cycle phase, with cyclins D and E being found in G1 phase, cyclin A 
in S and G2 phases and cyclin B in the M phase [124,127,130,131]. As the cell cycle 
proceeds, cyclins can interact and bind to CDKs, forming active cyclin/CDK complexes, in 
which the cyclin is the regulatory unit and CDK is its catalytic partner [124]. Cyclin/CDK 
complexes phosphorylate specific protein substrates and are the force that drives the cells 
through the cycle with activation of DNA replication (in S phase), and formation of the 
structural components correlated with mitosis (in late G2 and M phases) [124]. Nevertheless, 
the cell cycle system also comprises a group of other proteins that bind to the cyclin/CDK 
complexes and negatively regulate their activity (by inhibition). These are called CDK 
inhibitors (CDKIs) and are the inhibitory force of the cell cycle, since their binding gives rise 
to the inactivation of the cyclin/CDK complexes [129].  
 
       1.4.4.    Polyamines and the Cell Cycle 
  The polyamines have been shown to be required for normal cell cycle progression, 
with their cellular levels being changed during cell cycle [129]. Polyamine levels are 
increased through polyamine biosynthesis, after the cell receives growth stimulatory signals 
[127]. Polyamine biosynthesis exhibits a bicyclical variation during the cell cycle and, when 
inhibited (for instance by the interference with a drug), cell cycle progression is delayed [98]. 
Polyamine biosynthesis inhibition may be followed by growth arrest and, sometimes, also 
apoptosis. However, this effect may be reversed by the addition of exogenous polyamines 
[129]. 
  The cell cycle phase most sensitive to inhibition of polyamine biosynthesis is the S 
phase, with DNA replication being negatively affected when polyamine levels are reduced or 
not allowed to increase normally during cell growth. Nevertheless, some effects also occur 
later, namely in the G1 phase (of the next cycle) and in the G2/M phases transition [130]. 
Since in G0 cells are not proliferating, cells in this phase contain lower polyamine levels than 
those in the other cell cycle phases. 
  Since polyamine biosynthesis is essential for normal cell cycle progression, the studies 
of the enzymes acting in the polyamine metabolic pathway (ODC and AdoMetDC) are 
crucial. Distinct changes in both enzyme activities and intracellular polyamine levels have 
been shown to take place during the cell cycle. It has been reported that ODC and AdoMetDC 
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activities have their peak levels at the G1/S and S/G2 transitions, while displaying reduced 
levels in quiescent cells [127,130] Thus, polyamine biosynthesis appears to be strongly 
activated during these two transitions. While elevated polyamine levels (due to increases in 
ODC and AdoMetDC activities) have a positive role and are necessary for DNA replication, 
reduced polyamine levels (e.g. due to the induction of SSAT) will affect DNA replication in a 
negative manner, possibly by decreasing the DNA elongation rate [70,132]. 
  It has been shown that when cells in G0/G1 are seeded in the presence of agents 
preventing the increase in polyamine levels, the S phase of the first cell cycle is prolonged, 
while the other cell cycle phases are not affected. Thereafter, polyamine depletion can result 
in cell cycle arrest after one to several cell cycles, depending on the efficacy of polyamine 
depletion [127].  
 
 1.5.   Metal-Based Anticancer Agents 
 One of the main causes for breast cancer treatment failure is related with the 
development of resistance to the anticancer agents used [14]. For this reason, the search for 
new treatment strategies is required, with an urgent need to develop improved 
chemotherapeutic compounds able to efficiently eradicate cancer cells while displaying 
minimal adverse effects [133]. 
 In the last decades, there has been an intense research aiming at the design and 
development of new anticancer drugs, namely metal-based compounds, exhibiting highly 
suitable features for clinical practice [134]. Currently, the most studied ones include platinum 
(Pt(II)) and (Pt(IV)), palladium (Pd(II)), gold (Au(I)) and Au(III), ruthenium (Ru(II)) and 
Ru(III), bismuth (Bi(III)), rhenium (Re(I)), gallium (Ga(III)) and cooper (Cu(II))-based and 
Cu(II) agents [135,136]. 
 
       1.5.1.    Platinum-Based Compounds 
  1.5.1.1.    Cisplatin 
 Cis-Diamminedichloroplatinum (II), (Pt(NH3)2Cl2, cisplatin), is an inorganic neutral 
complex comprising one metal centre (Pt(II)) (Fig. 7). In 1845, in Turin, Michael Peyrone 
was the first to synthesise this compound, and its structure (square planar configuration) was 
deduced in Zurich, by Alfred Werner, forty-eight years later [137]. Werner also distinguished 
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between cisplatin’s cis and trans isomers [138]. However, it was only in 1965 that Barnett 
Rosenberg, a biophysics and chemistry professor at the Michigan State University in USA, 
discovered, quite by chance, the anticancer properties of cisplatin [139]. While studying 
electrical currents using an Escherichia coli culture, Barnet and his colleagues observed that a 
specific Pt-containing compound inhibited bacterial binary fission (cell division) [139]. A 
group of compounds was tested and it was found that the cis form of the Pt(II)-
diamminedichloro complex (cisplatin) was the most effective one. Its trans isomer was 
demonstrated to be ineffective as a chemotherapeutic agent [137].  
 In order to investigate the anticancer properties of cisplatin, Rosenberg and his group 
tested it in vivo (in 1969) [140]. They observed a total regression in the tumour mass in rats 
with sarcomas, thus proving that cisplatin was indeed a promising anticancer agent, namely 
for solid tumours [140]. Since then, several research groups extended cisplatin’s testing to 
other types of tumours, confirming its potential as chemotherapeutic agent. In the end of 
1978, cisplatin was approved by the Food and Drug Administration (FDA) for clinical use in 
the USA and became the first metal-based drug to be successfully used for cancer therapy 
[141-143]. 
 
 
 
Figure 7: Schematic representation of cisplatin. 
 
 Cisplatin has a central role in cancer chemotherapy, its activity relying on particular 
and specific interactions with DNA, leading to induction of severe DNA damage and finally 
cell death (by apoptosis) [135]. This drug has been widely used as first line therapy for the 
treatment of several types of cancer, including lymphomas, testicular, ovarian, head and neck, 
bladder and a few types of lung cancers, due to its high cytotoxic efficiency [135,143-145]. 
However, the occurrence of severe side effects, specifically neuro- and nephrotoxicity (due to 
the interaction of activated cisplatin with critical renal and nervous system tissues), and the 
development of acquired resistance in most types of cancer, were found to be limiting factors 
for cisplatin’s use in the clinic [137,144,146-149].  
Cisplatin
N H Pt Cl
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 Tumour resistance to cisplatin can be either intrinsic or acquired (after exposure to the 
drug for some time) [137]. The cellular cisplatin resistance mechanisms include a diminished 
accumulation in the cells by a reduced uptake or increased efflux of the drug, cytoplasmic 
inactivation of the drug through binding of cisplatin to nucleophiles and cellular thiol-
containing molecules (such as glutathione, methionine and metallothionein [150]), an 
increased ability of the cells to repair or tolerate the DNA damage caused by cisplatin, and a 
rise in the capacity of cancer cells to avoid cisplatin-induced cell death [137,143,149].  
 Additionally, since cisplatin therapy also affects normal cells by causing strong 
secondary effects, its use must be limited.  
 
  1.5.1.2.    Mechanism of Action of Cisplatin 
 Cisplatin’s mechanism of action has not yet been totally clarified, although it is widely 
accepted that it includes several specific steps. 
  For many years, the general conviction was that cisplatin and its analogues entered 
the cell by passive diffusion across the plasma membrane. However, in the last decades it has 
been reported that this agent can also enter the cell by active transport, via a specialised 
carrier-mediated mechanism. Recently, two transmembrane proteins involved in copper 
homeostasis (copper transporter 1 and 2, CTR1 and CTR2, respectively) were found to 
modulate the uptake of Pt(II)-based anticancer drugs, such as cisplatin [137,143,149,151].  
 After its entrance into the cells, the neutral cisplatin complex is activated by a series of 
spontaneous reactions with water, where its chloride ligands are successively substituted by 
one or two water molecules (mono- or diaqua species) at physiological pH, thus generating 
positively charged species that cannot readily leave the cell [143,150]. This cisplatin 
hydrolysis is due to a large decrease in the chloride concentration inside the cell (3–20 mM) 
as compared to the extracellular environment (100 mM), thereby favouring the aquation 
process [137,143,149]. The monoaqua platinum species are the most highly reactive ones and 
they are responsible for at least 98% of the platinum binding to DNA [137]. 
 Thus, once inside the nucleus, and in contrast with classical alkylating agents, the 
complex interacts with DNA through coordination of the Pt(II) centre to the nitrogen atoms of 
the nucleotide bases (mostly N7 of the purines adenine and guanine). This will lead to the 
formation of characteristic DNA adducts, preferentially through 1,2-intrastrand crosslinks, via 
two consecutive guanine bases (GpG) or with an adenine and a guanine (ApG) within the 
same DNA strand (corresponding to about 80% of the total DNA lesions) [137,143,150,151]. 
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The formation of these bifunctional adducts causes the purines to become destacked and the 
DNA helix to bend and unwind [135]. Since it has been shown that transplatin is inefficient in 
eradicating cancer cells, due to the favoured formation of the hydroxo species (stable) instead 
the aqua (unstable) ones, the 1,2-intrastrand adducts (only formed between cisplatin and 
DNA) are critical for the anticancer activity of cisplatin. 
 Formation of cisplatin-DNA adducts will further affect normal DNA replication (by 
blocking the action of DNA polymerase) and transcription, as well as the DNA repair 
mechanisms. It will also be responsible for disruption of the native DNA conformation, which 
will be further recognised by cellular DNA binding proteins (high mobility group (HMG) 
proteins) that are known to recognise and repair DNA damage (e.g. drug-induced), by tightly 
binding to the Pt-complex [149]. It has been shown that the HMG domain proteins are 
important for the activity of cisplatin, since cells that lack the corresponding gene were shown 
to be less sensitive to treatment with this drug, as compared to those containing this gene 
[137,152]. In an attempt to repair the induced damage, cisplatin causes cell cycle arrest in the 
S and G2 phases [143]. If damage due to cisplatin-DNA adducts cannot be efficiently 
repaired, the cells will eventually die by apoptosis [152]. Besides this strong interplay with 
DNA, cisplatin can also interact with RNA and sulphur-containing biomolecules in the 
cytoplasm (known to present a higher affinity for the soft Pt(II) centre than the purine 
nitrogens [137,148]), leading to drug deactivation and to an increased toxicity with severe 
side effects [137].  
 
  1.5.1.3.    Platinum-Based Drugs Approved for Clinical Use 
 Cisplatin’s approval for clinical use (by FDA and European Medicines Agency) along 
with the occurrence of severe side effects and development of resistance with cisplatin 
treatment, urged the pursuit for novel Pt-based agents able to bind to DNA and exhibiting 
improved anticancer properties (at lower doses), coupled with lower toxicity and lack or 
minimal acquired resistance [135]. Therefore, in order to overcome the adverse side effects of 
cisplatin and to enhance its clinical performance, several new cisplatin-based agents have 
been synthesised and tested. Currently, the Pt-based anticancer agents in clinical use 
worldwide are: 
 
 
 Cisplatin: approved by FDA as Platinol in 1978. It is the leading and most common 
Pt(II)-based anticancer agent, used to treat a wide spectrum of human malignancies 
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[135,153,154]. In testicular germ cell cancer, cisplatin activity is exceptional, 
displaying a cure rate beyond 90% [144,155]. However, it also exhibits diverse 
drawbacks, including severe toxicity and development of resistance [151,156]. 
 
 Carboplatin: second-generation Pt(II) compound (cis-diammine (1,1-
cyclobutanedicarboxylato)platinum (II)) (Fig. 8), that entered the US market as 
Paraplatin in 1989, initially for the treatment of advanced ovarian cancer. Carboplatin 
owes its lower toxicity to the ligand change, from diammine to the bidentate 
dicarboxylate moiety, which slows down the degradation of carboplatin into 
potentially toxic derivatives [135,144,151,155]. In addition, the slower hydrolysis rate 
of carboplatin is responsible for a longer plasma lifetime of the drug – retention time 
of about 30 h for carboplatin as compared to 1.5 to 3.6 h for cisplatin [157]. This agent 
yields the same type of DNA adducts as cisplatin and it is effective against the same 
type of cancers [135,144]. In comparison to cisplatin, the greatest benefit of 
carboplatin lies in its reduced side effects, particularly the eradication of nephrotoxic 
effects [135,145].  
 
 Oxaliplatin: third generation compound and the third Pt(II) approved for standard 
chemotherapy use in 2002 ([(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-
O,O')platinum(II)) (Fig. 8). It is active against many cisplatin and carboplatin resistant 
tumours, such as widespread colorectal cancer [144,145,151,157]. Oxaliplatin differs 
from cisplatin in that the two monodentate ammine groups are substituted by a 
bidentate 1,2-diaminocyclohexane stable ligand [135,151,157,158]. Oxaliplatin’s 
cytotoxicity is mainly due to the formation of DNA lesions via intra- and interstand 
crosslinks [158]. As a single agent, oxaliplatin presentes a poor outcome with no 
curative properties in cisplatin resistant cancers. Thus, it is currently combined with 
other drugs, such as 5-fluorouracil and leucovorin (displaying a different mechanism 
of action), aiming at a synergetic effect, for the standard treatment of metastatic 
colorectal cancer [135,144,155,158]. Apart from its success in this type of cancer, 
oxaliplatin has also been used against gastroesophageal and pancreatic tumours [158]. 
It has shown enhanced activity and the lack of cross resistance, coupled to a decreased 
toxicity relative to the other Pt(II) agents, and is a promising treatment option in 
cancers where cisplatin and carboplatin therapies have failed [135,144]. 
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Figure 8: Schematic representation of carboplatin and oxaliplatin. 
 
  1.5.1.4.    Platinum-Based Drugs in Advanced Clinical Trials 
 Apart from the Pt-based compounds presently under clinic use, there are other similar 
and promising agents that are currently being tested in advanced clinical trials. These include: 
 
 Satraplatin: the first Pt(IV)-based chemotherapeutic drug that can be administered 
orally (in contrast to the Pt(II) compounds that are intravenously administered) 
[144,145,151,157]. It is an octahedral Pt(IV) complex (Fig. 9) and the most interesting 
candidate for treatment of advanced clinical stage (phase III) cancers, specially for 
hormone-refractory prostate cancer [136,151,153,157]. It displays an increased 
activity in cisplatin resistant cancers and a minimal in vivo toxicity (either nephro- or 
neurotoxicity) [144,153].   
 
 Picoplatin: an orally administered Pt-based drug, particularly designed to overcome 
glutathione-mediated platinum resistance [135,157,159-161]. Picoplatin is a sterically 
hindered mononuclear Pt(II) agent (Fig. 9) undergoing phases I and II clinical trials. It 
has shown a high activity against cancer cell lines resistant to cisplatin, carboplatin 
and oxaliplatin, as well as in the treatment of patients with solid tumours 
[135,151,157].  
 
 ProLindac: a novel diaminocyclohexane (DACH) Pt(II) prodrug (nanopolymer-
oxaliplatin conjugate) presently being tested in phase II clinical trials in patients with 
solid tumours (mainly for recurrent ovarian cancer [135,151]). This therapeutic 
OxaliplatinCarboplatin
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polymer uses a safe, water soluble nanoparticulate system to specifically deliver Pt-
DACH into tumours, concomitantly reducing drug concentrations in normal tissue. As 
a result, there is an increased drug effectiveness and a significant decrease in its 
deleterious side effects. ProLindac’s activity has been shown to be either equal or 
higher than oxaliplatin’s, coupled with a greater tolerability, mainly in low pH 
environments (solid tumours) [135,151,162].   
 
 Lipoplatin: a novel liposomal cisplatin formulation, in which the Pt-based drug is 
encapsulated into liposome nanoparticles specially developed to reduce the drug’s 
systemic toxicity [135,163-166]. This formulation aims at increasing tumour targeting 
and therapeutic activity, since this small molecule is able to circulate in the body for a 
longer time, accumulating mainly in primary tumour sites and metastatic tissues, 
thereby providing a selective delivery to the target [151,163,164]. Lipoplatin has 
shown significantly reduced neuro-, nephro- and ototoxicity relatively to other 
clinically used Pt-based drugs, and has been successfully administered in phases I, II 
and III clinical trials with greater or similar efficiency than cisplatin 
[135,163,167,168]. This agent has been mainly applied to non-small-cell lung cancer, 
but also to pancreatic, breast, and head and neck tumours [151,163,164].  
 
 
 
Figure 9: Schematic representation of satraplatin and picoplatin. 
 
 
Satraplatin Picoplatin
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 Tânia M. Silva 
___________________________________________________________________________ 
 
40 
 
  1.5.1.5.    Polyamine-Bridged Polynuclear Complexes 
 The design and development of new Pt-based anticancer agents coordinated by 
biologically active molecules has been the target of an intense research in the last decades. In 
addition, mononuclear Pt complexes have been replaced by polynuclear complexes, 
comprising two or three metal centres [135], and Pt has been substituted by Pd with promising 
results [135,169-171].  
 There are three key pharmacological features influencing the clinical success of any 
type of Pt-based anticancer therapy. These include the drug’s cellular uptake and efflux, the 
number and type of DNA adducts and the extent of metabolic drug deactivation [172,173]. 
 The biogenic polyamines putrescine, spermidine and spermine have been used as 
suitable ligands for the design of new anticancer metal-based agents, since they yield stable 
and reasonably water soluble coordination compounds, with the advantage of a high 
conformational flexibility and an increased affinity for DNA [135,174-177]. In fact, linear 
alkylpolyamines have proved to be very suitable ligands for both Pt(II) and Pd(II) ions, 
yielding polynuclear chelates that will severely disrupt the DNA native conformation, through 
the formation of non-conventional interactions (long-range, interstrand) with the N7 atom of 
the purine bases, allowing a cross linking of DNA nucleobases over a long distance [133,178-
180].  
 Nicholas Farrell and his co-workers were the first to introduce (in 1988) a Pt(II) 
chelate comprising two metal centres coordinated to 1,4-diaminebutane [181], as a promising 
anticancer agent [182]. These complexes, displaying two or three metal centres and a 
polyamine bridging linker, constitute a unique class of potential anticancer agents active 
towards cisplatin resistant model systems [135,179,182,183]. Additionally, their cellular 
uptake is more efficient than that of the mononuclear analogues, and increases as the overall 
positive charge gets higher. Therefore, the cationic feature of these complexes may be directly 
associated with their cellular accumulation and DNA affinity [154]. The most promising 
multinuclear Pt complex synthesised by this group was the trinuclear Pt(II) compound 
BBR3464 (triplatinum BBR3464 – Triplatin, [{trans-PtCl(NH3)2}2-trans-Pt(NH3)2 
{NH2(CH2)6NH22](NO3)4, Fig. 10), which has an overall positive charge of 4+ and has shown 
to induce a higher cytotoxic effect than conventional mononuclear Pt-based drugs, through an 
identical mechanism of action [135,179,180,183], leading to irreversible changes in the DNA 
conformation, from B to Z type [184,185]. It exhibited antitumour activity in cisplatin 
resistant tumour models with much lower therapeutic doses [179,184-186].  However, despite 
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having reached clinical phases I and II (mainly in ovarian and lung cancer, but also in 
melanoma and pancreatic cancers), it has gone no further due to poor response rates and 
severe toxicity (namely irreversible protein bonding in human plasma) [172,179]. 
 In recent years, a cytotoxic trinuclear complex with three tetramineplatinum(II) 
moieties and an overall charge of 8+, TriplatinNC, has been investigated (Fig. 10). This is a 
“non-covalent” derivative of BBR3464, not capable of binding to DNA in a coordinative, 
conventional way [136,172]. Instead, TriplatinNC associates with the nucleic acid’s double 
helix through hydrogen bonds and electrostatic interactions (phosphate clamp) 
[135,154,172,187]. TriplatinNC is the first Pt(II) anticancer complex that interacts with 
biomolecules solely in a non-coordinative fashion [154]. It accumulates in significant 
amounts in cancer cells, leading to a similar or higher toxicity compared to cisplatin [172].  
 
 
 
Figure 10: Schematic representation of BBR3464 and TriplatinNC. 
 
In summary, Pt-based agents are widely used as chemotherapeutic compounds in 
today’s oncological practice, based on their ability to enter the cell nucleus and covalently 
bind to DNA, yielding stable adducts [135,146-148,188]. The formation of several crosslinks 
in DNA leads to a conformational distortion of the DNA molecule. Thus, essential biological 
processes, such as DNA transcription and replication are inhibited and protein synthesis, as 
well as cell division, will also be affected [147,148]. In addition, since the discovery of 
BBR3464, novel polynuclear metal-based complexes containing biogenic or modified 
biogenic polyamines of variable chain length as ligands have been synthesised and tested as 
Pt ClN               H          C              
BBR3464
4+
TriplatinNC 8+
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promising anticancer agents, particularly Pt(II)- and Pd(II)-chelates [133,134,144,156,169-
171,178,189-193].  
 
       1.5.2.    Palladium-Based Agents 
 Pd(II) for Pt(II) substitution has been tried over the last few decades, with a view to 
increase the therapeutic spectrum of the complex and hence its activity profile, despite the 
initial belief that Pd(II) compounds were biologically inactive as anticancer agents due to the 
high lability of the Pd(II) centre [135]. The Pd(II) ion is chemically very similar to Pt(II), 
displaying an identical affinity for polyamine ligands, and hence binding strongly to DNA’s 
purine and pyrimidine bases [135,194,195].  
 However, the higher lability of Pd(II) complexes (regarding both ligand exchange and 
ability to form trans isomers) relative to their Pt(II) analogues was found to be a major 
drawback in their use as chemotherapeutic agents. This is due to the lower stability of the 
drug-DNA adducts [135,196]. Additionally, the leaving groups in the Pd(II) complexes are 
more rapidly hydrolysed than their Pt(II) counterparts, yielding highly reactive species that 
will probably fail to reach their pharmaceutical target [135,195,196].  
 In order to overcome these initial limitations, a tailored design of improved Pd(II) 
anticancer agents was created. This involves particular conditions such as the binding of the 
metal to a strongly coordinated ligand to allow the stabilisation of the Pd-based complex (e.g. 
N-containing donor), coupled to a reasonably non-labile leaving group (e.g. nitrate) in order 
to ensure that the complex has time to reach and efficiently interact with its target [135,195]. 
This can be achieved through the use of specific bidentate ligands (such as polyamines), that 
are able to confer a higher stability to the complexes, hindering cis→trans isomerisation 
[192,196]. These ligands may not bind to DNA but instead interact with it via Van der Walls 
intermolecular interactions and hydrogen type close contacts. These complexes have been 
shown to yield non-directional and mainly intrastrand DNA adducts (both short and long 
range) and, similarly to their Pt(II) counterparts, the presence of more than one metal centre 
will cause a more severe and less reparable DNA damage, thereby enhancing their anticancer 
activity [135]. 
 It has been shown that Pd(II) complexes are often more efficient than their analogous 
Pt(II) complexes. Some Pd(II) complexes have shown improved antitumour activity against 
different cancer cell lines, coupled to less deleterious side effects (such as nephrotoxicity) and 
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higher efficacy compared to cisplatin and also to their Pt(II) homologues 
[133,169,171,192,195]. Several promising results have also been obtained for the Pd(II) 
counterparts of the polyamines presently studied, specifically for a spermine dinuclear Pd(II) 
chelate [192]. Despite the good antiproliferative effects displayed by several Pd(II) complexes 
both in vitro and in vivo, none of these compounds has yet entered clinical practice [135]. 
 In conclusion, Pd(II) and Pt(II) complexes were developed in order to overcome the 
limitations associated to the classical mononuclear Pt-drugs (such as cisplatin or carboplatin), 
aiming at attaining a higher efficiency, a reduced systemic toxicity, lack of cross resistance, 
enhanced specificity regarding DNA binding and, overall, improved pharmacological 
properties [144,153,156,169-171,190-193]. 
 
 In this work, four Pd(II) or Pt(II)-based chelates containing modified polyamines as 
linkers were synthesised (Fig. 11).  
 
 
 
Figure 11: Structural representation of the Pd(II) and Pt(II) complexes Pd-NSpd, Pt-NSpd, Pd-
BENSpm and Pt-CPENSpm. 
 
C N H Pd / Pt Cl
Pd-NSpd
Pd-BENSpm Pt-CPENSpm
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 1.6.   Spectral Identification and Characterisation by Vibrational Spectroscopy 
 Spectroscopy can be defined as “the study of the interaction of radiation with matter”. 
The name derives from the latin word spectare that means to observe, and it is one of the 
most important experimental techniques for determining the electronic structure of atoms and 
molecules and for obtaining information about the molecular structure and conformation of a 
sample, irrespective of its physical state [197].  
 In order to understand essential processes in life sciences, it is necessary to acquire a 
detailed knowledge underlying these biochemical mechanisms, namely an accurate structural 
information. Since the biological activity of an anticancer agent strongly depends on its 
structure and conformational preferences, along with its chemical characteristics, an accurate 
knowledge of these properties is essential for a better understanding of the biological 
behaviour of this type of therapeutic agents at the molecular level (Structure-Activity 
Relationships – SAR’s) [135,170,190,198]. This can be obtained by a number of modern 
spectroscopic methods, such as vibrational spectroscopy [199].  
  Vibrational spectroscopy is one of the most powerful and useful physical techniques to 
study the molecular structure and conformational preferences of biologically relevant 
compounds [190,200-205]. Vibrational spectroscopy has been used to identify and 
characterise compounds by the study and analysis of its molecular vibrational modes, 
therefore providing important structural evidence within the molecule [206]. It is a fast 
technique that can be applied to solids, liquids, solutions, gases, films or adsorbed species, 
and offers the potential to explore molecular events under conditions closely related to the 
physiological environment. Depending on its geometry, conformation and electronic 
structure, each molecule yields distinctive vibrational spectra that can be measured with the 
help of different methods, such as infrared (IR), Raman or inelastic neutron scattering (INS) 
spectroscopies. From the measured vibrational data it is possible to draw conclusions about a 
compound’s structure, since it can be used as a “fingerprint” of the molecule. Vibrational 
spectroscopy also provides essential information concerning the intramolecular and/or 
intermolecular interactions occurring within the system (namely in condensed phases), and 
the nature and strength of the chemical bonds [206].  
  All spectroscopic techniques work on the principle that, under certain conditions, 
materials can absorb, emit or diffuse energy, upon interaction with the incident radiation 
[197]. However, the diverse spectroscopic techniques refer to different and limited frequency 
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ranges within this broad spectrum, depending on the physical process underlying each 
specific technique. The total energy of a molecule includes the electronic, vibrational, 
rotational and translational levels. The energetic levels of a molecule can be obtained if we 
analyse the respective spectra in different regions of the electromagnetic radiation [207]. The 
electromagnetic spectrum covers all possible frequencies (Fig. 12), ranging from radio waves 
at low energy (capable of inducing nuclear spin transitions), up to X-rays at high energy 
(causing ionisation of the sample). 
 
 
 
Figure 12: Electromagnetic radiation spectrum. 
 
  All electromagnetic waves contain inherent energy expressed and quantised by the 
Planck equation: 
                                                                                                                                                             
 
where h is the Planck constant and ν is the frequency of the electromagnetic wave [207,208]. 
 The different possible vibrations within a molecule are called vibrational modes or 
vibrational degrees of freedom, and are determined by all the different ways the atoms in the 
molecule can move relative to each other (in the x, y, and z directions, corresponding to three 
independent degrees of freedom) [209]. Thus, for a molecule with N atomic nuclei, a linear 
molecule will present a total of 3N-5 vibrational degrees of freedom (or normal vibrational 
modes), while a non-linear one will display 3N-6 such modes. The vibrational degrees of 
freedom and, consequently, the number of molecular vibrations, are then a characteristic of a 
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particular compound and are exclusively determined by the number of atoms in the molecule 
[197,207,208,210]. 
  The simplest model representing the concept of molecular vibrations is a diatomic 
molecule AB with masses mA and mB connected by a massless spring [208,210] (Fig. 13): 
 
 
 
Figure 13: Schematic representation of a diatomic molecule AB. 
 
  The vibrational motion of this diatomic molecule can be approximated by the Hooke’s 
law for a simple harmonic oscillator:  
                                             
 
  
  
 
 
                             
    
       
                                     
 
where k represents the force constant of the oscillator, ν is the vibrational frequency, µ is the 
reduced mass of the oscillator and m is the atomic mass of each atom [208].   
  The two major optical vibrational techniques available are the IR and Raman 
spectroscopies. These are complementary techniques that often give rise to similar spectra and 
aim at determining the chemical functional groups in the analysed sample, but are based on 
different physical mechanisms. Briefly, in IR spectroscopy, the molecules are exposed to a 
continuum radiation in the IR region and those photons that have energies corresponding to 
the frequencies of the normal modes can be absorbed to excite the respective vibrations. In 
Raman spectroscopy, in turn, the vibrational transitions are induced after an inelastic 
scattering of monochromatic light by the molecule, such that the frequency of the scattered 
light is shifted by the frequency of the molecular vibration, thereby providing information 
about the vibrational modes in the system [210]. Therefore, IR spectroscopy is a direct 
absorption process while Raman spectroscopy is a scattering process. 
 For a given compound, absorption- and scattering-induced vibrational transitions may 
display different vibrational band patterns in IR and Raman spectra, respectively, which is an 
additional source of information on the structural and conformational properties of the 
molecule [210]. Vibrations along a molecular bond (change in bond length) are called 
stretching modes (Fig. 14 (A)), while vibrations involving a variation in bond angles are 
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named deformation modes (Fig. 14 (B)). In addition, vibrations corresponding to a free 
rotation over a simple bound within the molecule, and that involve the variation of a dihedral 
angle (defined by four atoms) are called torsional modes. Vibrational modes can be further 
classified as symmetrical or antisymmetrical (depending on its symmetry), in-plane or out-of-
plane and in-phase or out-of-phase (Fig. 14) [208]. 
 
 (A) 
 
 
 (B) 
 
 
Figure 14: Schematic representation of stretching (A) and deformation (B) vibrational modes in a 
molecule (A represent heavy atoms). 
 
  Experimental vibrational bands can be ascribed by comparison with vibrational spectra 
of reference systems (spectroscopic databases). However, a consistent assignment of 
experimental vibrational spectra presently relies on quantum mechanical calculations, capable 
of predicting the vibrational pattern of a molecule with very high accuracy [199-
201,204,205,211,212]. 
 
       1.6.1.    Infrared Spectroscopy 
 In 1800, Sir William Herschel, a famous astronomer and also a musician, discovered 
the IR light [213]. During his studies, Herschel hypothesised that colours themselves could 
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contain different levels of heat. In order to investigate this theory, he exposed a glass prism to 
the sunlight creating a “rainbow”, and measured the temperature of each colour of the 
spectrum thus obtained. Three thermometers were used in the experiment and Herschel 
noticed that the temperature increased from violet to red, being even higher in the region 
beyond the red. This invisible radiation, currently known as IR radiation, was named by 
Herschel as “calorific rays”. In later studies, Herschel also demonstrated that this radiation 
could be absorbed, transmitted, reflected or refracted similarly to the visible light. The 
discovery of IR radiation was of utmost importance in science, since this was the first time 
that a form of light invisible to the eye was identified. From then on, IR spectroscopy was 
developed and IR spectrometers were commercially available since the 1940’s [213-215]. 
These can analyse a large range of samples (gases, liquids, and solids) and measure the 
frequency of IR radiation which is absorbed by the analysed sample [214,215]. An IR 
spectrometer comprises three basic components: radiation source, monochromator, and 
detector.  
 Not all molecular vibrations absorb IR radiation. A sample can only absorb when the 
frequency of the incoming IR beam matches the frequency of the fundamental modes of 
vibration of the molecule and also when there is a net change in dipole moment [215]. In 
general, when this occurs, the bond’s stretching frequency causes absorption of the IR 
radiation and the substance is IR active. If a bond is symmetrically substituted and has a zero 
dipole moment, there will be no absorption of energy and its stretching mode will be absent 
from the IR spectrum – the substance is IR inactive. Smaller changes in the dipole moment 
will give rise to less intense IR bands and vice-versa. Therefore, symmetric molecules will 
have weaker IR active vibrations than antisymmetric compounds [214,215]. 
 The IR spectrum can be divided into three main regions: far-IR (low energy, 
wavenumbers below ca. 400 cm
-1
), mid-IR (400–4000 cm-1) and near-IR (high energy, 4000–
14000 cm
-1
). In the present study, the mid-IR region was used to obtain information on the 
compounds under investigation, since their fundamental molecular vibrations are within this 
region [215,216]. The low frequency vibrational modes (e.g. skeletal vibrations) are 
characteristic of the far-IR region, while the near-IR interval comprises overtones and 
combination bands [213]. 
  Over the last decades, many useful applications using infrared radiation in several 
fields of science have been reported [210,217-223] (Table 3). IR microscopy has been applied 
to analyse the vibrational spectra of the biochemical components of a cell [224]; mid-IR lasers 
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have been widely used in biology, chemistry and medicine since almost most of the molecules 
of importance to medicinal and clinical chemistry have unique spectra or ‘fingerprints’ in this 
specific region [216,225]. Near-IR spectroscopy and IR-imaging have been applied in 
cardiovascular radiology and brain imaging, as well as in cancer diagnosis and therapy 
[220,223,226]. In fact, Fourier-transform infrared spectroscopy (FTIR) has been shown to 
distinguish between normal and cancer cells, thus being an important tool for pathologists in 
clinical applications [227].  
 Table 3 displays the most important advantages and disadvantages of this technique. 
 
Table 3: Main advantages and disadvantages of IR spectroscopy. 
Infrared Spectroscopy 
Advantages Disadvantages 
 Simple sample preparation 
 
 Highly sensitivity technique 
 
 Allows the quantitative determination of 
compounds in mixtures 
 
 
 Analysis of aqueous solutions can be 
difficult to obtain 
 
 With certain IR techniques, the sample 
cannot be recovered 
 
 Background solvent or solid matrix must 
be relatively transparent in the spectral 
region of interest 
 
 
       1.6.2.    Raman Spectroscopy 
 In 1923, the Austrian quantum physicist Adolf Smekel theoretically predicted the 
inelastic scattering of light. However, it was not until 1928 that this phenomenon was 
successfully observed experimentally by the Indian scientist C. V. Raman, and was therefore 
named Raman effect [228]. 
  There are two types of scattered light [208] (Fig. 15): 
 
 
 Rayleigh scattering: the primary scattering process is an elastic scattering event 
resulting in scattered light comprising the same vibrational or rotational energy and 
having the same frequency as the incident light, meaning that no energy transfer 
occurs between the incident and scattered lights at the sample with no frequency 
change observed. In Rayleigh scattering the incident photon is absorbed and the 
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molecule is instantaneously raised into a virtual state. The molecule soon relaxes 
again, emitting a photon with identical frequency and energy to that absorbed, but in a 
random direction. 
 
 Raman scattering: a small proportion of the light is scattered non-elastically and is 
thus associated to a change in frequency, meaning that an energy transfer occurs 
between the incident and scattered lights at the sample.  
 
  Rayleigh scattering is 10
3
 times more intense than the Raman scattering process, 
which is typically a low sensitivity technique. Therefore, an intense and monochromatic 
source of light is usually employed – laser (light amplification by stimulated emission of 
radiation). 
 Raman spectroscopy is based on an inelastic scattering of monochromatic radiation 
and allows the observation of the vibrational modes in a system. It differs from IR 
spectroscopy mainly in that it is based on the scattering of photons by the sample, rather than 
on their absorption [210]. The energy difference between the incident and the scattered light 
corresponds to one or more normal vibrational modes. 
  A simple Raman spectrometer usually consists of four major components: a 
monochromatic excitation source, a sample illumination system (presently a laser) and light 
collection optics, a wavelength selector (spectrophotometer) and a detector. Briefly, after 
irradiating the sample with an intense light source at a specific wavelength (usually in the 
visible, near-IR or near-ultraviolet), the scattered light is collected and sent to a 
monochromator, and finally detected in a photomultiplier tube or a charge coupled device 
(CCD). 
  There are two types of Raman scattering [229] (Fig. 15): 
 
 If the final vibrational state of the molecule is more energetic than the initial one, the 
emitted photon will transfer energy to the sample and will be shifted to a lower 
frequency relative to the incident light (in order to maintain the total energy of the 
system). In this case, the photon raises the molecule from the ground to a virtual state 
and then it drop backs down to a higher energy vibrational state. Therefore, the 
scattered photon has less energy and a longer wavelength than the incident photon. → 
Stokes Raman scattering.  
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 If the final vibrational state is less energetic than the initial state, then the emitted 
photon will catch energy from the sample and will be shifted to a higher frequency. In 
this case, the molecule is in a vibrational excited state to begin with and, after being 
scattered into a virtual state, the molecule returns to its ground state (lower energy 
level). Here, the scattered photon has more energy and a shorter wavelength than the 
incident photon → Anti-Stokes Raman scattering. 
 
 The Stokes and anti-Stokes vibrational pattern are thus the mirror image of each other 
(Fig. 16). Most Raman studies rely on the analysis of the Stokes lines because they are 
significantly more intense than the anti-Stokes ones [229].  
 
 
 
Figure 15: Schematic representation of the vibrational/electronic transitions characteristic of IR 
absorption, Raman and Rayleigh scattering, and fluorescence. 
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Figure 16: Schematic representation of the Rayleigh, Stokes and anti-Stokes lines (adapted from 
[230]). 
 
 In Raman spectroscopy, when the electric field of the incident radiation interacts with 
the sample, a change in the molecular polarisability is induced. A molecular vibration will 
only be Raman active if the vibration that scatters Raman light is accompanied by a change in 
the polarisability of the molecule [207]. This tendency of the electron cloud of a molecule to 
distort from its normal shape is a response to an electric field and determines the Raman 
scattering intensity (Raman activity) [229].  
  Although many approaches have been explored to reduce the fluorescence impact in 
Raman spectroscopy, this is still one of the main limitations of the technique [208,231]. 
Fluorescence is a process that involves excitation of a molecule by absorption of light, from 
the ground electronic state to an excited electronic state, followed by emission without change 
in the sample’s spin state (fluorescence) [208,224]. Typically, fluorescence is a much more 
intense process than Raman scattering. Therefore, when fluorescence occurs (either intrinsic 
to the sample or caused by impurities), it can overrule the Raman features of the analysed 
compound, rendering the acquisition of Raman data very difficult if not impossible. 
Therefore, the continuous search for methods to avoid fluorescence emission is of utmost 
importance. Currently there are several approaches to overcome fluorescence, such as: 
selecting an appropriate laser excitation wavelength that does not allow absorption to take 
place between electronic states d [208,231]; purifying the sample when the fluorescence is 
due to impurities (extrinsic); using low laser intensities and with long integration times in 
order to improve spectral acquisition and minimise fluorescence interference; by means of a 
sensitive CCD device as the detection system [231].  
 Raman spectroscopy can be used to study solid, liquid and gaseous samples and is 
extremely useful for chemical identification and characterisation of molecular structure and 
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conformation (e.g. environment changes) [231]. Since vibrational information is specific to 
the chemical bonds, this spectroscopy provides a molecular fingerprint by which the molecule 
can be identified. 
 In the last years, Raman spectroscopy has been widely applied in a variety of fields 
that include biology [224,233,234], biomedicine [233,235] pharmacology [229,235], drug 
development [229,235], chemistry and biochemistry [208,234,236], forensic sciences [237], 
and medical diagnosis [235], including early detection of cancer [233]. In addition, the 
combination of optical microscopy with Raman scattering – Raman microspectroscopy – has 
proved to be a powerful technique in many areas, namely in clinical oncology applications 
[223,235,238]. This technique discriminates between normal and malignant tissues in 
different types of cancer, through in vivo and in situ observation (chemical imaging), and also 
provides information about the constitution and distribution of cellular components in 
individual living cells [239,240], therefore being an invaluable tool in the early diagnosis of 
cancer. The use of this method overcomes the intrinsic limitation of X-ray diffraction and 
permits the examination of single crystals displaying high signal-to-noise ratio [235].  
 Table 4 contains the main advantages and disadvantages of this technique. 
 
Table 4: Main advantages and disadvantages of Raman spectroscopy. 
Raman Spectroscopy 
Advantages Disadvantages 
 No particular sample preparation is 
required 
 
 Samples can be recovered 
 
 Very small amounts of sample are 
required → allowing to detect and analyse 
trace amounts of sample 
 
 Non-invasive technique (allows in situ 
analysis) 
 
 Allows the analysis of aqueous solutions 
(water hardly interferes) 
 
 Great flexibility of experimental setups  
 
 Sample’s intrinsic fluorescence can 
overrule the Raman spectrum 
 
 An intense laser radiation can harm the 
sample  
 
 Raman effect is very weak → low 
sensitivity  
 
 Raman effect is very weak → highly 
optimised instrumentation and very 
sensitive detectors are needed 
 
 Equipment is expensive 
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Table 4: Main advantages and disadvantages of Raman spectroscopy. (Continuation) 
 Allows the analysis of organic and 
inorganic compounds → the spectral ranges 
can reach very low wavenumbers 
 
 Short time scale: the spectra can be 
acquired very quickly, yielding near-
instantaneous results 
 
 
 
 As described above, IR and Raman are complementary techniques. Usually, vibrations 
yielding intense bands in IR (involving a large dipole moment variation), are weak in Raman. 
Similarly, non-polar functional groups giving rise to strong Raman features typically yield 
weak IR signals.  
 
       1.6.3.    Fourier Transform Spectroscopy 
  Fourier transform (FT) spectrometers were developed to overcome the limitations of 
the dispersive instruments and have been widely used in numerous distinct fields (from 
chemical analysis to pharmacological or even industrial applications) [227,229,241]. This 
type of instrument employs a specific interferometer (Michelson interferometer) and exploits 
the well-established mathematical process of Fourier transformation. In the present study, a 
FT technique was used both for IR and Raman spectroscopies. The FT-Raman technique was 
used to overcome the interference from fluorescence in some of the presently investigated 
samples [213].  
 A simple FT spectrometer usually consists of three basic components: a radiation 
source, an interferometer and a detector. Briefly, the radiation rising from the source is passed 
through an interferometer to the sample, before reaching the detector. The interferometer 
divides the radiant beams, generates an optical path difference between the beams and then 
recombines them in order to produce repetitive interference signals, which will be then 
measured as a function of optical path difference by a detector. Then the data is converted to a 
digital form and transferred to a computer for Fourier transformation [214].  
  The interferometer used in FT spectroscopy is based on the principle of the Michelson 
interferometer that consists of two perpendicular plane mirrors (one movable and one fixed) 
and a beamsplitter, which is a semi-reflecting device (Fig. 17). When the incoming light 
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strikes the beamsplitter, two beams of roughly the same intensity are produced. The 
beamsplitter ideally transmits half of the beams to the fixed mirror and reflects the remaining 
half to the movable mirror. The movable mirror then produces a change in the optical path 
length between the two arms of the interferometer. Afterwards, the divided beams reflected by 
the two mirrors return to the beamsplitter where they recombine and interfere with each other. 
[210]. Due to changes in the relative position of the two mirrors, an interference pattern is 
created. If the distance travelled by the two beams is the same, the recombination will result 
in a constructive interference. If the beam from the movable mirror has travelled a different 
distance than that from the fixed mirror, they will interfere destructively. The reconstructed 
beam then goes through the sample and is focused onto the detector, and an interferogram is 
obtained. This interferogram, that represents the radiation output as a function of time, has the 
unique property that every data point (a function of the movable mirror position) has 
information about every frequency of the light collected from the sample. However, the 
measured interferogram signal cannot be interpreted directly and has to be Fourier 
transformed in order to convert it into a spectrum (intensity as a function of energy) 
[214,215].  
 
 
 
Figure 17: Schematic representation of a Michelson interferometer. 
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  The main advantage of using FT spectroscopy over the dispersive techniques is the 
fact that information is gathered simultaneously for all frequencies, which allows a quick 
collection of the spectra and with a higher signal-to-noise ratio (“multiplex” advantage).  
 
 1.7.   Aims of the Study 
 Disruptions in cellular polyamine homeostasis have long been closely associated with 
proliferative disorders. Thus, depletion of the intracellular polyamine pools through the use of 
polyamine analogues may constitute a promising therapeutic anticancer strategy. In fact, 
several polyamine analogues deplete cells of their natural polyamines, both in vitro and in 
vivo, leading to the retardation of cell growth and, in some cases, initiation of cell death.  
Since the clinical use of cisplatin leads to the occurrence of various side effects and to 
the development of acquired resistance, it is of great relevance to search and test for new 
metal-based antitumour agents, particularly polyamine Pd(II) and Pt(II) chelates that can 
exhibit a higher anticancer activity along with lower deleterious side effects.    
 The main goal of the present work (Fig. 18) was to develop new improved 
antiproliferative agents by combining the recognised antitumour activity of polyamine 
analogues (N-alkylated biogenic amines) with the anticancer properties of Pd(II) and Pt(II) 
complexes. Novel Pd(II) and Pt(II) chelates with polyamine analogues were synthesised and 
their anticancer properties were tested in several human breast cancer cell lines with different 
genetic backgrounds (reflecting different breast cancer sub groups), with a view to consider 
the heterogeneity of breast cancer.  
 The specific aims were: 
 
Section 3.1: 
 To synthesise novel Pd(II) and Pt(II) complexes of the polyamine analogues NSpd, 
BENSpm and CPENSpm.   
 
 To characterise these compounds with respect to their structure and conformational 
behaviour, by vibrational spectroscopy – FTIR and Raman – coupled to quantum 
mechanical calculations. 
 
 To investigate the influence of the structural and conformational preferences of both 
ligands and complexes (e.g. type, number and chemical environment of the metal 
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centre, nature and coordination mode of the ligands) on their biological activity, and 
compare it with previously obtained data for biogenic polyamines and their Pd(II) and 
Pt(II) chelates. 
 
Section 3.2: 
 To assess the cytotoxicity profile, including cytostatic and cytocidal effects, of the 
spermidine analogue NSpd and its newly synthesised trinuclear Pd-NSpd and Pt-NSpd 
complexes in different human breast cancer cell lines and one immortalised normal-
like breast epithelial cell line. 
 
 To determine the effect of the compounds on various aspects of polyamine 
homeostasis. 
 
 To investigate the ability of the compounds to induce DNA damage. 
 
Section 3.3: 
 To determine the cytotoxicity profile, including cytostatic and cytocidal effects, of 
BENSpm, CPENSpm and the Pd-BENSpm, Pt-CPENSpm and Pd-Spm in different 
human breast cancer cell lines and one immortalised normal-like breast epithelial cell 
line. 
 
 To evaluate the effect of the compounds on various aspects of polyamine homeostasis. 
 
 To evaluate the effect of the compounds on CSC and on the ability of treated cells to 
form colonies in soft agar.  
 
 To assess the capacity of the compounds to induce DNA damage. 
 
 To investigate if glutathione may have a role in the cytotoxic profile. 
 
 The results obtained within this study will hopefully allow the development of reliable 
SAR models, which will enable a rational design of new polynuclear Pd(II)- and Pt(II)-
polyamine complexes, with optimised antiproliferative and cytotoxic activities, coupled to 
low toxicity and minimal acquired resistance. 
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Figure 18: Schematic representation of the aims of the study.  
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“Pleasure in the job puts perfection in the work.” “Happiness depends upon ourselves.”  
Aristotle 
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2.  Materials and Methods 
 In this study, a full conformational characterisation of several modified biogenic 
polyamines and their newly synthesised Pd(II) and Pt(II) complexes was performed through 
vibrational spectroscopic techniques (infrared and Raman). Furthermore, their cytotoxic effect 
against human breast cancer cell lines (as well as towards a non-tumourigenic line) was 
evaluated, using several biological methods. The detailed experimental procedures will be 
described in this chapter. 
 
 2.1.   Reagents 
Table 5: List of the reagents used along the study. 
Reagent Supplier 
Synthesis 
Potassium tetrachloropalladate 98% Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Potassium tetrachloroplatinate 
> 99.9% 
Sigma-Aldrich Chemical S.L., Sintra, Portugal 
NSpd trihydrochloride 98% Sigma-Aldrich Chemical S.L., Sintra, Portugal 
BESpm tetrahydrochloride Biogen Cientifica S.L., Madrid, Spain 
BENSpm tetrahydrochloride Dr. Patrick Woster, Charleston, SC, USA 
CPENSpm tetrahydrobromide Dr. Patrick Woster, Charleston, SC, USA 
Pd-Spm complex 
Synthesised at the Molecular Physical-Chemistry 
Research Group, Coimbra University [243], 
Coimbra, Portugal 
Hydrochloric acid 37% Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Sodium hydroxide 99% Sigma-Aldrich Chemical, S.L., Sintra, Portugal 
Acetone  ≥ 99.5% Absolve, Odivelas, Portugal 
Ethanol Absolve, Odivelas, Portugal 
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Table 5: List of the reagents used along the study. (Continuation) 
Cell Culture 
aDMEM/Ham’s F12 medium Biochrom, Berlin, Germany 
b
RPMI medium 1640 Biochrom, Berlin, Germany 
Fetal calf serum Biochrom, Berlin, Germany 
Culture medium components Biochrom, Berlin, Germany 
Aminoguanidine Sigma, Stockholm, Sweden 
Sigma-Aldrich S.A., Sintra, Portugal Cholera toxin Sig a, Stockholm, Sweden 
Epidermal growth factor Invitrogen AB, Stockholm, Sweden 
Insulin Sigma, Stockholm, Sweden 
Hydrocortisone Sigma, Stockholm, Sweden 
Phosphate-buffered saline  Oxoid Ltd., Basingstoke, Hampshire, UK 
Trypsin-EDTA Sigma, Stockholm, Sweden 
MTT Assay 
3-(4,5-dimethyl-thiazolyl-2)-2,5 
Diphenyltetrazolium bromide 
Sigma, Stockholm, Sweden 
Dimethyl sulphoxide  Merck KGaA, Darmstadt, Germany 
Radioactivity-Based Uptake Assay 
Hydrochloric acid  VWR, Stockholm, Sweden 
Sodium hydroxide  VWR, Stockholm, Sweden 
Spermidine trihydrochloride (
3
H-
Spd) 
PerkinElmer, Boston, MA, USA 
Enzyme Activity Assays 
L-[1-
14
C]Ornithine New England Nuclear, DuPont, Scandinavia AB, 
Stockholm, Sweden Dithiothreitol Sigma, Stockholm, Sweden 
Pyridoxal-5-phosphate Sigma, Stockholm, Sweden 
14
[C]Acetyl-coenzyme A 
New England Nuclear, DuPont, Scandinavia AB, 
Stockholm, Sweden 
Spermidine Sigma, Stockholm, Sweden 
Sucrose VWR, Stockholm, Sweden 
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Table 5: List of the reagents used along the study. (Continuation) 
Polyamine Analysis 
Perchloric acid Merck, Stockholm, Sweden 
θ-Phthalaldehyde Sigma, Stockholm, Sweden 
Flow Cytometry 
Nonidet P-40 VWR, Lund, Sweden 
Propidium iodide  Sigma , Stockholm, Sweden 
Ribonuclease A  Sigma , Stockholm, Sweden 
Bromodeoxyuridine DAKO Cytomation Denmark A/S, Glostrup, 
Denmark Primary monoclonal antibody against 
BrdUrd (M744) 
Dakopatts, Glostrup, Denmark 
Secondary fluorescein isothiocyanate 
(FITC)-conjugated antibody (F313) 
Dakopatts, Glostrup, Denmark 
Accutase Sigma, Stockholm, Sweden 
Antibody against CD24-
phycoerythrin (PE)  
Becton Dickinson, Stockholm, Sweden 
Antibody against CD44-FITC Becton Dickinson, Stockholm, Sweden 
PE-conjugated mouse 
immunoglobulin 1 (IgG1) 
Becton Dickinson, Stockholm, Sweden 
FITC-conjugated mouse IgG1  Becton Dickinson, Stockholm, Sweden 
Colony Forming Efficiency Assay 
Agarose FMC BioProducts, Rockland, ME, USA 
Poly(2-hydroxyethyl methacrylate)  Sigma, Stockholm, Sweden 
Formaldehyde VWR, Stockholm, Sweden 
Intracellular Metal Accumulation 
Nitric acid  VWR, Stockholm, Sweden 
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Table 5: List of the reagents used along the study. (Continuation) 
Comet Assay 
Agarose gel supporting medium FMC BioProducts, Rockland, ME, USA 
Nusieve
®
 GTG low-melting-point 
agarose 
FMC BioProducts, Rockland, ME, USA 
Ethidium bromide  Sigma, Stockholm, Sweden 
GSH-Glo™ Glutathione Assay 
GSH-Glo
™
 Glutathione kit Promega Biotech AB, Nacka, Sweden 
Western Blot 
Bromophenol blue VWR, Stockholm, Sweden 
Glycerol VWR, Stockholm, Sweden 
Sodium dodecyl sulfate VWR, Stockholm, Sweden 
β-Mercaptoethanol VWR, Stockholm, Sweden 
NuPAGE
®
 MOPS running buffer Invitrogen Corporation, Carlsbad, California, USA 
NuPAGE
®
 antioxidant Invitrogen Corporation, Carlsbad, California, USA 
Magic Marker
™
 XP standard Invitrogen Corporation, Carlsbad, California, USA 
Sea Blue
® 
Pre-stained standard Invitrogen Corporation, Carlsbad, California, USA 
Antizyme inhibitor antibody Dr. Senya Matsufuji, Tokyo, Japan 
Horseradish peroxidase-conjugated 
goat anti-mouse antibody (P0447)  
DAKO Cytomation Denmark A/S, Glostrup, 
Denmark 
Enhanced Chemiluminescence
®
 
nitrocellulose membranes 
GE Healthcare, Buckinghamshire, United Kingdom 
Tween
®
 20 Sigma, Stockholm, Sweden 
Enhanced Chemiluminescence
™
 
Advanced Blotting Detection Kit 
GE Healthcare, Buckinghamshire, United Kingdom 
a
Culture medium used for JIMT-1 cells. 
b
Culture medium used for L56Br-C1, MCF-7, MDA-MB-231 and MCF-10A cells. 
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 2.2.   Equipment 
 
Table 6: List of the equipment used along the study. 
Equipment Supplier 
Synthesis  
AB54-S/FACT Analytical Balance  Mettler Toledo, Switzerland 
pH-meter BASIC 20
+
 Crison Instruments, Barcelona, Spain 
E2M2 High Vacuum Pump 2 stage Edwards, Sussex, England 
Cell Culture 
c
Class II Safety Cabinet Biowizard 
(BW)-100 
Kojair Tech Oy, Vilppula, Finland 
d
Class II Biological Safety Cabinet ESCO, Wiltshire, England 
c
MCO-19A Incubator
 
Sanyo Electric Co. Ltd., Japan 
d
Heraeus HERAcell 150 Incubator Thermo Scientific, Stockholm, Sweden 
c
NE1B-14 Water bath
 
Clifton, England 
d
GFL-1083 Shaking Water bath GFL, Manchester, United Kingdom  
c
Olympus CKX41 Microscope with 
an Olympus DP20-5E Digital 
Camera coupled 
Olympus Optical Co. Ltd., Japan 
d
Olympus CKX41 Microscope with 
an Olympus SC30 Digital Camera 
coupled 
Olympus Optical Co. Ltd., Japan 
c
MPW-350R Centrifuge
 
MPW Medical Instruments, Poland 
d
Heraeus Megafuge 16 Centrifuge Thermo Fisher Scientific, Gothenburg, Sweden 
MTT Assay 
d
Labsystems iEMS Reader MF Labsystems Oy, Helsinki, Finland 
Radioactivity-Based Uptake Assay 
Tri-Carb 2800TR Liquid 
Scintillation Counter 
PerkinElmer, Sweden 
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Table 6: List of the equipment used along the study. (Continuation) 
Enzyme Activity Assays 
Sonicator Optilab Instruments AB, Stockholm, Sweden 
Tri-Carb 2800TR Liquid 
Scintillation Counter 
PerkinElmer, Sweden 
Polyamine Analysis 
Hewlett Packard 1100 series HPLC 
system 
Agilent Technologies Sweden AB, Kista, Sweden 
Flow Cytometry 
Ortho Cytoron Absolute Flow 
Cytometer 
Ortho Raritan, NJ, USA 
Accuri C6 Flow Cytometer BD Biosciences , San Jose, CA, USA 
Intracellular Metal Accumulation 
Thermo X7 Mass Spectrometer Thermo Elemental, Winsford, UK 
Comet Assay 
Electrophoresis device Invitrogen Corportation, Carslbad. CA, USA 
Olympus AX70 Fluorescence 
Microscope 
Olympus Optical Co Ltd., Japan 
Olympus DP50 Digital Camera Olympus Optical Co Ltd., Japan 
GSH-Glo™ Glutathione Assay 
Labsystems iEMS Reader MF Labsystems Oy, Helsinki, Finland 
Western Blot 
Xcell Sure Lock
™
 Mini-cell system Invitrogen Corporation, Carlsbad, CA, USA 
iBlot
™
 Dry Blotting system Invitrogen Corporation, Carlsbad, CA, USA 
ChemiDoc XRS system Bio-Rad Laboratories Inc., Hercules, CA, USA 
c“Molecular Physical-Chemistry Research Unit”, University of Coimbra, Portugal. 
d
Biology Department, University of Lund, Sweden. 
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 2.3.   Synthesis 
 The synthesis of Pd(II) and Pt(II) complexes with polyamine analogues, one of the 
goals of this work, was performed according to optimised procedures based on previously 
reported methods for similar compounds, namely the synthesis of Pt(II) and Pd(II) chelates of 
natural polyamines [176,244].  
 The modified polyamines used were the symmetrically (BENSpm) or unsymmetrically 
(CPENSpm) substituted spermine analogues and the alkylpolyamine NSpd (Fig. 4). The 
corresponding chelates were (PdCl2)3(NSpd)2 (abbreviated Pd-NSpd), (PtCl2)3(NSpd)2 
(abbreviated Pt-NSpd), (PdCl2)2(BENSpm) (abbreviated Pd-BENSpm), (PtCl2)2(CPENSpm) 
(abbreviated Pt-CPENSpm) (Fig. 10) and (PdCl2)2(Spm) (abbreviated Pd-Spm). 
 
       2.3.1.    Palladium Complexes 
 Two mmol of K2PdCl4 were dissolved in a minimal amount of water and an aqueous 
solution containing 3 or 1 mmol of the ligand (NSpd or BENSpm, respectively) was added 
dropwise, under continuous stirring, in the dark. The pH was then adjusted to approximately 8 
(with 1 M HCl for the NSpd chelate and 1 M NaOH for the BENSpm complex). Upon stirring 
for about 5 to 6 h, followed by overnight rest, a yellow powder of the complex was obtained. 
This powder was filtered, washed repeatedly with cold acetone and ethanol and dried under 
vacuum. Yield: 81.2% and 88.6% for Pd-NSpd and Pd-BENSpm, respectively. 
 The Pd-Spm complex was previously synthesised [170] and kindly provided by S. M. 
Fiuza from the “Molecular Physical-Chemistry” Research Unit of the University of Coimbra, 
Portugal. 
 
 [(PdCl2)3-(norspermidine)2] – Pd-NSpd  
 
3 K2PdCl4 (aq) + 2 H2N(CH2)3NH(CH2)3NH2 (aq) →                                                   (2.1) 
→ [Pd3(H2N(CH2)3NH(CH2)3NH2)2Cl6] (s) + 6 KCl (aq) 
 
 [(PdCl2)2-(N
1
,N
11
-diethylnorspermine)] – Pd-BENSpm  
 
2 K2PdCl4 (aq) + C2H5NH(CH2)3NH(CH2)3NH(CH2)3NHC2H5 (aq) →                       (2.2) 
→ [Pd2Cl4(C2H5NH(CH2)3NH(CH2)3NH(CH2)3NHC2H5)] (s) + 4 KCl (aq) 
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       2.3.2.    Platinum Complexes 
 A solution containing 3 or 1 mmol of the ligand (NSpd or CPENSpm, respectively) 
was added dropwise to an aqueous solution containing 2 mmol of K2PtCl4, under continuous 
stirring, in the dark. The pH was then adjusted to approximately 8 and 12, respectively for the 
NSpd and CPENSpm chelates (with 1 M HCl and 1 M NaOH). Upon stirring for about 5 to 6 
h, followed by overnight rest, a white-yellow powder of the complex was obtained. This 
powder was filtered, washed repeatedly with cold acetone and ethanol and dried under 
vacuum. Yield: 45.7% and 66.3% for Pt-NSpd and Pt-CPENSpm, respectively.  
 
 [(PtCl2)3-(norspermidine)2] – Pt-NSpd  
 
3 K2PtCl4 (aq) + 2 H2N(CH2)3NH(CH2)3NH2 (aq) →                                                    (2.3) 
→ [Pt3(H2N(CH2)3NH(CH2)3NH2)2Cl6] (s) + 6 KCl (aq) 
 
 [(PtCl2)2-(N
1
-cyclopropyl-methyl-N
11
-ethylnorspermine)] – Pt-CPENSpm  
   
2 K2PtCl4 (aq) + C2H5NH(CH2)3NH(CH2)3NH(CH2)3NHC4H7 (aq) →                        (2.4) 
→ [Pt2Cl4(C2H5NH(CH2)3NH(CH2)3NH(CH2)3NHC2H5)] (s) + 4 KCl (aq) 
 
 2.4.   Characterisation of the Complexes 
 The complexes were first fully characterised by elemental analysis, carried out at the 
Central Analysis Laboratory and Chemistry Department (Mass Spectrometry Laboratory) of 
the University of Aveiro, Portugal (C, N and H analysis), and at the Elemental Analysis 
Laboratory of the University of Santiago de Compostela, Spain (Pt and Pd analysis).  
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Table 7: Elemental analysis results for the complexes Pd-NSpd, Pt-NSpd, Pd-BENSpm and Pt-
CPENSpm. 
 Experimental (%) Calculated (%) 
Complex C H N Pd / Pt C H N Pd / Pt 
Pd-NSpd 18.10 4.20 10.32 39.90 18.14 4.32 10.58 40.18 
Pt-NSpd 13.33 3.16 7.89 55.01 13.6 3.24 7.92 55.19 
Pd-BENSpm 25.88 5.10 9.13 35.25 26.06 5.39 9.36 35.52 
Pt-CPENSpm 22.03 4.12 6.77 48.10 22.45 4.28 6.98 48.62 
  
Full identification of the complexes was carried out by vibrational analysis, using both 
FTIR and FT-Raman spectroscopies, clearly evidencing the presence of the bands 
characteristic of these particular metal-polyamine chelates. 
 
 2.5.   FTIR Spectroscopy 
 The FTIR spectra were recorded at room temperature in a Bruker Optics Vertex 70 
FTIR spectrometer, in the range 400–4000 cm-1, using KBr discs (ca. 2% (w/w)), a KBr 
beamsplitter and a liquid nitrogen-cooled Mercury Cadmium Telluride (MCT detector). The 
spectra were collected for ca. 75 scans, with a 2 cm
-1
 resolution. The errors in wavenumbers 
were estimated to be less than 1 cm
-1
. 
 
 2.6.   Raman Spectroscopy 
 The Raman spectra were obtained for the pure compounds, at room temperature, in a 
triple monochromator Jobin-Yvon T64000 Raman system (focal distance 0.640 m, aperture 
f/7.5) equipped with holographic gratings of 1800 grooves.mm
-1
. The premonochromator 
stage was used in the subtractive mode. The detection system was a liquid nitrogen cooled 
non-intensified 1024x256 pixel (1") CCD chip. 
 The 514.5 nm line of an Ar
+
 laser (Coherent, model Innova 300-05) was used as the 
excitation radiation, providing ca. 90 mW at the sample position. A 90º geometry between the 
incident radiation and the collecting system was employed. The entrance slit was set to 200 
m, as well as the slit between the premonochromator and the spectrograph. Samples were 
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sealed in Kimax glass capillary tubes of 0.8 mm inner diameter. Under the above mentioned 
conditions, the error in wavenumbers was estimated to be within 1 cm
-1
. 
 FT-Raman spectra were obtained at room temperature in a RFS 100/S Bruker 
spectrophotometer. The 1064 nm line provided by a Nd:YAG laser was used, yielding 200 
mW at the sample position. Resolution was set at 2 cm
-1
 and a 180
o
 geometry was employed. 
 
 2.7.   Quantum Mechanical Calculations 
 The quantum mechanical calculations were performed using the GAUSSIAN 03W 
program [245] within the Density Functional Theory (DFT) approach. The widely employed 
hybrid method denoted by B3LYP, which includes a mixture of HF and DFT exchange terms 
and the gradient-corrected correlation functional of Lee, Yang and Parr [246,247], as proposed 
and parameterised by Becke [248,249] was used, along with the double-zeta split valence 
basis set 6-31G** [250]. 
 Molecular geometries were fully optimised by the Berny algorithm, using redundant 
internal coordinates [251]: The bond lengths to within ca. 0.1 pm and the bond angles to 
within ca. 0.1º. The final root-mean-square (rms) gradients were always less than 3x10
-4
 
hartree.bohr
-1
 or hartree.radian
-1
. No geometrical constraints were imposed on the molecules 
under study. 
 The harmonic vibrational wavenumbers, as well as the Raman activities and infrared 
intensities, were also obtained, at the same theory level as the geometry optimisation 
procedure. The widely employed scale factors of Merrick et al. [252] were used for 
wavenumbers above 600 cm
-1
, leading to a quite good agreement between theoretically 
predicted and experimental frequencies. 
 
 2.8.   Stock Solutions 
 Stock solutions (2 mM) of the polyamine analogues NSpd, BENSpm and CPENSpm 
were made by dissolving each compound in phosphate-buffered saline (PBS: 8 g/L NaCl, 0.2 
g/L KCl, 1.15 g/L Na2HPO4, 0.2 g/L KH2PO4, pH 7.3), followed by sterile-filtration and 
storage at 4°C.  
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 Stock solutions of the complexes Pd-NSpd (2 mM), Pt-NSpd (2 mM), Pd-BENSpm (1 
mM), Pd-Spm (1 mM) and Pt-CPENSpm (2 mM) were prepared by dissolving the compounds 
in 4% dimethyl sulphoxide (DMSO) in PBS, followed by sterile-filtration and storage at -
20°C.  
 Further dilutions of these stock solutions were made in complete cell culture medium, 
in order to obtain the final concentrations required for the biological assays. In all the 
experiments performed with NSpd, Pd-NSpd and Pt-NSpd, aminoguanidine (1 mM) was 
added to the culture medium with the view to inhibit the activity of the polyamine oxidase 
present in the fetal calf serum (FCS). In all the experiments, the highest concentration of 
DFMO used in the cell for both control and treated samples was 0.2%. 
 
 2.9.   Cell Lines and Cell Culture Conditions 
 Four human breast cancer cell lines and one immortalised normal-like breast epithelial 
cell line were tested in the present work. The cell lines were cultured as monolayers at 37°C 
in a humidified incubator with 5% CO2 in air. The MCF-10A, JIMT-1 and MDA-MB-231 cell 
lines were sub-cultured twice a week, while the L56Br-C1 and MCF-7 cells were sub-cultured 
once a week with an additional change of growth medium once a week. 
 
       2.9.1.    JIMT-1 
The human ductal carcinoma breast cancer cell line JIMT-1 was isolated from the 
pleural effusions of a 62-year old breast cancer female patient presenting clinical and intrinsic 
resistance to trastuzumab, the first immunotherapeutic drug used for breast cancer treatment 
[253]. It was purchased from the German Collection of Microorganisms and Cell Cultures, 
DSMZ, Braunschweig, Germany. 
JIMT-1 cells (Fig. 19) show an epithelial-like morphology and have mutated p53. This 
cell line is classified as HER-2 positive since it has an amplification of the HER-2 oncogene, 
however it is insensitive to HER-2-inhibiting drugs. JIMT-1 is the only cell line used in this 
study displaying HER-2 overexpression [253-255]. JIMT-1 cells were cultured in 
DMEM/Ham’s F12 medium supplemented with 10% FCS, non-essential amino acids (1 mM), 
insulin (10 µg/ml), penicillin (100 U/ml) and streptomycin (100 µg/ml). The JIMT-1 cell line 
has a population doubling time of approximately 24 h. 
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Figure 19: Phase contrast image of JIMT-1 cells, after 48 h of seeding. 
 
       2.9.2.    L56Br-C1 
 The human breast adenocarcinoma cell line L56Br-C1 was derived from the human 
tumour xenograft L56Br-X1 that originated (in the 1990s) from the mammary lymph node 
metastasis of a 53-year old Swedish Caucasian female carrying a BRCA1 germ-line mutation, 
one of the most commonly detected alterations in hereditary breast cancer [256]. It was 
established at the Department of Oncology, Clinical Sciences, Lund University, Sweden.   
 L56Br-C1 cells (Fig. 20) have a somatic p53 mutation and possess no wild type 
BRCA1 allele [256,257]. A highly distinctive characteristic of these cells is the spontaneous 
occurrence of about 10 to 20% cell death by apoptosis. L56Br-C1 cells were maintained in 
RPMI 1640 medium supplemented with 10% heat-inactivated FCS, non-essential amino acids 
(1 mM), insulin (10 µg/ml), penicillin (100 U/ml), streptomycin (100 µg/ml) and sodium-
pyruvate (1 mM). The L56Br-C1 cell line has a population doubling time of approximately 32 
h.  
 
 
 
Figure 20: Phase contrast image of L56Br-C1 cells, after 48 h of seeding. 
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       2.9.3.    MCF-7 
 The human epithelial breast adenocarcinoma cell line MCF-7 was isolated from a 
pleural effusion of a 69-year old Caucasian female in 1970 [258]. It was purchased from the 
American Type Culture Collection, Manassas, VA, USA. 
 MCF-7 cells (Fig. 21) have a wild type p53 protein and lack normal expression of 
caspase-3 mRNA and protein due to a gene deletion. No DNA laddering occurs in these cells 
when apoptosis is induced. MCF-7 is the only estrogen receptor positive breast cancer cell 
line used in this study [259-261]. MCF-7 cells were maintained in RPMI 1640 medium 
supplemented with 10% FCS, non-essential amino acids (1 mM), insulin (10 µg/ml), 
penicillin (100 U/ml) and streptomycin (100 µg/ml). The MCF-7 cell line has a population 
doubling time of approximately 34 h. 
 
 
 
Figure 21: Phase contrast image of MCF-7 cells, after 48 h of seeding. 
 
       2.9.4.    MDA-MB-231 
The human epithelial breast adenocarcinoma cell line MDA-MB-231 was established 
in 1973 from a pleural effusion of a 51-year old Caucasian female patient with invasive ductal 
breast cancer [262]. It was purchased from the American Type Culture Collection, Manassas, 
VA, USA. 
MDA-MB-231 cells (Fig. 22) have mutated p53 and express the WNT7B oncogene 
[263,264]. These cells were grown and maintained in RPMI 1640 medium supplemented with 
10% FCS, non-essential amino acids (1 mM), insulin (10 µg/ml), penicillin (100 U/ml), 
streptomycin (100 µg/ml) and sodium pyruvate (1 mM). The MDA-MB-231 cell line has a 
population doubling time of approximately 28 h. 
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Figure 22: Phase contrast image of MDA-MB-231 cells, after 48 h of seeding. 
 
       2.9.5.    MCF-10A 
 MCF-10A is a spontaneously transformed normal-like breast epithelial cell line 
originating from a fibrocystic mammary gland tissue of a 36-year old female with no family 
history of breast malignancy [265]. It was obtained from the American Type Culture 
Collection, Manassas, VA, USA. 
 MCF-10A cells (Fig. 23) have wild type p53 and do not form tumours in nude mice 
[265,266] nor do they form colonies in soft agar. MCF-10A cells were maintained in RPMI 
1640 medium supplemented with 10% heat-inactivated FCS, non-essential amino acids (1 
mM), insulin (10 µg/ml), penicillin (100 U/ml), streptomycin (100 µg/ml), epidermal growth 
factor (20 ng/ml), cholera toxin (50 ng/ml) and hydrocortisone (500 ng/ml). The MCF-10A 
cell line has a population doubling time of approximately 15 h. 
 
 
 
Figure 23: Phase contrast image of MCF-10A cells, after 48 h of seeding. 
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 2.10.   Cell Proliferation Studies 
 Cell proliferation can be defined as the increase in the number of viable cells as a 
result of growth and division and may be determined by direct cell counting using a 
hemocytometer. In this thesis, in vitro cell proliferation experiments have been carried out. To 
determine the effect of the compounds under study on cell proliferation, two types of growth 
curve experiments were set up.  
 
       2.10.1.    One Treatment Cycle 
 Cells were seeded in a number of Petri dishes (5 cm diameter) at a density of 0.3 x 10
6 
cells/Petri dish (MCF-10A) or 0.6 x 10
6 
cells/Petri dish (JIMT-1, L56Br-C1 and MCF-7) and 
were allowed to attach and grow for 24 h, prior to the addition of the test compounds to a 
given concentration based on earlier studies, and also on information regarding clinically 
feasible doses. In each experiment, the number of Petri dishes seeded with cells was at least 
so many to be able to harvest cells in at least three for each treatment at each time point. After 
seeding, the cells in each Petri dish were treated independently. For NSpd, Pd-NSpd and Pt-
NSpd two different concentrations were tested: 25 µM and 100 µM, while for BENSpm, Pd-
BENSpm, CPENSpm, Pt-CPENSpm and Pd-Spm a concentration of 10 µM was used. 
Twenty-four, 48 or 72 h after seeding, the cells were harvested by trypsinisation and counted 
in a hemocytometer, and the data were used to draw growth curves. 
 
       2.10.2.    Repeated Treatment Cycles 
 One of the goals in cancer treatment is to kill the cancer cells, while the normal cells 
should be reversibly damaged. In cancer therapy, patients are treated with repeated cycles of 
chemotherapeutic drugs, to give time for normal cells to recuperate. 
 The repeated treatment experiments were aimed at investigating the extension of 
damage caused by this type of therapeutic scheme, and the ability of the cells to recover after 
each treatment. Cells were seeded in a number of 25 cm
2
 cell culture flasks in 5 ml of medium 
at a density of 0.3 x 10
6 
cells/25cm
2
 flask (MCF-10A) or 0.7 x 10
6 
cells/25cm
2
 flask (JIMT-1, 
L56Br-C1 and MCF-7) and were allowed to attach and grow for 24 h, prior to addition of the 
test compounds at the desired concentrations (25 µM for NSpd, Pd-NSpd or Pt-NSpd and 10 
µM for BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm). In each experiment, 
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the number of flasks seeded with cells was at least so many to be able to harvest at least three 
for each treatment at each time point. After seeding, the cells in each flask were treated 
independently. After 72 h of treatment, the medium was removed and new fresh culture 
medium was added to the vessels. The cells were harvested by trypsinisation, counted in a 
hemocytometer and reseeded at the same density as before, 72 h after removal of the drugs. 
Cells were cultivated in cycles using the same treatment procedure, resulting in a long total 
treatment time of 5 cycles (35 days). The data are presented as the total amount of cells that 
theoretically would have accumulated if all cells had been reseeded with a known cell density 
after the end of each treatment cycle. Thus, by using the cell number obtained at each passage 
of a culture seeded with a known cell density, it was possible to calculate the number of cells 
that would have been obtained if all cells were reseeded at a lower density at each passage.  
 
 2.11.   Dose Response Assay – MTT Assay 
 The MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) 
colorimetric assay was established by Mosmann in 1983 [267]. It is based on the reduction of 
the soluble yellow tetrazolium salt MTT (Fig. 24) into insoluble purple formazan crystals, by 
mitochondrial NADH-dependent dehydrogenases of metabolically active cells. The amount of 
formazan formed reflects the cell’s metabolic activity, and is assumed to be directly 
proportional to the number of viable cells. An alteration in cell number results in a 
concomitant change in the amount of formazan formed, indicating the degree of cytotoxicity 
caused by the test compound. This is an easy, rapid, convenient, reliable and economic 
method for obtaining dose response data when treating cells with a wide concentration range 
of a compound [267-269]. 
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Figure 24: Molecular structure of 3-[4,5-Dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide 
(MTT). 
 
 In the present study, the MTT assay was performed as previously described [112]. 
Briefly, cells were trypsinised, counted in a hemocytometer, pelleted and resuspended in cell 
culture medium. Aliquots of 180 µl cell suspension containing 3000 (MCF-10A), 5000 
(JIMT-1) or 8000 (L56Br-C1 and MCF-7) cells were seeded in 96-well plates and the 
compounds to be tested were added 24 h later. At 24, 48 and 72 h of drug treatment, 20 µl of 
MTT solution (5 mg/ml in PBS) was added to the cell culture medium of each well. After 
incubation with MTT for 1 h, the MTT containing medium was removed and DMSO was 
added to each well to dissolve the purple formazan crystals formed by reduction in live 
attached cells. The plates were swirled gently at room temperature for 10 minutes to dissolve 
the precipitate. Absorbance was measured at 540 nm using a Labsystems iEMS Reader MF 
and the software DeltaSoft II v.4.14 (Biometallics Inc., Princeton, NJ, USA) was used for data 
analysis. The results are presented as percentage of control. 
 
 2.12.   Methods to Study Polyamine Metabolism 
 Polyamines are essential for eukaryotic cell proliferation and differentiation. 
Polyamine levels have to be maintained within very narrow limits because a decrease in their 
intracellular concentrations inhibits cell proliferation while an excess of polyamines appears 
to be toxic. Therefore, polyamine metabolism has to be controlled by the use of four different 
mechanisms: de novo synthesis, catabolism and transport (cellular uptake and efflux) [64].  
 In this thesis, polyamine metabolism was evaluated using radio-labelling and 
enzymatic assays and also by measuring the intracellular polyamine content.  
Br -
 Tânia M. Silva 
___________________________________________________________________________ 
 
78 
 
       2.12.1.    Radioactivity-Based Uptake Assay 
 The uptake of extracellular polyamines and export of intracellular polyamines are 
known to be well-regulated events in cells. Most cells seem to have a single transporter with 
different affinities instead of specific ones for putrescine, spermidine or spermine since other 
polyamines, like cadaverine and homospermidine, can also use the same transporter [87].  
 The present assay was set up to determine the capacity of the compounds under study 
to competitively inhibit 
3
H-spermidine uptake in the normal-like and in the breast cancer cell 
lines (Fig. 25). Cells (0.1 x 10
6
 cells per well) were seeded in replicates into 1.5 ml of medium 
in 12-well plates. Forty-eight h later, the medium was removed and 1 ml new medium 
containing 2% FCS, 1 µM 
3
H-spermidine (0.5 Ci/mmol) and NSpd, Pd-NSpd or Pt-NSpd (0 – 
10 mM) was added to the wells. After an incubation period of 30 minutes at 37°C, the cells 
were washed three times with PBS, followed by addition of 200 µl NaOH (1 M) with gentle 
shaking of the plates. The cells were again incubated for 1 h, followed by addition of 200 µL 
HCl (1.5 M) to each well. After gentle swirling of the plates, the radioactivity was measured 
in an aliquot using scintillation counting. The results are presented as a percentage of the 
control. 
 
 
 
Figure 25: Schematic representation of the radioactivity-based uptake assay.  
Incubation for 48 h
Cell seeding Addition of new medium + 3H-Spd + drug
• 37 C
• 5% CO2 in air
Incubation
for 30 min
 Washing with PBS
 Addition of NaOH
Incubation for 1 h
 HCl addition
 Radioactivity measurement and Data analysis
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       2.12.2.    Enzyme Activity Assays 
 The activity of the biosynthetic enzyme ODC and of the catabolic enzyme SSAT can 
be measured by using radioactively-labelled precursors. The labelled end products are 
captured and quantified by liquid scintillation counting [270]. 
 
  2.12.2.1.    ODC activity  
 ODC is the first rate-limiting enzyme in polyamine biosynthesis and its activity is 
closely related to cell proliferation. The measurement of ODC activity can be very useful in 
clinical oncology since the ODC activity can be affected by treatment with different 
substances that deplete the intracellular polyamine pools [76].  
 To determine the ODC activity, cells were seeded as described for the proliferation 
assay. After 24, 48 and 72 h of treatment with 25 µM NSpd, Pd-NSpd or Pt-NSpd, cells were 
collected, counted in a hemocytometer, pelleted and stored at -80°C until analysis. Samples 
were then sonicated in ice-cold Tris-HCl (0.1 M, pH 7.5) containing EDTA (0.1 mM) and 
dithiothreitol (2.5 mM). ODC activity of the sonicates was determined by measuring the 
release of 
14
CO2 from carboxyl-labelled L-ornithine in the presence of saturating levels of 
pyridoxal 5-phosphate (0.1 mM) and L-ornithine (0.2 mM) [271]. The corresponding 
radioactivity was detected using a liquid scintillation counter. The ODC level is expressed as 
nmoles/10
6
 cells. 
 
  2.12.2.2.    SSAT activity 
SSAT is the rate-limiting enzyme of the polyamine catabolic pathway, being involved 
in the conversion of spermine and spermidine back to putrescine. SSAT can be readily 
detected after induction of polyamine catabolism when cells are treated with polyamine 
analogues. Earlier studies have shown that overexpression of SSAT can been found in several 
human tumour cell types treated with specific antineoplastic polyamine analogues [272,273]. 
To determine the SSAT activity, L56Br-C1 cells were seeded as described for the 
proliferation assay. After 24 h of treatment with 10 µM BENSpm, Pd-BENSpm, Pd-Spm, 
CPENSpm or Pt-CPENSpm, cell were collected, counted in a hemocytometer, pelleted and 
stored at -80°C until analysis. Samples were then sonicated in Tris-HCl (50 mM, pH 7.5) 
containing sucrose (0.25 M). SSAT activity of the sonicates was determined by measuring the 
 Tânia M. Silva 
___________________________________________________________________________ 
 
80 
 
synthesis of 
14
[C]acetylspermidine after incubation of total cell extracts with 
14
[C]acetyl-
coenzyme A and spermidine. The 
14
[C]acetylspermidine formed by active SSAT was captured 
on filter discs. The corresponding radioactivity was detected using a liquid scintillation 
counter [270]. The SSAT level is expressed as nmoles/10
6
 cells. 
 
       2.12.3.    Polyamine Analysis 
 Measurements of biogenic polyamines, polyamine analogues or their metabolites in 
tissues, cells or body fluids are of utmost importance in biochemistry, biology and oncology 
[274]. The intracellular polyamine levels are tightly regulated and can be affected by 
treatment with different substances.  
 In this study, high-performance liquid chromatography (HPLC) was used to measure 
the polyamine levels in cell extracts. HPLC is a chromatographic technique that uses a liquid 
mobile phase to separate components in a sample through the use of a higher pressure that 
pushes the solvent through the column, allowing the establishment of chemical or physical 
interactions between the sample and the chromatography column.  
 L56Br-C1 cells for polyamine analysis were seeded as described for the proliferation 
assay. After 24 h of treatment with 10 µM BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or 
Pt-CPENSpm, cells were collected, counted in a hemocytometer, pelleted and stored at -20°C 
until analysis. The cells were then sonicated in perchloric acid (0.2 M), kept at 4°C over night 
to precipitate proteins, and then the samples were centrifuged. After centrifugation, the 
polyamines were found in the supernatant. Finally, chromatographic separation and 
quantitative determination of these polyamine pools in breast cancer cell extracts were carried 
out by HPLC using θ-phthaldialdehyde as the reagent [275]. The polyamine levels are 
expressed as nmoles/10
6
 cells. 
 
 2.13.   Methods using Flow Cytometry 
 Flow cytometry (FCM) is a method used to measure properties of single cells, by 
suspending them in a stream of rapidly moving fluid that allows the cells to pass one by one 
through a laser beam. Depending on the granularity of the cells, the laser light will scatter 
differently. If any fluorescent molecules are present in the cells, they will be able to emit light 
after laser excitation. Detectors will pick up both scattered and emitted light. Then, by passing 
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them through an electronic detection apparatus, information on the physical and chemical 
structure of each individual cell can be provided and analysed in the form of histograms. In 
this study, the results obtained with FCM were used to analyse cell cycle phase distribution, 
cell death and cell cycle kinetics and to identify cell surface markers. 
 
       2.13.1.    Cell Cycle Phase Distribution and Cell Death Analysis  
 The cell cycle involves a complex sequence of events that include cell growth, genome 
duplication and mitosis. The DNA distribution of a cell population provides important 
information about the cell cycle phase distribution and cell death. FCM was applied to 
investigate the effects of the tested compounds on the cell cycle phase distribution and on the 
induction of cell death. For the investigation of cell death, both attached and suspended (dead 
or dying cells floating in the medium) cells were harvested together.  
 Cells were seeded as described for the proliferation assay and then allowed to attach 
and grow for 24 h, prior to addition of the test compounds at the desired concentrations (25 or 
100 µM for NSpd, Pd-NSpd or Pt-NSpd and 10 µM for BENSpm, Pd-BENSpm, Pd-Spm, 
CPENSpm or Pt-CPENSpm). After 24, 48 and 72 h of treatment, cells were collected, 
counted in a hemocytometer, pelleted, resuspended, then fixed in ice-cold 70% ethanol and 
stored at -20°C until analysis. Before FCM analysis of the DNA content, cells were pelleted, 
washed with PBS and then incubated with propidium iodide (PI)-nuclear isolation medium 
(PBS containing 100 µg/ml PI, 0.60% Nonidet P-40 and 100 µg/ml Ribonuclease A (RNase 
A)) overnight at 4°C to stain the DNA [276]. PI (Fig. 26) is a fluorochrome excitable at 488 
nm, resulting in red fluorescence at 620 nm where the intensity of the emitted red 
fluorescence is a measurement of the DNA content within the cell nucleus. PI binds 
stoichiometrically to double-stranded regions of nucleic acids (DNA and RNA). Therefore, in 
order to determine only the DNA content of the cell nuclei, RNase A and nonidet P-40 were 
included in the PI staining solution to digest RNA and disrupt the cell membrane, 
respectively. Immediately prior to FCM analysis, the nuclear suspension was suctioned 
through a syringe and filtered through a nylon mesh. The samples were analysed with respect 
to DNA content using an Ortho Cytoron Absolute flow cytometer (for NSpd-, Pd-NSpd- or 
Pt-NSpd-treated cells) or an Accuri C6 flow cytometer (for BENSpm-, Pd-BENSpm-, Pd-
Spm-, CPENSpm- or Pt-CPENSpm-treated cells) [132]. Computerised analysis of FCM-
derived data (cell cycle phase distribution) was performed using the MultiCycle
®
 software 
(Phoenix Flow Systems, San Diego, CA, USA). The appearance of signals with DNA content 
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lower than that of G1 cells (sub-G1 region) due to DNA degradation and nuclear 
fragmentation is considered to be a marker of cell death. Hence, apoptotic and necrotic cells 
were detected as a sub-G1 peak.  
 
 
 
Figure 26: Molecular structure of propidium iodide (PI). 
 
       2.13.2.    Cell Cycle Kinetic Analysis 
Cell cycle kinetics refers to the rate of movement of a cell through the distinct cell 
cycle phases and can be analysed by using a bromodeoxyuridine (BrdUrd)-DNA flow 
cytometry method. BrdUrd (Fig. 27) is a thymidine analogue containing a bromine 
substitution of the methyl group. After addition to the cell culture medium, BrdUrd is taken 
up by the cells in the same way as thymidine, and is then incorporated into the newly 
synthesised DNA in cells in the S phase of the cell cycle, thereby replacing thymidine during 
DNA replication and serving as a suitable marker for cell proliferation [277].  
 
I - I -
NH2
H2N
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Figure 27: Molecular structure of bromodeoxyuridine (BrdUrd). 
 
In this study, a BrdUrd-DNA flow cytometry technique was used to investigate the 
effects of the different potential therapeutic agents under study on cell cycle progression, after 
evaluation of the changes that took place in the cell cycle phase distribution. This technique, 
which allows the simultaneous measurement of the cellular DNA content along with the 
cellular amount of incorporated BrdUrd, can be divided into four main steps: 
 
1) BrdUrd Labelling 
 Cells were seeded in a number of Petri dishes (9 cm diameter) in 12 ml of medium at a 
density of 0.4 x 10
6 
cells/Petri dish (MCF-10A and JIMT-1) or 1.3 x 10
6 
cells/Petri dish 
(L56Br-C1 and MCF-7) and then allowed to attach and grow for 24 h, prior to addition of 25 
µM NSpd, Pd-NSpd or Pt-NSpd. In each experiment, the number of Petri dishes seeded with 
cells was at least so many to be able to harvest at least three for each treatment at each time 
point. After seeding, the cells in each Petri dish were treated independently. After 72 h of 
treatment, cells were labelled with BrdUrd (5 µM) for 30 minutes (cells in S phase 
incorporate the BrdUrd into their DNA), followed by a complete medium removal, washing 
the cell layer with medium containing 0.5% FCS at 37°C (to ensure that no more BrdUrd 
labelling occurs) and addition of fresh BrdUrd-free medium with and without the compounds 
(to allow progression of the cells through the cell cycle). Next, cells were harvested by 
trypsinisation at specific time points post-labelling (0, 3, 6, 9 and 12 h), pelleted, resuspended 
and fixed in ice-cold 70% ethanol and stored at -20°C until analysis.  
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HN
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2) Cell Labelling  
 The preparation of the cells for FCM-mediated assessment of DNA and BrdUrd 
contents was carried out as previously described in detail by [129,132]. Briefly, cells were 
incubated with a freshly made pepsin-HCl solution (0.1 M) for 30 minutes to digest cellular 
proteins. After washing with PBS, the cells nuclei were incubated in HCl (2 M) for exactly 20 
minutes, in order to partially denature DNA, resulting in intermittent double-stranded DNA 
stretches with single-stranded DNA loops. The partial DNA denaturation is assumed to be 
stoichiometric i.e. proportional to the DNA content. Next, cells were incubated with a primary 
monoclonal antibody against BrdUrd that only binds to BrdUrd exposed in the single-stranded 
DNA loops, and the primary antibody was then detected by the use of a secondary FITC-
conjugated antibody. The nuclei were then stained with PI, which binds to the double-
stranded regions of DNA. Since BrdUrd is light sensitive, all the analysis was performed 
under restrained light conditions.  
 
3) FCM Analysis of DNA and BrdUrd Contents 
 The FCM analysis of DNA content (red fluorescence) and BrdUrd content (green 
fluorescence) was monitored with an Ortho Cytoron Absolute flow cytometer with an argon 
ion laser as excitation light source. In the flow cytometer, both fluorochromes (PI and FITC) 
were excited at 488 nm. The DNA and BrdUrd contents were recorded as the fluorescence 
intensity at 620 and 520 nm, respectively. 
 
4) Data Analysis 
 The computer analysis of the data was performed using Multi2D
®
 and MultiCycle
®
 
software programs (Phoenix Flow Systems, San Diego, CA, USA). The data was analysed 
and calculations made as previously described [129,278].  
 The lengths of the S and G2+M phases were calculated as previously described. The 
length of the S phase corresponds to the DNA replication time and was obtained by following 
the progression of the BrdUrd-labelled cells through the S phase, according to the principles 
of Begg et al. [279], as previously described [280]. The length of G2+M phase corresponds to 
the time required for cells to proceed through the G2 and M phases of the cell cycle [278]. In 
order to calculate the movement of cells through the G2+M phase, the percentage of BrdUrd-
labelled divided cells (originally found in S phase) in relation to the total number of BrdUrd-
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labelled cells was plotted against the post-labelling time, being the intercept of the line with 
the x-axis an approximate measure of the length of this phase. 
 
       2.13.3.    Identification of Cell Surface Markers 
Several types of solid tumours, including breast cancer, display a functional hierarchy 
of cancer cells but only a small subpopulation of self-renewing stem like cells (known as 
CSCs) can give rise to the differentiated cells that forms the bulk of the tumour. In human 
breast cancers, these breast CSC are enriched in a population of cells with a CD44
+
/CD24
-
/low/
epithelial-specific antigen (ESA)
+ 
phenotype. The cellular heterogeneity of human breast 
tissues has been characterised based on the expression of the cell surface markers CD44 and 
CD24 and it has been shown that primary human breast cancer cells with a CD44
+
/CD24
-
phenotype resulted in increased tumour formation in vivo [46].  
In this thesis, the effect of treatment with the different compounds was investigated on 
the putative cancer stem cell population CD44
+
CD24
- 
in the JIMT-1 breast cancer cell line. 
JIMT-1 cells were seeded in a number of Petri dishes (5 cm diameter) in 5 ml of medium at a 
density of 0.6 x 10
6 
cells/Petri dish and then allowed to attach and grow for 24 h, prior to 
addition of 10 µM BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm. In each 
experiment, the number of Petri dishes seeded with cells was at least so many to be able to 
harvest at least three for each treatment at each time point. After seeding, the cells in each 
Petri dish were treated independently. After 72 h of treatment, cells were detached and 
dissociated from the surface by the use of Accutase treatment, thereby preventing the 
disruption of the cell surface proteins CD44 and CD24. After washing the live cells with ice-
cold PBS containing 1% FCS, they were then incubated with the monoclonal antibodies 
CD44-FITC and CD24-PE for 15 minutes, while shaking on ice. Finally, cells were washed 
again with ice-cold PBS containing 1% FCS and identified based on their expression of the 
cell surface markers CD44 and CD24 using an Accuri C6 flow cytometer. The data was 
analysed using the CFlow software (BD Biosciences, San Jose, CA, USA). 
 
 2.14.   Colony Forming Efficiency Assay 
 The colony forming efficiency (CFE) assay is a clonogenic test that measures the 
ability of single cells to form colonies when inoculated at low density. Unlike other 
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conventional biochemical methods, CFE is a highly sensitive assay that does not measure a 
specific biological effect, but instead determines the ability of a cancer cell to form a viable 
colony after treatment with a certain compound [281]. In addition, it has been shown that the 
human tumour CFE assay can be efficiently used for the screening of new and promising 
drugs against selected tumour types (breast, colorectal, kidney, lung, melanomas and ovarian) 
[282]. 
 
                               
                         
                      
                          
 
   For the CFE assay, cells were seeded as described for the proliferation assay and then 
allowed to attach and grow for 24 h, prior to addition of the test compounds at the desired 
concentrations (25 µM for NSpd, Pd-NSpd or Pt-NSpd and 10 µM for BENSpm, Pd-
BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm). After 72 h of treatment, cells were 
resuspended in agarose-containing medium (0.3% agarose) at cloning density, i.e. 1 cell per 
microliter, and seeded in 48 well plates coated with poly(2-hydroxyethyl methacrylate) 
(polyHEMA). After an incubation period of 14 days, the number of colonies was counted 
using an inverted phase contrast microscope [283]. 
 
 2.15.   Determination of the Intracellular Pd(II) and Pt(II) Accumulation 
 Inductively Coupled Plasma Mass Spectrometry (ICP-MS) (Fig. 28) is a powerful 
technique used to obtain an accurate and precise elemental analysis through the ionisation of 
the elements present in the sample with inductively coupled plasma, followed by the 
separation and quantification of the resultant ions in a mass spectrometer.  
 In this study, ICP-MS was used to determine the intracellular accumulation of Pd(II) 
or Pt(II) in cells treated with Pd(II)- or Pt(II)-polyamine chelates. Cells were seeded in a 
number of Petri dishes (9 cm diameter) in 12 ml of medium at a density of 1 x 10
6 
cells/Petri 
dish (MCF-10A) or 2 x 10
6 
cells/Petri dish (JIMT-1 and L56Br-C1) and then allowed to attach 
and grow for 24 h, prior to addition of the test compounds at the desired concentrations (25 
µM for NSpd, Pd-NSpd or Pt-NSpd and 10 µM for BENSpm, Pd-BENSpm, Pd-Spm, 
CPENSpm or Pt-CPENSpm). In each experiment, the number of Petri dishes seeded with 
cells was at least so many to be able to harvest at least three for each treatment at each time 
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point. After seeding, the cells in each Petri dish were treated independently. After 72 h of 
treatment, cells were washed with ice-cold PBS, harvested by trypsinisation, counted in a 
hemocytometer, pelleted by centrifugation and stored at -80°C until analysis. Prior to 
analysis, the pellets were digested in 65% HNO3 for 2 h at 65°C, diluted to a 5% acid solution 
and finally centrifuged at 600 g for 14 minutes. The analysis of metal content was performed 
by ICP-MS (Thermo X7), as previously described [186]. The data of metal content was used 
to calculate the intracellular concentration of each complex (based on the corresponding 
stoichiometry). 
 
 
 
Figure 28: Schematic representation of an inductively-coupled plasma mass spectrometer for 
detection of Pd(II) and Pt(II). 
   
 2.16.   Methods to Classify Drugs as Potential DNA Damage Induction Agents 
  In the present study, the two complementary methods described below were used to 
determine if the compounds under study caused DNA damage. This was investigated in two 
ways: indirectly by the evaluation of induction of genes involved in DNA damage detection 
and repair; and directly by investigating DNA strand breaks.   
 
       2.16.1.    Anthem’s Genotox Screen Assay 
 The Anthem’s Genotox screen is a patented human cell-based technology that 
employs the genetically engineered HCT116 human colon carcinoma cell line. The assay was 
Sample’s
Ionisation
(by inductively coupled
plasma)
Mass Separation Device
and Detector
Data Analysis
Sample’s
Introduction
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developed as a mammalian genotoxicity screen that can be used for the detection of potential 
genotoxins during drug development, prior to their in vivo evaluation. In addition, the 
genetically engineered cell line allows the identification of pathways activated by treatment 
with compounds by the use of particular reporter genes. A single cell clone of the HCT116 
cell line carries the Genotox early-sensor cassettes. The cassette includes the p21 and 
GADD153 promoters and p53 response elements and are respectively and operatively linked 
to Renilla luciferase, firefly luciferase and β-galactosidase reporter genes. 
 In this study, the Anthem’s in vitro reporter-based Genotox assay was applied to 
elucidate if the compounds were genotoxic and to get an insight into which molecular 
pathways were activated. Shortly, 1.3 x 10
4
 Genotox early-sensor HCT116 cells were seeded 
per well in 96-well plates 16 h before tested compound treatment. The cells were incubated in 
replicates with five concentrations (1, 10, 25, 50 and 100 µM) of NSpd, Pd-NSpd, Pt-NSpd, 
BENSpm or Pd-BENSpm. Aminoguanidine hemisulfate was added to the FCS containing cell 
culture medium to a final concentration of 1 mM for cells treated with NSpd, Pd-NSpd or Pt-
NSpd. Cells treated with methyl methanesulfonate (400, 200 and 100 µM) were included as 
assay positive control and vehicle-treated (1% DMSO) cells as negative control. At 72 h post-
incubation, the cells were gently washed twice with PBS and lysed using lysis buffer (750 
mM HEPES, 1.25% Triton X-100, 5 mg/mL porcine gelatin, 50% glycerol and 0.25% 
antifoam). The cell lysates were processed for Renilla luciferase, firefly luciferase and β-
galactosidase reporter assays. Briefly, 20 µl of the cell lysate was reacted with substrates 
(coelentrazine and D-luciferin for Renilla luciferase and firefly luciferase, respectively and 
ortho-nitrophenyl-β-galactoside for β-galactosidase) and assay buffers (Luciferase assay 
buffer: 1 M Tricine, 0.5 M MgSO4, 0.5 M EDTA and 1 M DTT; β-galactosidase buffer: 60 
mM Na2HPO4, 60 mM NaH2PO4, 10 mM KCl and 1 mM MgSO4) in white luminometer 
plates (for luciferase assays) or absorbance plate (for β-galactosidase activity assay). The 
assay plates were then read using a BioTek plate reader and the raw data were recorded. The 
results are expressed as average fold induction of reporter gene expression in comparison to 
the vehicle treated controls. The test compound is considered as genotoxic if the average fold 
reporter gene induction at any of the tested dose is over 1.5 fold (i.e. a 50% increase 
compared to vehicle treated controls).     
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       2.16.2.    Single Cell Gel Electrophoresis or Comet Assay 
The Single Cell Gel Electrophoresis (SCGE) assay or Comet assay (Fig. 29) is a 
sensitive and fast technique used for the detection of DNA double strand breaks in individual 
cells [284]. This method can be employed for both in vitro and in vivo studies and allows the 
evaluation of DNA damage and repair, biomonitoring and genotoxicity [285].  
In this study, the SCGE assay was used to investigate if compounds induced DNA 
strand breaks. The SCGE assay was performed as previously described [286-288].  
Cells were seeded in a number of Petri dishes (5 cm diameter) in 5 ml of medium at a 
density of 0.3 x 10
6 
cells/Petri dish (MCF-10A) or 0.7 x 10
6 
cells/Petri dish (JIMT-1 and 
L56Br-C1) and then allowed to attach and grow for 24 h, prior to addition of the test 
compounds at the desired concentrations (25 µM for NSpd, Pd-NSpd or Pt-NSpd and 10 µM 
for BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm). In each experiment, the 
number of Petri dishes seeded with cells was at least so many to be able to harvest at least 
three for each treatment at each time point. After seeding, the cells in each Petri dish were 
treated independently. After 72 h of treatment, cells were harvested and, since trypsin itself 
induces DNA damage, special attention was given to using an exact trypsinisation time. The 
cells were then counted in a hemocytometer, pelleted and diluted in low melting agarose. The 
mixture was added to a Gel Bond
®
 membrane and it was allowed to solidify completely, 
followed by the addition of an extra agarose layer. This cell-containing gel was first incubated 
in lysis buffer for 1 h in the dark (to expose the nucleoid) and then in a high pH 
electrophoresis buffer (to unwind the DNA helix), followed by electrophoresis that allowed 
the migration of DNA strand pieces towards the anode, while intact chromosomal DNA was 
kept intact inside the nucleoid. Finally, the samples were washed in neutralisation buffer (to 
renature the complementary DNA strands) and stained with ethidium bromide (EtBr), a 
fluorochrome that intercalates in the DNA. The comets were observed with an Olympus 
AX70 fluorescence microscope where damaged DNA appeared as comets, with the head 
constituting the nucleoid and the tail representing the migrated DNA, while an intact nucleoid 
without a tail corresponded to undamaged DNA. The cells were photographed with an 
Olympus DP50 digital camera and the images were obtained using Viewfinder Lite and 
Studio Lite 1.0 software (Olympus Optical Co Ltd., Japan).  
The CometScore™ Freeware was used to analyse the comets in cells treated with 
NSpd, Pd-NSpd or Pt-NSpd. The evaluation of the DNA damage in these comets was 
performed by measuring the TMOM (tail moment) that corresponds to the product of the 
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DNA percentage in the tail by the tail length. An increase in the percentage of DNA found in 
the tail and the tail length reflects an increase in DNA damage.  
Seven to 22 random images were captured for each sample treated with BENSpm, Pd-
BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm. In each image, all nucleoids were counted 
by visual inspection. Then, nucleoids with comet tails were visually counted in each image. A 
nucleoid with comet tail was defined as a nucleoid with a visible tail independent of tail size. 
A mean was calculated for the images of each sample. At least 30 comets were scored for 
each sample. Afterwards, the mean of the samples for each treatment was calculated (in %). 
 
 
 
Figure 29: Schematic representation of the single cell gel electrophoresis (SCGE) assay.  
 
 2.17.   GSH-Glo
™
 Gluthathione Assay 
 The GSH-Glo
™ 
Glutathione assay is a luminescence-based method used for the 
detection and quantification of the total glutathione (GSH) levels in cells, tissue extracts or 
blood. GSH is an antioxidant largely found in eukaryotic cells that plays a critical role in 
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many metabolic processes. This is a simple, fast and highly sensitive assay that requires less 
sample than, for instance, HPLC or fluorimetric methods. 
 The glutathione assay was performed according to the instructions of the manufacturer 
(GSH-Glo
™
 Glutathione Assay Technical Bulletin TB369, Promega Biotech AB, Nacka, 
Sweden). Briefly, cells were trypsinised, counted in a hemocytometer, pelleted and 
resuspended in cell culture medium. Aliquots of 180 µl cell suspension containing 3000 
(MCF-10A) or 8000 (JIMT-1 and L56Br-C1) cells were seeded in the wells of white, opaque 
flat-bottomed 96-well plates. At 48 h of drug treatment with 10 µM BENSpm, Pd-BENSpm, 
Pd-Spm, CPENSpm or Pt-CPENSpm, the medium was removed from the plates very 
carefully. Next, luciferin-NT and glutathione S-transferase were added to GSH-Glo
™ 
reaction 
buffer to make GSH-Glo
™ 
reagent, which was further added to the wells of the plates. Before 
a 30-minute incubation period at room temperature, the plates were swirled gently and briefly. 
Then, the luciferin detection reagent was added to the wells of the plates, which were again 
gently and briefly swirled, followed by incubation for 15 minutes at room temperature. 
Finally, luminescence was monitored in a Labsystems iEMS Reader MF using the DeltaSoft 
II v.4.14 software (Biometallics Inc., Princeton, NJ, USA). 
 
 2.18.   Western Blot Analysis 
   Western blotting, also called immunoblotting or protein blotting, is one of the most 
widely used immunochemical techniques in molecular biology research. The method was 
introduced by Towbin and co-workers in 1979 [289] and antibodies are used to detect and 
identify specific proteins bound in a sample bound to a membrane. The proteins are detected 
mainly according to their size [289]. The method can be divided into several steps: 
 
1) The sample is loaded on a gel and the proteins are separated according to their size by 
denaturing gel electrophoresis; 
 
2) The proteins are blotted from the gel to a nitrocellulose membrane; 
 
3) The blot is then blocked with a protein such as albumin or casein in dry milk, followed 
by incubation with primary antibodies, which are able to bind to the protein of interest 
and then secondary antibodies; 
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4) The proteins are detected on the membrane surface by addition of enhanced 
chemiluminiscence (ECL) solution, which is converted to light by the secondary 
antibodies labelled with horseradish peroxidase. The intensity of the signal obtained 
correlates to the abundance of antigen (protein of interest) on the membrane. 
  
  In this work, Western blot analysis was used to investigate to which extent polyamine 
depletion affected the expression of the AzI protein in different human breast cell lines. Cells 
were seeded in a number of replicate cultures and were allowed to attach and grow for 24 h, 
prior to addition of the test compounds to the desired concentrations. After 24, 48 and 72 h of 
treatment, cells were collected, counted in a hemocytometer, pelleted at 700x g for 10 minutes 
at 4°C and stored at -80°C until analysis. Then, a known number of pelleted cells were 
resuspended in sample loading buffer (200 µl per 10
6
 cells; 62.5 mM Tris-HCL, pH 6.8, 20% 
glycerol, 2% sodium dodecyl sulfate, 5% β-mercaptoethanol and 0.5% bromophenol blue), 
sonicated, heat-denaturated at 95°C for 5 minutes and then put on ice immediately. Aliquots 
of the cell lysates were loaded into wells of precast polyacrylamide gels (according to the cell 
number) and the proteins were electrophoretically separated under reducing conditions 
(according to size) in a Xcell Sure Lock
™
 Mini-Cell system at a constant 150 V for 1.5 hours, 
in NuPAGE
©
 MOPS running buffer. Separated proteins were transferred to ECL
®
 
nitrocellulose membranes by use of the iBlot
™
 Dry Blotting system. The membranes were 
incubated with 5% non-fat dry milk in PBS-T (PBS containing 0.05% Tween 20, a 
polyethylene glycol sorbitan monolaurate) for 2.5 h at room temperature, in order to block 
remaining hydrophobic binding sites on the membrane and, consequently, to prevent 
nonspecific binding of the antibodies to the membrane surface. After an overnight incubation 
with the AzI primary antibody (kindly donated by Dr. Senya Matsufuji) at 4ºC, the 
membranes were washed and incubated, for 1 h at room temperature, with horseradish 
peroxidase-conjugated goat anti-mouse IgG secondary antibody (1:20000) in PBS-T. The 
protein bound antibodies were detected as bands with the ECL
™
 Advance Blotting Detection 
Kit. The ChemiDoc XRS system and the Quantity One software (Bio-Rad Laboratories Inc., 
Hercules, CA, USA) were used for imaging. 
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 2.19.   Statistical analysis 
A two-tailed Student’s t-test was used to assess the differences between the control 
and the treated samples. A 1-way ANOVA followed by the Newman-Keuls Multiple 
Comparison test was used for the statistical significance evaluation. Differences were 
considered statistically significant for p < 0.05. 
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“Somewhere, something incredible is waiting to be known.” 
Carl Sagan 
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3.  Results 
 The very first step of this study consisted in the synthesis of novel Pd(II) and Pt(II) 
complexes with polyamine analogues, following optimised procedures previously used within 
the QFM-UC research group (for the synthesis of Pd(II) and Pt(II) complexes with biogenic 
polyamines).  
 
 3.1.   Characterisation of the Compounds by Vibrational Spectroscopy 
Vibrational spectroscopy techniques – FTIR and Raman – were used to structurally 
characterise the polyamine analogues BESpm, NSpd, BENSpm and CPENSpm and their 
newly synthesised complexes with Pd(II) and Pt(II) – Pd-NSpd, Pt-NSpd, Pd-BENSpm and 
Pt-CPENSpm. In addition, the most stable structures for the polyamine analogues under study 
were obtained through quantum mechanical methods, as the lowest energy geometries among 
the several possible conformations calculated for each molecule.  
 A full spectral assignment was performed for BESpm (Fig. 30), BESpm and 
CPENSpm (in the solid state) (Fig. 31) and for NSpd (Fig. 32) in the light of the data obtained 
by quantum mechanical methods – optimised geometries and predicted vibrational pattern. A 
good agreement was found between experimental and calculated wavenumbers, after scaling 
according to Merrick and co-workers [252] in order to correct for anarmonicity effects. The 
Raman spectra previously gathered for spermine (Spm) and spermidine [203] were used for 
comparison, which allowed an accurate and clear assignment of the features corresponding to 
the common molecular core between the biogenic polyamines and its analogues BESpm, 
BENSpm, CPENSpm and NSpd (Fig. 5). A quite good agreement was obtained in all cases 
(Tabs. 8 to 11). 
 
 
 
 
 
 
 
 
 Tânia M. Silva 
___________________________________________________________________________ 
 
98 
 
 
 
Figure 30: Experimental FTIR (A) and Raman (B) spectra for BESpm. The experimental Raman 
spectrum for Spm (C) is included for comparison [203]. 
 
 
 
Figure 31: Experimental (solid line) and calculated (dotted line) Raman spectra for BENSpm 
and CPENSpm. The experimental Raman spectrum for Spm is included for comparison [203]. 
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Figure 32: Experimental FTIR (A) and Raman (B) spectra for NSpd (pure liquid). The 
experimental Raman spectrum for spermidine (C) is included for comparison [203]. 
 
 Tabs. 8 to 11 comprise the main vibrational features for the modified polyamines 
(Figs. 30 to 35): NH2 symmetric and antisymmetric stretching vibrations, detected at ca. 3400 
cm
-1
 (BESpm), at ca. 3100 (BENSpm and CPENSpm) and between 3180 and 3370 for NSpd; 
NH2/NH3 deformation modes at about 1600 cm
-1
 (as theoretically predicted); CH2 
deformations (twisting and wagging) as intense features from 1300-1400 (BESpm), 1450-
1500 cm
-1
 (BENSpm and CPENSpm) and 1200-1400 cm
-1
; strong signals predominantly due 
to NH2/NH3 deformations (also containing a contribution from CH2 deformations), detected at 
ca. 1260 and 1200 cm
-1
 for BENSpm and CPENSpm, and between 1113 and 1126 cm
-1
 for 
NSpd; the NH2 rocking vibration, in turn, was observed at 745-970 cm
-1
 for the terminally 
alkylated polyamines, while for NSpd a broad band, centred at 770 cm
-1
 was detected 
(particularly intense in infrared), encompassing both NH2 and NH3 rocking modes; CC and 
CN stretchings observed between 900 and 1100 cm
-1
 (for all the polyamine analogues). For 
the alkylated molecules BESpm, BENSpm and CPENSpm, a characteristic deformation mode 
of the terminal methyl group appeared around 1390-1500 cm
-1
 (Tabs. 8, 10 and 11). All the 
modified polyamines presently studied are solids, except for NSpd which is a liquid at room 
temperature leading to an expected broadening of the FTIR and Raman signals (Fig. 32). 
B
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Table 8: Main experimental (solid state) and calculated Raman and FTIR wavenumbers (cm
-1
) for 
BESpm. 
Experimental 
a
Calculated 
b
Approximate description 
FTIR Raman   
  3341 νas(NH2) + νas(NH2) 
3433  3341 νs(NH2) + νs(NH2) 
2978 2975 3028 νas(CH3) 
2953 2948 3012 νas(CH2) + νas(CH3) 
 2930 3012 νas(CH2) + νas(CH3) 
2920 2913 2976 νas(CH2) 
 2880 2947 νs(CH2) 
2874 2871 2935 νs(CH3) + νs(CH3) 
 2855 2919 νs(CH2) 
2820 2804 2919 νs(CH2) 
2775 2776 2911 νs(CH2) 
2752 2755 2909 νs(CH2) 
1596 1594 1571 sciss(NH2) + sciss(NH2) 
  1519 sciss(NH2) 
1488 1488 1470 sciss(NH2) + sciss(CH2) 
 1469 1466 sciss(CH2) 
1460 1461 1461 sciss(CH2) + as(CH3) 
1451  1454 sciss(CH2) + as(CH3) 
 1437 1438  ω(NH2) 
1406 1407 1408 t(NH2) + ω(CH2) 
1391 1390 1392 t(NH2) + t(CH2) + ω(CH2) + as(CH3) 
1354 1336 1339  ω(CH2) + t(CH2) 
 1310 1313 t(CH2) + t(CH2) 
1252 1264 1262  ω(NH2) + ω(CH2) 
 1230 1231 ω(NH2) + ω(CH2) + r(CH2) 
 1201 1199 r(CH2) 
1142 1149 1154 r(NH2) + r(CH2) 
 1110 1105 t(NH2) + t(CH2) 
1047 1052 1083 ν(CC) + ν(CN) 
 1031 1031 ν(CC) + ν(CN) 
988 1008 984 ν(CC) + ν(CN) 
 967 971 ν(CC) + ν(CN) 
928 931 939 ν(CC) + ν(CN) 
878 558 892 r(NH2) + r(CH2) + t(CH2) + as(CH3) 
 842 851 r(NH2) + r(CH2) + t(CH2) 
804 798 811 r(NH2) + r(CH2) + t(CH2) 
777 776 777 r(NH2) + r(CH2) + as(CH3) 
756  748 r(CH2) 
483  488 (CCN)long 
418  423  (CCN)long 
a
At the B3LYP/6-31G** level. Wavenumbers above 600 cm
-1
 are scaled by 0.9614 [252] (IR intensities in 
km.mol
-1
. Raman scattering activities in Å.amu
-1
). stretching;  – in-plane deformation; t – twisting; r – 
rocking;  – wagging; sciss – scissoring; s – symmetric; as – antisymmetric; long – longitudinal. 
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Table 9: Main experimental and calculated Raman and FTIR wavenumbers (cm
-1
) for NSpd, Pt-NSpd 
and Pd-NSpd. 
NSpd Pt-NSpd Pd-NSpd Approximate description 
Exp. 
a
Cal
c. 
Exp. Exp.  
FTIR Raman  FTIR Raman FTIR Raman  
3362 3362 3442 3262 3267 3269 3283 νs(NH3) 
3278 3302 3346 3248 3250 3224 3227 νs(NH3) + νs(NH2) 
3187 3188 3220 3215 3219 3172 3172 νas(NH3) +  νas(NH2) 
  3217 3148 3152 3154 3158 νs(NH2) 
2939 2955 3137 2942 2942 2939 2940 νas(CH2) 
2905 2909  2877 2915 2874 2903 νas(CH2) 
2852 2861  2854 2878 2846 2876 νs(CH2) 
1600 1600  1608  1605  sciss(NH2) 
1466 1478 1470 1462 1459 1460 1459 sciss(CH2) 
1439 1444 1410 1446  1449  sciss(CH2) 
1365 1360      sciss(CH2) 
1307 1300 1252 1258  1249  sciss(CH2) + t(CH2) 
   1172 1170 1171  ω(CH2) + t(CH2) +  (NH3) + ν(CC) 
1126 1113 1186 1148  1146 1143 ω(CH2) + t(CH2) + (NH3) + ν(CC) 
1070 1070 1112 1064 1036 1053 1062 ω(CH2) + t(CH2) 
   1035  1031  ω(CH2) + t(CH2) 
979 980 1018     ν(CC) + ν(CN) 
915 915 970     t(CH2) + s(NH3) + sciss(NH2) + ν(CC) 
884 865 906     sciss(NH2) + ω(NH2) 
843 841 880     r(NH3) 
766 772 766     r(CH2) + r(NH3) + r(NH2) 
557 554      r(NH3) 
   522 
536 
(b524) 
 522 νs(N
c
MN) 
   483 
482 
(b508) 
498 498 νas(N
c
MN) 
    391  388 ν(Cl
c
MCl) 
    
333 
(b323) 
 340 νs(Cl
c
MCl) 
    
316 
(b317) 
 307 νas(Cl
c
MCl) 
 281      dLAM 
    229 
(b255) 
 225 (NMN) 
    171 
(b162) 
 173  ClMCl) 
 118      dTAM 
a
At the B3LYP/6-31G** level. Wavenumbers above 600 cm
-1
 are scaled by 0.9614 [252] (IR intensities in 
km.mol
-1
. Raman scattering activities in Å.amu
-1
). stretching;  – in-plane deformation; t – twisting; r – 
rocking;  – wagging; sciss – scissoring; s – symmetric; as – antisymmetric. bFrom [290]. cM=Pt(II) or Pd(II). 
d
LAM and TAM refer to longitudinal and transverse acoustic modes, respectively. 
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Table 10: Main experimental (solid state) and calculated Raman and FTIR wavenumbers (cm
-1
) for 
BENSpm and Pd-BENSpm. 
BENSpm Pd-BENSpm Approximate description 
Exp. 
a
Calc. Exp.  
FTIR Raman  FTIR Raman  
3147 3167 3342 3221 3229 νs(NH2) 
3123     νs(NH2) 
3083 3031 3028   νas(CH3) 
  3011   νas(CH2) + νas(CH3) 
2989 2976 2975 2981 2992 νas(CH2) 
2951 2932 2947 2971 2968 νs(CH2) 
  2934   νs(CH3) 
2927 2909 2923 2923 2923 νs(CH2) 
2889 2881  2865 2865 νs(CH2) 
1635 1694  1625 1623 sciss(NH2) 
1596 1595 1623   sciss(NH2) + sciss(CH2) 
1490 1488 1511   (CH3) 
1461 1471 1500 1463 1455 ω(CH2) + t(CH2) + ω(NH2) + (NH2) 
1405 1437 1468 1439 1433 ω(CH2) + t(CH2) + ω(NH2) + (NH2) 
1394 1392 1456 1386 1388 sciss(CH2) + t(NH2) 
1357  1405 1354 1355 sciss(CH2) + t(CH2) + ω(CH2) 
 1312 1363 1306 1307 ω(CH2) + t(CH2) + t(NH2) 
   1296 1293 ω(CH2) + ω(NH2) + (NH2) 
1264 1257 1309 1281 1252 ω(CH2) + t(CH2) + t(NH2) 
   1175 1178 ω(CH2) + r(NH2) 
1152 1149 1173 1146 1141 ν(CC) + ν(CN) 
1050 1049 1084 1069 1074 ν(CC) + ν(CN) 
1035 1035 1075 1038 1039 ν(CC) + ν(CN) 
   1023 1014 ν(CC) + ν(CN) 
999 999 1023 993 989 ν(CC )+ ν(CN) 
   966 936 t(CH2) + r(CH2) + r(NH2) 
906 884 931 892 887 t(CH2) + r(CH2) + r(NH2) 
   835 833 r(NH2) 
805 804 838 804 809 r(CH2) + r(NH2) 
782 780 778 745 748 r(CH2) + r(NH2) 
   697 700 r(CH2) 
    563 νs(NPdN) 
    505 νas(NPdN) 
    487 νas(NPdN) 
    424 νs(ClPdCl) 
    325 νas(ClPdCl) 
    295 (NPdN) 
    222 (ClMCl) 
a
At the B3LYP/6-31G** level. Wavenumbers above 600 cm
-1
 are scaled by 0.9614 [252] (IR intensities in 
km.mol
-1
. Raman scattering activities in Å.amu
-1
). stretching;  – in-plane deformation; t – twisting; r – 
rocking;  – wagging; sciss – scissoring; s – symmetric; as – antisymmetric. 
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Table 11: Main experimental (solid state) and calculated Raman and FTIR wavenumbers (cm
-1
) for 
CPENSpm and Pt-CPENSpm. 
BENSpm Pd-BENSpm Approximate description 
Exp. 
a
Calc. Exp.  
FTIR Raman  FTIR Raman  
3129  3330 3139 3165 νas(NH2) 
3072 3070 3228  3061 νs(NH2) 
  3215   νas(CH3) 
2973 2973 3231 2960 2995 νas(CH2) 
2935 2934 3135 2937 2939 νs(CH2) 
 2907 3134   ν(CH)cyclop 
  3121   νs(CH3) 
2864 2878 2949 2879 2880 νs(CH2) 
 2808 2885   ν(CH/CH2)
cyclop
 
1592   1608  sciss(NH2) 
1575 1577    sciss(CH2) + sciss(NH2) 
1481 1485 1500   (CH3) 
1452 1463  1465 1461 ω(CH2) + t(CH2) + (NH2) + ω(NH2) 
1408 1414 1477 1455 1451 sciss(CH2) 
1391 1385 1464 1386 1373 sciss(CH2) 
1355 1349 1391   sciss(CH2) + t(CH2) 
 1314 1333 1320 1310 ω(CH2) + t(CH2) + t(NH2) 
1263 1256 1289   ω(CH2) + t(CH2) + t(NH2) 
1212 1201 1199 1191 1196 ω(CH2) + t(CH2)
cyclop 
+ t(NH2) 
1148 1147 1175 1159  ω(CH2) + t(NH2) 
1049 1048 1104 1048  ν(CC) + ν(CN) 
1027  1033   ν(CC) + ν(CN) 
1000  1013   ν(CC) + ν(CN) 
 884 920 878  t(CH2) + r(CH2) + t(NH2) + ω(NH2) 
830 833 858 834 831 t(CH2) + r(CH2) + t(NH2) 
800 802 807 808 810 t(CH2)
cyclop
 
777 778 786 773 779 r(CH3) + r(NH2) 
    516 νs(NPtN) 
    483 νas(NPtN) 
    386 νs(ClPtCl) 
    368 νs(ClPtCl) 
    321 νas(ClPtCl) 
 252    ν(CC)cyclop 
    220 (NPtN) 
 216    bLAM 
    197 (ClPtCl) 
    168 (ClPtCl) 
a
At the B3LYP/6-31G** level. Wavenumbers above 600 cm
-1
 are scaled by 0.9614 [252] (IR intensities in 
km.mol
-1
. Raman scattering activities in Å.amu
-1
). stretching;  – in-plane deformation; t – twisting; r – 
rocking;  – wagging; sciss – scissoring; s – symmetric; as – antisymmetric. bLAM refers to a longitudinal 
acoustic mode. 
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 Bands from the rocking deformations of the terminal NH3 groups were clearly 
detected for NSpd at 841/843 cm
-1
 by both FTIR (very intense band) and Raman (Table 9, 
Fig. 32), and were absent in BESpm, BENSpm and CPENSpm (Figs. 30, 33 and 34), while 
the bands assigned to NH2 symmetric and antisymmetric deformations were observed (as 
theoretically predicted) at ca. 1600 cm
-1
 for the four modified polyamines. 
Furthermore, the cyclopropyl-containing polyamine, CPENSpm, displayed several 
bands characteristic from this group (Table 11): the CH2 twisting modes, at 1201 cm
-1
, quite 
intense in the Raman spectrum (Table 11, Fig. 34) while hardly observed by infrared; 
methylene deformations at 800 cm
-1
, present in both the FTIR and the Raman pattern (Fig. 
34); and the ring C–C stretching, detected by Raman at 252 cm-1 (Fig. 34). As opposed to 
NSpd, the Raman bands corresponding to the amine stretching modes were not detected. 
 In addition, some acoustic modes were detected in the Raman spectra presently 
obtained (Tabs. 9 and 11): the symmetric LAM (accordion mode) at 281 and 216 cm
-1
 for 
NSpd and CPENSpm, respectively (Figs. 32 and 34), and one TAM was observed for NSpd at 
120 cm
-1
 (Fig. 32).  
 Regarding the newly synthesised chelates, upon metal binding, the vibrational pattern 
of the ligands underwent clear changes: no bands assigned to the NH2/NH3 groups were 
detected, namely (NH2) around 1600 cm
-1
, as well as r(NH3) (Figs. 33, 34 and 35) (e.g. for 
NSpd, (NH3) at ca. 555/770 cm
-1
 and (NH3) at ca. 1120 cm
-1
). Additionally, a marked shift 
of NH stretching bands to higher frequencies were plainly detected by FTIR for the terminally 
alkylated ligands BENSpm and CPENSpm (Figs. 33 and 34, second region) – ascribed to the 
change from ν(NH2)/ ν(NH3) symmetric and antisymmetric vibrations, in the free ligands, to 
the corresponding modes for the metal-coordinated amine groups. For the non-alkylated 
polyamine NSpd, in turn, these features (ν(NH2)/ ν(NH3)) were detected for both the complex 
and the uncoordinated molecule, undergoing a significant intensity decrease upon metal 
binding (Fig. 35). Concomitantly, distinct new signals appeared in the Raman pattern below 
ca. 600 cm
-1
, characteristic of the metal coordination profile: deformations, between 165 and 
225 cm
-1
 ((Cl–M–Cl)) and 220 to 295 cm-1 ((N–M–N)), as well as symmetric and 
antisymmetric (Cl–M–Cl) and (N–M–N) stretching modes, between 305 to 425 cm-1 and 480 
to 565 cm
-1
, respectively (Tabs. 9 to 11). A Pd for Pt substitution (in the NSpd complexes) was 
found to lead to a change in the band profile assigned to the symmetric and antisymmetric 
(metal–N) stretching modes – either a broad feature or a well resolved two-band pattern in the 
460–540 cm-1 interval (Fig. 35).  
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Figure 33: Experimental FTIR (A) and Raman (B) spectra for BENSpm and Pd-BENSpm. 
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Figure 34: Experimental FTIR (A) and Raman (B) spectra for CPENSpm and Pt-CPENSpm. 
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Figure 35: Experimental FTIR (A) and Raman (B) spectra for NSpd, Pt-NSpd and Pd-NSpd. 
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 3.2.   Evaluation of the Cellular Impact 
 After the structural characterisation of the polyamine analogues and their Pd(II) and 
Pt(II) complexes by vibrational spectroscopy, their effects on a range of human breast cancer 
cell lines were anaylsed using a variety of cell biological techniques.  
 This section is divided in two parts. First the antiproliferative effect of the polyamine 
analogue (NSpd) was tested on various breast cancer cell lines and one normal-like breast cell 
line, and compared with those of its Pd(II) and Pt(II) chelates. Second the antiproliferative 
effect of two other polyamine analogues (BENSpm and CPENSpm) and their Pd(II) or Pt(II) 
complexes were analysed using the same breast cell lines and the results interpreted in the 
light of their structural features.   
 
       3.2.1.    NSpd, Pd-NSpd and Pt-NSpd 
In the present work, the spermidine analogue NSpd and its newly synthesised 
trinuclear Pd(II) and Pt(II) complexes, Pd-NSpd and Pt-NSpd [190], were evaluated regarding 
their antiproliferative activity against four different human breast cancer cell lines (JIMT-1, 
L56Br-C1, MCF-7 and MDA-MB-231) and one immortalised normal-like breast epithelial 
line (MCF-10A).  
 
MTT Reduction 
In order to evaluate the toxicity of NSpd, Pd-NSpd or Pt-NSpd against the five cell 
lines investigated, a MTT dose response test that is assumed to reflect cell number was 
performed, using concentrations ranging from 0.1 to 100 µM [112,291]. This assay showed 
that MTT reduction decreased in all cases when increasing both concentration as well as time 
of treatment, although the reactions to each treatment varied between the five cell lines (Fig. 
36). The dose response curves show that while Pt-NSpd was found to be the least cytotoxic 
compound, Pd-NSpd and NSpd were more toxic and gave in general similar dose responses. 
The results also show that L56Br-C1 was the most sensitive cell line (Fig. 36 D–F). The 
effects of drug treatment were more obvious between 10 and 100 µM concentrations, for both 
48 and 72 h of treatment. 
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Figure 36: Dose response effect of NSpd, Pd-NSpd or Pt-NSpd treatment. The four breast cancer cell 
lines JIMT-1 (A–C), L56Br-C1 (D–F), MCF-7 (G–I), MDA-MB-231 (J–M) and the normal-like breast cell line 
MCF-10A (N–P) were used. Twenty-four h after seeding of cells in 96-well plates, the polyamine analogue and 
its complexes were added to the final concentrations shown in the figure and were treated for 24, 48 and 72 h, 
before evaluation using an MTT assay. The results are expressed as % of control (n=12 independent samples 
from two independent experiments) with bars representing ± SD.  
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Effect of Short and Long Time Treatment on Cell Proliferation 
Based on the dose response curves, we decided to compare 25 and 100 µM 
concentrations for further investigations. We examined the effect of NSpd, Pd-NSpd or Pt-
NSpd treatment on cell proliferation using both concentrations. The proliferation of MCF-
10A cells (Fig. 37 D) was only slightly affected by treatment with a 25 µM concentration of 
NSpd, Pd-NSpd or Pt-NSpd, while in JIMT-1 and MCF-7 cells the proliferation was more 
affected than in MCF-10A cells and differential effects of the drugs were clearly discernible 
(Fig. 37 A, C). L56Br-C1 cells were the most sensitive cells to these compounds and there 
was even a decrease in cell number implicating cell death after 72 h of treatment with NSpd 
and Pd-NSpd (Fig. 37 B). Figure 38 shows the morphology of the cells after 72 h of treatment 
with the compounds. L56Br-C1 cells had to be rinsed with PBS to remove all dead floating 
cells before photography of attached cells that were found in small patches.  
For the 100 µM concentration, the results obtained exhibited more distinct differences 
between the tested compounds and the cell lines than after treatment with a 25 µM 
concentration (Fig. 37 E–I). MCF-10A cells were still the least sensitive cells with smallest 
differences between the various treatments (Fig. 37 H). Pd-NSpd treatment appeared to totally 
inhibit cell proliferation in JIMT-1 and MCF-7 cells almost immediately, while Pt-NSpd and 
NSpd slowed cell proliferation in these cell lines, with the former being slightly more 
efficient than the later (Fig. 37 E, G). In L56Br-C1 cells, treatment with 100 µM NSpd, Pd-
NSpd or Pt-NSpd immediately inhibited cell proliferation and a marked reduction in cell 
number was observed in Pd-NSpd-treated cultures (Fig. 37 F), implicating cell death. 
Proliferation of MDA-MB-231 cells was clearly reduced by treatment with NSpd and Pd-
NSpd, the latter displaying a stronger antiproliferative effect (Fig. 37 I). 
The effect of repeated cycles of 72 h treatment with 25 µM NSpd, Pd-NSpd or Pt-
NSpd followed by 96 h of drug withdrawal, on cell proliferation (Fig. 37 J–M) was also 
investigated. MCF-10A normal-like breast cells were not affected by repeated treatment 
cycles with either NSpd or Pt-NSpd and were only slightly affected by Pd-NSpd (Fig. 37 M). 
In L56Br-C1 cells, repeated treatment cycles with NSpd or Pd-NSpd resulted in unchanged 
and decreasing cell numbers, respectively, compared to the number of cells seeded at time 0, 
while repeated treatment with Pt-NSpd only slightly affected the cell number compared to 
control (Fig. 37 K). In JIMT-1 and MCF-7 cells, the accumulated cell number was lower for 
cells treated with either NSpd or Pd-NSpd, but not with Pt-NSpd, when compared with 
untreated cells, especially after the second treatment cycle (Fig. 37 J, L). 
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Figure 37: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on the proliferation of JIMT-1, 
L56Br-C1, MCF-7, MCF-10A and MDA-MB-231 cells. Twenty-four h after seeding of cells (0 h time of 
treatment in the figure), NSpd, Pd-NSpd or Pt-NSpd was added to give a final concentration of 25 µM (A–D) or 
100 µM (E–I). Cells were harvested by trypsinisation and counted in a hemocytometer. The results are presented 
as mean values (n=3–6 independent samples from one or two independent experiments) and bars represent ± SD. 
When not visible, the bars are covered by the symbols. J–M: Cells were seeded and NSpd, Pd-NSpd or Pt-NSpd 
was added to the final concentration of 25 µM after 24 h of seeding. After 72 h of treatment, the drug-containing 
medium was aspirated and drug free culture medium was added. After an additional 72 h of incubation (recovery 
time), cells were harvested by trypsinisation and counted in a hemocytometer. These 7 days were defined as one 
treatment cycle. The total recovery time between each treatment was 96 h. The cells were reseeded at the same 
density as at the previous passage and treated with the same drug for the next treatment cycle. All together this 
was repeated for 5 treatment cycles. The data are presented as the total amount of cells (mean values (n=3–6 
samples from one or two independent experiments) and bars represent ± SD) that theoretically would have 
accumulated if all cells had been reseeded with a known cell density after each treatment cycle. When not 
visible, the bars are covered by the symbols. Please note that the y-axis has different scales for the different cell 
lines because of different rates of cell proliferation. 
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Figure 38: Phase contrast images of JIMT-1, L56Br-C1, MCF-7 and MCF-10A cells treated with 
NSpd, Pd-NSpd or Pt-NSpd. Twenty-four h after seeding the cells, NSpd, Pd-NSpd or Pt-NSpd was added 
to give a final concentration of 25 µM. After 72 h of treatment, the cells were photographed with a digital 
camera attached to a phase contrast microscope. The L56Br-C1 cultures were rinsed with PBS to remove all 
dead cells floating which were prominent in NSpd- and Pd-NSd-treated cultures, where attached cells were 
found in small groups seen in the image. 
 
Drug Competition for 
3
H-spermidine Uptake 
This assay was used to evaluate the ability of NSpd, Pd-NSpd or Pt-NSpd to 
competitively inhibit the uptake of 
3
H-spermidine in the four breast cell lines, using five 
different concentrations of the compounds. Fig. 39 shows that, in all cell lines, only NSpd was 
clearly found to compete with 
3
H-spermidine, resulting in a 50% inhibition of 
3
H-spermidine 
uptake at a 6 to 8 µM NSpd concentration. The dosage needed for a 50% inhibition of 
3
H-
spermidine uptake was about 100 times higher for Pt-NSpd than for its polyamine ligand, in 
all of the four cell lines investigated. As opposed to Pt-NSpd, Pd-NSpd caused a 50% 
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inhibition of 
3
H-spermidine uptake, at concentrations that were only twice as high as NSpd in 
JIMT-1 cells (about 15 µM) and between five and six times higher in the other cell lines. 
 
 
 
Figure 39: Effect of NSpd, Pd-NSpd or Pt-NSpd on the uptake of 
3
H-spermidine in JIMT-1, 
L56Br-C1, MCF-7 and MCF-10A cells. The cells were seeded in 12-well plates and incubated for 48 h, 
whereupon the polyamine analogue and its complexes were added to give the final concentrations shown in the 
figure. The concentration of 
3
H-spermidine used was 1 µM. The results are presented as mean values (n=4 
samples from two independent experiments) and bars represent ± SD. 
 
ODC Activity 
In all cell lines, there was an evident rise in ODC activity during the first day after 
seeding (Fig. 40). Thereafter, ODC activity decreased rapidly in all cell lines except in 
L56Br-C1 cells, where it remained elevated for at least another day before slowly decreasing. 
Treatment with NSpd or Pd-NSpd clearly decreased the ODC activity in all the cell lines 
examined, except for the JIMT-1 cells where only minor differences were seen (Fig. 40). The 
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effect on ODC activity was most evident in L56Br-C1 cells, as the ODC activity remained 
relatively high in the control cells for the entire experimental period. Pt-NSpd only slightly 
inhibited the ODC activity in all cell lines analysed. 
 
 
 
Figure 40: ODC activity in JIMT-1, L56Br-C1, MCF-7 and MCF-10A cells treated with NSpd, 
Pd-NSpd or Pt-NSpd. Twenty-four h after seeding of cells (0 h time of treatment in the figure), NSpd, Pd-
NSpd or Pt-NSpd was added to give a final concentration of 25 µM. The ODC activity was determined using a 
radiometric assay. The results are presented as mean values (n=3 independent samples from one independent 
experiment) and bars represent ± SD.  
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Cell Cycle Phase Distribution and Cell Death 
FCM represents a fast method to determine the cell cycle phase distribution based on 
the stoichiometric binding of a fluorescent probe to DNA. As the drugs used in the present 
study were shown to affect cell proliferation, FCM was used to further examine whether there 
were changes in the cell cycle phase distribution induced by the compounds and whether they 
induced cell death (studied by monitoring the appearance of a sub-G1 peak). Only data from 
treatment with 100 µM are shown (Fig. 41), as the pattern of changes was similar, but less 
pronounced, after treatment with 25 µM.  
The data show that the only cell line in which the percentage of cells in the sub-G1 
region increased substantially was the L56Br-C1 cell line (Fig. 41). When treating L56Br-C1 
cells with NSpd or Pd-NSpd, cell death was induced after 48 h of treatment as indicated by 
the increased number of cells in the sub-G1 region, which further increased after 72 h of 
treatment. No cell death was observed in the other cell lines analysed.  
The most obvious changes in cell cycle phase distribution were found in JIMT-1 and 
L56Br-C1 cells, while there were no clear changes compared to control in MCF-7 and MCF-
10A cells (Fig. 41). In JIMT-1 cells, the percentage of cells in the G1 phase increased from 30 
to almost 70% during the first 24 h of treatment with 100 µM Pd-NSpd and then remained at 
that level. During the same time period, the percentage of cells in the S phase decreased from 
60 to 20%. Less evident differences in cell cycle phase distribution were observed in NSpd 
and Pt-NSpd-treated JIMT-1 cells. In L56Br-C1, the percentage of cells in the G1 phase 
decreased, while it increased in both the S and G2 phases after treatment with Pd-NSpd. 
Although not as striking, treatment with NSpd or Pt-NSpd resulted in similar changes in cell 
cycle phase distribution in the L56Br-C1 cells. 
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Figure 41: Sub-G1 region and cell cycle phase distribution of JIMT-1, L56Br-C1, MCF-7 and 
MCF-10A cells treated with NSpd, Pd-NSpd or Pt-NSpd. Twenty-four h after seeding the cells, NSpd, 
Pd-NSpd or Pt-NSpd was added to give a final concentration of 100 µM. At 24, 48 and 72 h of treatment, both 
detached and attached cells were harvested, pooled and fixed in 70% ice-cold ethanol. The nuclei were stained 
with PI and the analysis was performed using FCM. The results are presented as mean values (n=3–6 
independent samples from one or two independent experiments) and bars represent ± SD. 
 
Cell Cycle Kinetics 
Since we found effects on the cell cycle phase distribution and cell death in L56Br-C1 
cells, it was of interest to further study cell cycle kinetics. For this purpose, the length of both 
S and G2+M phases were evaluated by the use of a BrdUrd-FCM method [129,280]. 
The length of the S phase corresponds to the DNA replication time and was calculated 
by following the movement of BrdUrd-labelled cells during the cell cycle according to the 
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principles of Begg et al [279], as previously described [132,280]. The S phase was 
significantly prolonged in all cell lines after 72 h of NSpd or Pd-NSpd treatment, compared to 
control cells (Table 12). However, the prolongation was different in the four cell lines. Pt-
NSpd treatment resulted in the smallest increase in S phase length and no increase in MCF-
10A cells.  
The length of G2+M phase was also evaluated and corresponds to the time required for 
cells to proceed through the G2 and M phases of the cell cycle [278]. The data indicated a 
prolongation of the G2+M phase in all four cell lines after 72 h of treatment with NSpd, Pd-
Npd or Pt-NSpd, compared to control cells.  
 
Table 12: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on the length of the S and G2+M phases
1
. 
S phase lenght (h) 
Cell Line Control NSpd Pd-NSpd Pt-NSpd 
JIMT-1 13.1 ±1.0 21.4 ± 0.9 *** 20.2 ± 1.3 *** 14.1 ± 1.0 
L56Br-C1 15.7 ± 1.0 18.5 ± 1.6 *** 22.5 ± 1.3 *** 16.7 ± 0.5 * 
MCF-7 11.8 ± 1.1 15.2 ± 2.4 ** 14.8 ± 1.7 ** 13.3 ± 1.4 * 
MCF-10A 7.6 ± 0.3 8.7 ± 1.1 * 15.7 ± 1.1 *** 7.1 ± 0.1 
G2/M phase lenght (h) 
Cell Line Control NSpd Pd-NSpd Pt-NSpd 
JIMT-1 4.5 5.7 5.7 5.1 
L56Br-C1 5.8 7.5 7.5 7.2 
MCF-7 4.2 5.1 5.3 4.9 
MCF-10A 3.7 6.2 5.8 4.3 
1
Cells were seeded and the drugs (25 µM) were added 24 h later. After 72 h of treatment, the cells 
were labelled with BrdUrd for 30 minutes, before the cells were allowed to progress through the cell 
cycle in BrdUrd free medium. Cells were sampled for analysis of DNA and BrdUrd contents by FCM 
at 3, 6, 9 and 12 h post-labelling. Data was collected from one experiment, n=5–12. * p < 0.05; ** p < 
0.01; *** p < 0.001. 
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Effect of NSpd, Pd-NSpd or Pt-NSpd Treatment on Colony Forming Efficiency 
This assay is designed to measure the ability of cells to proliferate and form colonies 
in an anchorage independent manner and it can be used to assess the sensitivity of human 
tumours to anticancer drugs. The normal-like cell line MCF-10A does not form colonies in 
soft agar and was not used in this assay. In the breast cancer cell lines, the colony forming 
efficiency decreased by all treatments compared to the control, with Pd-NSpd being the most 
effective compound and Pt-NSpd the least effective one (Table 13).  
 
Table 13: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on colony forming efficiency in soft agar
1
. 
Cell line JIMT-1 L56Br-C1 MCF-7 
Control (%) 24.2 ± 2.1 30.7 ± 2.3 28.3 ± 2.7 
NSpd (%) 14.2 ± 3.1 (58.5) 14.1 ± 2.6 (46) 18.5 ± 2.1 (65.5) 
Pd-NSpd (%) 12.3 ± 2.4 (50.8) 12.1 ± 2.7 (39.4) 15.8 ± 2.4 (55.9) 
Pt-NSpd (%) 19.3 ± 2.8 (79.8) 24.0 ± 1.3 (78.1) 24.2 ± 1.7 (85.5) 
1
Cells were seeded and the drugs (25 µM) were added 24 h later. After 72 h of treatment, the cells 
were harvested, counted and reseeded at low density in soft agar. Colonies were counted after 14 days 
of incubation. The results are presented as mean values (n=3 independent cultures) ± SD and as 
percentage of control (in brackets). 
 
Intracellular Pd(II) and Pt(II) Accumulation  
The cellular contents of Pd(II) and Pt(II) complexes after treatment with 25 µM Pd-
NSpd and Pt-NSpd, respectively, for 72 h were estimated by measuring the amount of Pd(II) 
and Pt(II) in the cells using ICP-MS. As shown in Fig. 42, the intracellular concentrations of 
Pd-NSpd and Pt-NSpd were considerably higher in the most sensitive cell line, L56Br-C1 
compared to the least sensitive one, MCF-10A. Moreover, the concentration of Pt-NSpd was 
2–3 times as high as that of Pd-NSpd in MCF-10A cells (Fig. 42 B), whereas in L56Br-C1 
cells the concentrations were similar (Fig. 42 A).   
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Figure 42: Intracellular accumulation of Pd-NSpd and Pt-NSpd in L56Br-C1 and MCF-10A 
cells. At 72 h of treatment with 25 µM of Pd-NSpd and Pt-NSpd, cells were harvested, pooled and digested in 
HNO3 (see Materials and Methods). The supernatant was used for analysis of Pd(II) and Pt(II) by ICP-MS and 
the data used to calculate the intracellular Pd-NSpd and Pt-NSpd concentrations. The results are presented as 
mean values (n=3 independent samples from one independent experiment) and bars represent ± SD.  
 
Assessment of the Genotoxic Potentials of NSpd, Pd-NSpd and Pt-NSpd  
The Anthem’s Genotox screen is a patented human cell-based technology that 
employs a genetically engineered stable p53 proficient HCT116 cell line. This mammalian 
genotoxicity screen can help in the identification of potential genotoxins in an early phase of 
drug development, before in vivo assessment, and also to identify pathways activated through 
the utilisation of reporter genes. In the present study, this assay was used as a complement to 
the SCGE assay, to analyse if the test compounds were potential genotoxins. A compound is 
considered to be genotoxic if the average reporter gene induction at any dose tested is over 
1.5 fold. Taking this into account, Fig. 43 shows that 100 µM NSpd induced both p21 and 
p53, Pt-NSpd induced only p21 at the concentrations of 50 and 100 µM and Pd-NSpd did not 
induce either of the early DNA damage sensors (p21, GADD153 and p53) at any 
concentration in the Anthem’s Genotox screen. Thus, NSpd and Pt-NSpd (Fig. 43 A, C) were 
found to be potential genotoxins, but not Pd-NSpd (Fig. 43 B). 
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Figure 43: Genotoxic effect of NSpd, Pd-NSpd or Pt-NSpd in genetically engineered reporter-
based HCT-p21-GADD-p53 cells. The genetically engineered reporter-based HCT-p21-GADD-p53 cells 
carrying the DNA damage early sensors p21, GADD153 and p53 were seeded in 96-well plates and allowed to 
attach for 16 h. The p21 promotor was operatively linked to Renilla luciferase reporter gene, the GADD 153 
promotor operatively linked to firefly luciferase reporter gene and the p53 response elements operatively linked 
to β-galactosidase reporter gene. Sixteen h after seeding, the compounds to be tested were added to the final 
concentrations shown in the figure and incubated for 72 h. Samples were analysed for Renilla luciferase, firefly 
luciferase and β-galactosidase. The results are presented as mean values (n=3 independent samples from one 
independent experiment) and bars represent ± SD. 
 
Single Cell Gel Electrophoresis 
The SCGE assay was performed to investigate if the compounds induced DNA strand 
breaks. None of the compounds induced any significant amount of DNA strand breaks with a 
25 µM concentration in any of the cell lines tested. Only data for the most sensitive cell line 
(L56Br-C1) are shown (Fig. 44). Figure 44 A shows representative comets from the different 
treatments. The tail length and the %DNA in the tail was evaluated for each comet and plotted 
in cytograms (Fig. 44 B). TMOM for each cell was calculated and plotted (Fig. 44 C). Figure 
44 D shows a table with the mean TMOM value of the 10% highest TMOM values. 
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Figure 44: SCGE assay for the evaluation of DNA damage in L56Br-C1 cells. Twenty-four h after 
seeding of L56Br-C1 cells, NSpd, Pd-NSpd or Pt-NSpd was added to give a final concentration of 25 µM. After 
72 h of treatment, cells were harvested for SCGE analysis. The EtBr-stained nucleoids were photographed and 
then examined using the Comet Score
™
 Freeware. A: Images of comets obtained by the SCGE assay. DNA 
damage results in comets with head and tail, whereas undamaged DNA results in a round head. B: Percentage 
DNA in tail on the x-axis versus tail length on the y-axis for individual cells. C: Tail moment TMOM (%DNA in 
tail multiplied by tail length) for individual cells. Data were collected from three independent experiments, 
n=207 cells. D: Table showing the mean TMOM value of the 10% highest TMOM values i.e. 20 highest values 
± SD. *p < 0.05 compared to control; ***p < 0.001 compared to control. 
 
Effect of NSpd, Pd-NSpd or Pt-NSpd Treatment on the Antizyme Inhibitor Levels 
The expression levels of AzI were determined by Western blot analysis in the normal-
like breast cell line MCF-10A and in the breast cancer cell lines JIMT-1, MCF-7 and L56Br-
C1. A strong band corresponding to the molecular weight of AzI (49 kDa) was found in all 
the cell lines examined (Fig. 45). In JIMT-1 cells, the AzI signal appeared stronger for all 
time points in cells treated with Pd-NSpd, compared to control and NSpd-treated cells (Fig. 
45). In MCF-10A cells, a strong AzI signal was observed 24 h after seeding (when treatment 
started), which remained elevated for at least another day, before slowly decreasing. There 
were no major differences between the treatments (Fig. 45). In MCF-7 cells, treatment with 
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NSpd or Pd-NSpd appeared to increase the cellular AzI levels at 24 and 72 h after treatment, 
compared to control cells (Fig. 45). However, no major difference was observed between the 
two treatments. In L56Br-C1 cells, treatment with Pd-NSpd decreased the AzI levels after 48 
and 72 h, while NSpd treatment did not affect the cellular AzI levels, compared to control 
(Fig. 46). No major differences were observed between the various treatments after 24 h. A 
small increase in the AzI levels was observed after 48 h of treatment with Pt-NSpd. 
 
 
 
Figure 45: Effect of NSpd or Pd-NSpd treatment on the AzI protein levels in JIMT-1, MCF-10A 
and MCF-7 cells. Twenty-four h after seeding of cells (0 h time of treatment in the figure), NSpd or Pd-NSpd 
was added to a final concentration of 25 µM. Western blot analysis was used to detect the AzI protein. Loading 
was based on cell number: 75000 cells per lane. The data are representative of two independent cultures from 
one experiment. C: control, NS: NSpd, Pd: Pd-NSpd. 
 
 
 
Figure 46: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on the AzI protein levels in L56Br-C1 
cells. Twenty-four h after seeding of cells (0 h time of treatment in the figure), NSpd, Pd-NSpd or Pt-NSpd was 
added to a final concentration of 25 µM. Western blot analysis was used to detect the AzI protein. Loading was 
based on cell number: 75000 cells per lane. The data are representative of two independent cultures from one 
experiment. C: control, NS: NSpd, Pd: Pd-NSpd, Pt: Pt-NSpd. 
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       3.2.2.    BENSpm, CPENSpm, Pd-BENSpm, Pd-Spm and Pt-CPENSpm 
It has been previously shown that several breast cancer cell lines were highly sensitive 
to treatment with Pd(II)-polyamine analogues and that these chelates were more toxic than 
their Pt(II) counterparts against the same breast cancer cell lines [169]. This led us to 
investigate the cytotoxic effects of two known and widely used polyamine analogues, 
BENSpm and CPENSpm, and three synthesised complexes, Pd-BENSpm, Pd-Spm and Pt-
CPENSpm on three different human breast cancer cell lines (JIMT-1, L56Br-C1 and MCF-7) 
and one immortalised normal-like breast epithelial line (MCF-10A).  
 
MTT Reduction 
The MTT assay was used to analyse the toxicity of BENSpm, Pd-BENSpm, 
CPENSpm or Pt-CPENSpm against the four cell lines investigated, using concentrations that 
ranged from 0.1 to 100 µM. In general, MTT reduction decreased, when increasing 
concentration as well as time of treatment. However, the reactions to each treatment differed 
between the four cell lines (Fig. 47). The dose response curves show that Pt-CPENSpm was 
found to be the least cytotoxic compound and that BENSpm, Pd-BENSpm and CPENSpm all 
had similar effects on the individual cell lines. In fact, Pt-CPENSpm treatment resulted in 
similar toxicity in all cell lines. Since BENSpm, Pd-BENSpm or CPENSpm treatment was 
highly cytotoxic in L56Br-C1 cells, the difference between those three drugs and Pt-
CPENSpm was most obvious in this particular cell line. Based on these data and on 
previously published data on BENSpm and CPENSpm [107,112,292-294], the concentration 
10 µM was used for further studies. 
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Figure 47: Dose response effect of BENSpm, Pd-BENSpm, CPENSpm or Pt-CPENSpm 
treatment. The normal-like breast cell line MCF-10A (A–C) and the three breast cancer cell lines JIMT-1 (D–
F), L56Br-C1 (G–I) and MCF-7 (J–M) were used. Twenty-four h after seeding of cells in 96-well plates, the 
compounds to be tested were added to the final concentrations shown in the figure and the cells were treated for 
24, 48 and 72 h, before evaluation using an MTT assay. The results are expressed as % of control (n=12 
independent samples from two independent experiments) with bars representing ± SEM. When not visible, the 
bars are covered by the symbols. 
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Effect of Short Time Exposure on Cell Proliferation 
We next investigated the effects of the compounds on cell proliferation (Fig. 48 A-D). 
As shown in the MTT assay, Pt-CPENSpm was the least cytotoxic compound (Fig. 47). 
Actually, Pt-CPENSpm did not affect proliferation of MCF-10A (Fig. 48 A) and L56Br-C1 
(Fig. 48 C) cells, but slightly inhibited proliferation of JIMT-1 (Fig. 48 B) and MCF-7 (Fig. 
48 D) cells. Pd-Spm treatment did not affect proliferation of MCF-10A cells, while BENSpm, 
Pd-BENSpm and CPENSpm slightly reduced the cell numbers at 48 h and 72 h of treatment 
(Fig. 48 A). In L56Br-C1 cells, treatment with BENSpm, Pd-BENSpm or CPENSpm resulted 
in a decrease in cell number after 48 h and 72 h compared to the cell number at 24 h, 
implicating cell death (Fig. 48 C). Pd-Spm also resulted in a slight decrease in cell number in 
L56Br-C1 cells. In JIMT-1 (Fig. 48 B) as well as in MCF-7 (Fig. 48 D) cells, the inhibition of 
cell proliferation was similar after treatment with BENSpm, Pd-BENSpm, CPENSpm or Pd-
Spm. In conclusion, the cell proliferation assay shows that the least sensitive cell line was 
MCF-10A and the most sensitive one was L56Br-C1. 
 
Effect of Long Time Exposure on Cell Proliferation 
In addition to the 72 h proliferation study, we also evaluated the effect of repeated 
treatment cycles with 10 µM BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm 
on cell proliferation of MCF-10A, JIMT-1 and L56Br-C1 cells (Fig. 48 E–G). The cells were 
cultivated in cycles with drug treatment for 72 h along with drug free periods of 96 h in 
between, for a total period of 5 cycles. Proliferation of MCF-10A normal-like breast cells 
were not affected by repeated treatment cycles with either Pt-CPENSpm or Pd-Spm (Fig. 48 
E), while repeated treatments with these compounds had a somewhat inhibitory effect on the 
growth of JIMT-1 cells (Fig. 48 F). In L56Br-C1 cells, repeated treatments with Pd-Spm 
resulted in a reduction of cell number after 4 treatment cycles. Repeated treatment with 
BENSpm, Pd-BENSpm or CPENSpm resulted in a decrease in cell number, compared to the 
number of cells seeded at time 0, in all cell lines (Fig. 48 E–G).   
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Figure 48: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm treatment on 
the cell proliferation. Twenty-four h after seeding of MCF-10A, JIMT-1, L56Br-C1 and MCF-7 cells (0 h 
time of treatment in the figure), BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm was added to a 
final concentration of 10 µM (A–D). Cells were harvested by trypsinisation and counted in a hemocytometer. 
The results are presented as mean values (n=6 samples from two independent experiments) and bars represent ± 
SEM. The bars are covered by the symbols. E–G: Cells were seeded and BENSpm, Pd-BENSpm, Pd-Spm, 
CPENSpm or Pt-CPENSpm was added to the final concentration of 10 µM, after 24 h of seeding. After 72 h of 
treatment, the drug-containing medium was aspirated and drug free culture medium was added. After an 
additional 72 h of incubation, cells were harvested by trypsinisation and counted in a hemocytometer. These 7 
days were defined as one treatment cycle. The cells were reseeded at the same density as at the previous passage 
and treated with the same drug for the next treatment cycle. All together this was repeated for 5 treatment cycles. 
The total recovery time between repeated treatments was 96 h. The results are presented as mean values (n=3 
samples from one independent experiment) and bars represent ± SEM. The bars are covered by the symbols. 
Please note that the y-axis has different scales for the different cell lines because of different rates of cell 
proliferation. *** p < 0.001 compared to control for the curves below the symbol. 
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Intracellular Pd(II) and Pt(II) Accumulation  
ICP-MS was used to quantify the Pd(II) or Pt(II) content in cells treated with 10 µM 
Pd-BENSpm, Pd-Spm or Pt-CPENSpm for 72 h and the data were used to calculate the 
intracellular concentrations of the drugs (Fig. 49). The data demonstrate that the intracellular 
concentration of Pd-BENSpm was approximately 20, 40 and 360 pmol/10
6
 cells in MCF-10A 
(Fig. 49 A), JIMT-1 (Fig. 49 B) and L56Br-C1 (Fig. 49 C) cells, respectively. The Pd-Spm 
and Pt-CPENSpm concentrations were between 2 and 15 pmoles/10
6
 cells in the three cell 
lines, with the highest concentrations in MCF-10A cells and the lowest concentrations in 
L56Br-C1 cells. 
 
 
 
Figure 49: Intracellular concentration of Pd-BENSpm, Pd-Spm and Pt-CPENSpm in MCF-10A, 
JIMT-1 and L56Br-C1 cells. At 72 h of treatment with 10 µM of Pd-BENSpm, Pd-Spm or Pt-CPENSpm, 
cells were harvested, pooled and digested in HNO3 (see Materials and Methods). The supernatant was used for 
analysis of Pd(II) and Pt(II) by ICP-MS and the data used to calculate the intracellular Pd-BENSpm, Pd-Spm and 
Pt-CPENSpm concentrations in MCF-10A (A), JIMT-1 (B) and L56Br-C1 (C) cells. The results are presented as 
mean values (n=3 independent samples from one independent experiment) and bars represent ± SEM. *** p < 
0.001 compared to Pd-Spm or Pt-CPENSpm treatment. 
 
Analysis of Polyamine Levels 
Since L56Br-C1 was found to be the most sensitive cell line, it was of interest to 
measure the polyamine levels in these cells (by HPLC), after 24 h of incubation with 10 µM 
of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm (Fig. 50). As expected, the 
putrescine (Fig. 50 A), spermidine (Fig. 50 B) and spermine (Fig. 50 C) contents decreased 
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significantly upon treatment with BENSpm, Pd-BENSpm or CPENSpm, compared to control. 
Pt-CPENSpm treatment resulted in a minor increase in polyamine levels compared to control, 
while Pd-Spm treatment only had a neglible effect (Fig. 50 A–C).  
 
 
 
Figure 50: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm treatment on 
the polyamine content in L56Br-C1 cells. After 24 h of treatment with 10 µM of BENSpm, Pd-BENSpm, 
Pd-Spm, CPENSpm or Pt-CPENSpm, cells were harvested, counted in a hemocytometer and then putrescine 
(A), spermidine (B) and spermine (C) contents were determined by HPLC. The results are presented as mean 
values (n=3 independent samples from one independent experiment) and bars represent ± SEM. When not 
visible, the bars are covered by the symbols. * p < 0.05 compared to control; ** p < 0.01 compared to control; 
*** p < 0.001 compared to control. 
 
SSAT Activity 
 Since the polyamines were efficiently depleted by BENSpm and Pd-BENSpm, the 
next step was to measure the activity of the polyamine catabolic enzyme SSAT. The SSAT 
activity was very low in the untreated L56Br-C1 cells, but increased dramatically after 
treatment with BENSpm, Pd-BENSpm or CPENSpm (Fig. 51). The increase in SSAT activity 
was twice as high in cells treated with BENSpm or Pd-BENSpm than in CPENSpm-treated 
cells. In Pd-Spm- or Pt-CPENSpm-treated cells the SSAT activity was found to be zero.  
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Figure 51: SSAT activity in L56Br-C1cells treated with BENSpm, Pd-BENSpm, Pd-Spm, 
CPENSpm or Pt-CPENSpm. After 24 h of treatment with 10 µM of BENSpm, Pd-BENSpm, Pd-Spm, 
CPENSpm or Pt-CPENSpm, cells were harvested, counted in a hemocytometer and then the SSAT activity was 
determined using a radiometric assay. The results are presented as mean values (n=6 independent samples from 
two independent experiments) and bars represent ± SEM. ** p < 0.01 compared to control; *** p < 0.001 
compared to control. 
 
Cell Cycle Phase Distribution and Cell Death 
Since the various compounds used in the present study were shown to affect cell 
proliferation differently, the effects of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-
CPENSpm on cell cycle phase distribution as well as on cell death were analysed by FCM. 
The data show that the only cell line in which the percentage of cells in the sub-G1 
region, which reflects cell death, increased substantially was the L56Br-C1 cell line (Fig. 52). 
When treating L56Br-C1 cells with BENSpm, Pd-BENSpm or CPENSpm, cell death was 
already induced after 48 h of treatment. No cell death was observed in MCF-10A and JIMT-1 
cells. As also seen in Fig. 52, a large fraction of untreated L56Br-C1 cells was found in the 
sub-G1 region indicating (or demonstrating) a high degree of spontaneous apoptotic cell death 
[295]. 
In MCF-10A cells, the number of cells in the G1 phase increased from around 50% to 
80% between 24 and 48 h of treatment with BENSpm, Pd-BENSpm or CPENSpm. During 
the same time period, the percentage of cells in the S phase decreased from 40 to 10%. Less 
evident changes were found in the cell cycle phase distribution of JIMT-1 cells after treatment 
(Fig. 52), with the exception of Pd-Spm treatment, which increased the number of cells in S 
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phase approximately 10% after 24 and 48 h of treatment, compared to the other treatments. In 
L56Br-C1 cells, cell death was so prominent that is was not possible to evaluate the DNA 
histograms at 48 and 72 h of treatment.  
 
 
 
Figure 52: Sub-G1 region and cell cycle phase distribution of MCF-10A, JIMT-1 and L56Br-C1 
cells treated with BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm. Twenty-four h 
after seeding the cells, BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm was added to a final 
concentration of 10 µM. At 24, 48 and 72 h of treatment, both detached and attached cells were harvested, 
pooled and fixed in 70% ice-cold ethanol. The nuclei were stained with PI and the analysis was performed using 
FCM. The results are presented as mean values (n=3 independent samples from one independent experiment) 
and bars represent ± SEM. 
 
Identification of the Cancer Stem Cell Population CD44
+
CD24
-
  
 To investigate the effects on the putative breast CSC population, here defined as 
CD44
+
CD24
- 
[283], JIMT-1 cells were treated for 72 h with 10 µM BENSpm, Pd-BENSpm, 
Pd-Spm, CPENSpm or Pt-CPENSpm and the data was analysed by FCM. As shown in Fig. 
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53 (A, B), treatment with both BENSpm and Pd-BENSpm significantly reduced the levels of 
the CD44
+
CD24
-
 subpopulation from 50% (total population in the control cells) to 30% and 
33%, respectively, whereas treatment with Pd-Spm, CPENSpm and Pt-CPENSpm gave a not 
statistically significant increase in the CD44
+
CD24
-
 subpopulation (Fig. 53). 
 
 
 
Figure 53: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm treatment on 
the CD44
+
CD24
-
 putative cancer stem cell population in JIMT-1 cells. After 72 h of treatment with 
10 µM of the drugs, cells were harvested with Accutase and identified based on their expression of the cell 
surface markers CD44 and CD24 by FCM. A: Representative cytograms of the flow cytometric analysis of cell 
surface-expressed CD44 and CD24 in the JIMT-1 breast cancer cell line. B: Table showing the data obtained 
with each treatment. The results are presented as percentage of total population (n=9 independent samples from 
three independent experiments) ± SEM. *** p < 0.001 compared to control. 
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Colony Forming Efficiency 
The immortalised normal-like cell line MCF-10A does not form colonies in soft agar 
and was not used in this assay. In the JIMT-1 and L56Br-C1 breast cancer cell lines, all the 
treatments decreased the CFE, compared to the control (Table 14). The CFE was similar in 
JIMT-1 and L56Br-C1 control cells, around 30%. Pd-BENSpm treatment was most efficient 
in reducing the number of colonies and L56Br-C1 was the most sensitive cell line to all the 
treatments (Table 14). 
 
Table 14: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm treatment on 
colony forming efficiency in soft agar
1
. 
1
Cells were seeded and the drugs (10 µM) were added 24 h later. After 72 h of treatment, the cells were 
harvested, counted and reseeded at low density in soft agar. Colonies were counted 14 days after incubation. 
The results are presented as mean values (n=3 independent cultures) ± SEM or as percentage of control (in 
brackets). *** p < 0.001 compared to control.
 
 
Assessment of the Genotoxic Potentials of BENSpm and Pd-BENSpm  
Regarding genotoxicity classification, a test compound is considered to be genotoxic if 
the average reporter gene induction at any dose tested is over 1.5 fold. The Anthem’s Genotox 
screen was used for assessing the genotoxic potential of BENSpm and Pd-BENSpm, in a 
genetically engineered stable p53 proficient HCT116 cell line. 
Fig. 54 shows that both p21 and p53, but not GADD153, where induced by BENSpm 
(Fig. 54 A) and Pd-BENSpm (Fig. 54 B) treatments, at 5 and 10 µM concentrations. Thus, 
both compounds can be considered as genotoxins in this screen, indicating that they may 
induce DNA strand breaks.  
Cell line JIMT-1 L56Br-C1 
Control (%) 29.4 ± 1.0 32.7 ± 1.9 
BENSpm (%) 15.1 ± 0.5 (51.2) *** 10.8 ± 0.5 (33.0) *** 
Pd-BENSpm (%) 12.1 ± 0.3 (41.3) *** 7.8 ± 0.1 (23.7) *** 
Pd-Spm (%) 20.5 ± 0.3 (69.7) *** 17.0 ± 1.0 (51.8) *** 
CPENSpm (%) 16.4 ± 0.8 (55.7) *** 11.8 ± 1.0 (36.2) *** 
Pt-CPENSpm (%) 24.1 ± 0.4 (82.1) *** 24.0 ± 0.5 (73.2) *** 
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Figure 54: Genotoxic effect of BENSpm or Pd-BENSpm in genetically engineered reporter-
based HCT-p21-GADD-p53 cells. The genetically engineered reporter-based HCT-p21-GADD-p53 cells 
carrying the DNA damage early sensors p21, GADD153 and p53 were seeded in 96-well plates and allowed to 
attach for 16 h. The p21 promotor was operatively linked to Renilla luciferase reporter gene, the GADD 153 
promotor operatively linked to firefly luciferase reporter gene and the p53 response elements operatively linked 
to β-galactosidase reporter gene. Sixteen h after seeding, the polyamine analogue and its complex were added to 
the final concentrations shown in the figure and incubated for 72 h. The samples were analysed for Renilla 
luciferase, firefly luciferase and β-galactosidase. The results are presented as mean values (n=3 independent 
samples from one independent experiment) and bars represent ± SD. 
 
Single Cell Gel Electrophoresis  
The SCGE assay was performed to investigate if any of the compounds induced DNA 
strand breaks. Table 15 shows the percentage of comets in relation to the total number of 
nucleoids scored, after 72 h of treatment. There were fewer nucleoids with comets in control 
MCF-10A and JIMT-1 cells, compared to L56Br-C1 cells. All treatments resulted in an 
increase in the number of nucleoids with a comet in all cell lines, although the increase was 
most prominent in L56Br-C1 cells. Of the five tested compounds, Pd-BENSpm was the most 
efficient in increasing the number of nucleoids with comets. Figure 55 shows the comets of 
the most sensitive cell line (L56Br-C1). 
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Table 15: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm treatment on the 
number of comets in MCF-10A, JIMT-1 and L56Br-C1 cell lines, evaluated by the SCGE assay
1
. 
Cell Line MCF-10A JIMT-1 L56Br-C1 
Control 4.6 ±1.0 4.5 ± 1.5 8.1 ± 0.8 
BENSpm 11.0 ± 1.6 ** 18.3 ± 3.7 * 30.5 ± 2.4 *** 
Pd-BENSpm 11.2 ± 1.0 ** 23.8 ± 4.0 ** 41.2 ± 3.8 *** 
Pd-Spm 9.2 ± 0.9 14.3 ± 3.0 * 24.2 ± 2.4 ** 
CPENSpm 11.3 ± 1.5 ** 16.1 ± 3.9 * 27.2 ± 2.2 *** 
Pt-CPENSpm 9.0 ± 1.6 11.1 ± 2.0 18.4 ± 2.1 * 
1
Cells were seeded and the drugs (10 µM) were added 24 h later. After 72 h of treatment, the cells were 
harvested by trypsinisation and the SCGE assay was performed as previously described. The results show 
the percentage of comets in relation to the total number of nucleoids scored and are presented as mean 
values of three independent samples from one experiment (n=150 cells) ± SEM. * p < 0.05 compared to 
control; ** p < 0.01 compared to control; *** p < 0.001 compared to control. 
 
 
 
Figure 55: Evaluation of DNA damage in L56Br-C1 cells by the SCGE assay. Twenty-four h after 
seeding the cells, BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm was added to a final 
concentration of 10 µM. After 72 h of treatment, the cells were harvested for SCGE assay analysis. The EtBr-
stained nucleoids were photographed with a digital camera attached to an epifluorescence microscope. The total 
number of nucleoids and the nucleoids with comet tails were visually counted in each image. A nucleoid with 
comet tail was defined as a nucleoid with a visible tail independent of tail size. For every sample, the % of 
nucleoids with a comet tail was calculated. Thus, for every treatment, three values (in %) were obtained, which 
were used for the calculation of mean ± SEM. The green arrows represent undamaged cells while the blue 
arrows represent the smallest nucleoids with comet tail counted. Images of comets obtained for the untreated 
(A), BENSpm- (B), Pd-BENSpm- (C), Pd-Spm- (D), CPENSpm- (E) or Pt-CPENSpm-treated (F) samples.  
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GSH-Glo
™
 Glutathione Assay 
The GSH-Glo
™ 
Glutathione assay is a luminescence-based method used for the 
detection and quantification of GSH levels in cells, tissue extracts or blood. Since the toxicity 
of cisplatin has been shown to be dependent on the cellular GSH level [296], we decided to 
investigate the effect of the compounds on the GSH level.  
Table 16 shows that Pd-Spm treatment efficiently reduced the GSH levels in all cell 
lines. In Pd-Spm-treated cells, the level was below the detection limit of the assay and thus 
the value was set to 0. Treatment with BENSpm, Pd-BENSpm or CPENSpm resulted in a 
marked reduction of cellular GSH levels. The decrease in cellular GSH was most prominent 
in the L56Br-C1 cells. Pt-CPENSpm treatment, on the other hand, only slightly reduced or 
even increased the GSH level, depending on the cell line. 
In addition to the effects of the various treatments on the GSH level, Table 16 also 
shows the effects on cell growth (given as % of cells relative to control at 48 h of treatment). 
The cell data are derived from the growth curves shown in Fig. 48 A–C. Comparing the GSH 
levels and cell growth, it is clear that there is no obvious correlation between decrease in GSH 
and reduction of cell number in any of the cell lines.  
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Table 16: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm treatment on the 
levels of GSH in MCF-10A, JIMT-1 and L56Br-C1 cell lines, evaluated by the GSH-Glo
™
 
Glutathione Assay
1
. 
Cell Line MCF-10A 
 
Control BENSpm Pd-BENSpm Pd-Spm CPENSpm Pt-CPENSpm 
GSH 
(nmol/106cells) 
34.3 ± 1.7 25.8 ± 1.8 26.9 ± 2.6 0.0 22.7 ± 2.5 40.7 ± 2.5 
GSH 
(% of control)  
75.1*** 78.4*** 0.0*** 66.2*** 118.5** 
Cells 
(% of control)  
55.4 58.8 75.5 52.1 90.4 
Cell Line JIMT-1 
GSH 
(nmol/106cells) 
30.9 ± 1.5 17.1 ± 1.9 7.9 ± 0.8 0.0 18.6 ± 2.4 20.0 ± 5.8 
GSH 
(% of control)  
55.1*** 25.6*** 0.0*** 60.0*** 64.8*** 
Cells 
(% of control)  
65.9 57.6 70.8 67.7 79.4 
Cell Line L56Br-C1 
GSH 
(nmol/106cells) 
15.1 ± 1.0 2.8 ± 0.4 0.5 ± 0.5 0.0 1.0 ± 0.2 21.3 ± 4.2 
GSH 
(% of control) 
        18.6*** 3.0*** 0.0*** 6.8*** 140.3*** 
Cells 
(% of control)  
19.0 14.9 41.5 20.1 87.0 
1
Cells were seeded in white opaque 96-well plates and the compounds were added 24 h later to a final 
concentration of 10 µM. After 48 h of treatment, the plates were removed from the incubator and the GSH-
Glo
™
 Glutathione assay was performed according to the instructions of the manufacturer. The results of the 
GSH assay are presented as nmol/10
6
 cells (mean ± SD) (n=3 independent samples from one experiment) and 
as percentage of control. In Pd-Spm-treated cells, the level was below the detection limit of the assay and 
thus the value was set to 0. The data in the row defined as Cells were derived from the growth curves (Fig. 48 
A–C). The number of cells in each treatment as % of control was calculated at 48 h of treatment. ** p < 0.01 
compared to control; *** p < 0.001 compared to control. 
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“The important thing in Science is not so much to obtain new facts as to discover new 
ways of thinking about them.” 
Sir William Lawrence Bragg 
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4.  Discussion  
The leading aim of many research groups across the world is to find a proper and 
highly efficient anticancer drug that can be applied in the treatment of human tumours, 
overcoming the resistance often developed upon drug administration [133]. Among all types 
of cancer, the one that causes one of the highest death rates among women worldwide is still 
breast cancer [297]. For this reason, new treatment strategies are needed and the initial step is 
to synthesise new chemotherapeutic agents and further test them in breast cancer cell lines, in 
order to select promising candidates that can be used in the clinic.  
 In this thesis, three different modified (N-alkylated) biogenic polyamines (NSpd, 
BENSpm and CPENSpm) and their newly synthesised Pd(II) and Pt(II) chelates Pd-NSpd, Pt-
NSpd, Pd-BENSpm, Pt-CPENSpm and Pd-Spm (Fig. 9) were structurally characterised by 
vibrational spectroscopy and analysed for their anticancer activity against various human 
breast cancer cell lines. This type of agents were chosen in view of the promising results 
already obtained for bi- and trinuclear Pd(II) and Pt(II) spermidine and spermine complexes, 
regarding their interaction with DNA and their antineoplastic properties [156,170,171,191-
193].  
 
 Characterisation of the Compounds by Vibrational Spectroscopy 
 Linear alkylpolyamines, such as the biogenic polyamines spermidine and spermine or 
the presently investigated analogues, can adopt numerous conformations depending on the 
dihedral angles that determine their overall orientation, the most common ones being 60
o
 
(gauche), 180
o
 (trans) and –60o (gauche´). At physiological pH, all the nitrogen atoms of 
these polyamines are protonated, which hinders the formation of intramolecular (N)H 
…
 N or 
(C)H 
…
 N hydrogen bonds and favouring the all-trans conformation energetically. Under 
these conditions, electrostatic and steric effects determine the energetically favoured 
geometrie(s) for these molecules. Previous conformational analysis of α,ω-diamines 
(H2N(CH2)nNH2, n=2 to 10 and n=12), as well as of the larger spermidine (triamine) and 
spermine (tetramine) systems [201,203,298-302] have demonstrated that the all-trans 
conformation is the predominant or even the sole conformation at room temperature for this 
kind of totally extended polycationic molecules, in the solid state.  
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 The conformational preferences of the compounds used in the present study were 
obtained through vibrational analysis – FTIR and Raman spectroscopies. Interpretation of the 
experimental data was assisted by the calculated geometries and corresponding vibrational 
pattern, and a quite good agreement was obtained. 
 The bands due to the rocking modes of the terminal NH3 groups (particularly intense 
in infrared, Fig. 31) were only observed for NSpd, as expected, since BESpm, BENSpm and 
CPENSpm are alkylated at the terminal nitrogen atoms. However, the features occurring at 
about 1600 cm
-1
, assigned to NH2 symmetric and antisymmetric deformations (from the 
central amine groups), were detected in all the modified polyamines. As expected, the NH 
stretching vibrations have a larger IR intensity as compared to Raman. It is interesting to note 
that the Raman spectrum of NSpd displays quite strong (NH3) modes from the terminal NH3 
groups (that are absent in the alkylated polyamines), while the corresponding vibrations for 
the central NH2 moieties are hardly detectable. 
 Some of the typical acoustic modes of this kind of all-trans extended molecules, 
comprising repeated CH2/NH2 units [300,302] – either longitudinal (LAM’s) or transverse 
(TAM’s) – were detected in the low frequency region of the Raman spectra for NSpd and 
CPENSpm. Additionally, NSpd and BENSpm being centrossymmetric species, a 
complementary IR and Raman pattern was obtained, as opposed to their biogenic counterparts 
spermidine and spermine [201,203]. 
 The polyamine chelates presently studied vary in their coordination pattern, according 
to the type of ligand – either tri- or tetramine: in (MCl2)3(NSpd)2 (M-NSpd) (M = Pt(II) or 
Pd(II)), two of the metal ions are bound to each of the NSpd ligands, while the third is shared 
by both amines. In Pd-BENSpm and Pt-CPENSpm, in turn, the two metal centres coordinate 
to the four nitrogens of the spermine-like molecule (Fig. 10). The spectroscopic data presently 
gathered confirms this type of coordination, both Pt(II) and Pd(II) being known to have a 
significant affinity for nitrogen atoms. Hence, upon metal binding to the polyamines, some 
expected changes occurred in the vibrational features of the ligands. These include:  
 
(i)  intensity variation of the amine stretching bands – for BENSpm and CPENSpm they 
are hardly observable for the free ligands but become quite intense for the corresponding 
complexes (Figs. 32 and 33). In contrast, for NSpd and its complexes the intensity of these 
features lowers upon metal binding (Fig. 34);  
(ii)  marked shift of the NH stretching bands to higher frequencies;  
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(iii) loss of the main deformation bands assigned to the NH2/NH3 groups, namely 
(NH2), (NH3) and r(NH3) (Figs. 32 to 34);  
(iv) detection of characteristic Raman bands below ca. 600 cm
-1
, ascribed to (Cl-M-Cl) 
and (N-M-N) deformations, as well as to symmetric and antisymmetric (Cl–M–Cl) and (N–
M–N) stretching modes (Figs. 32 to 34, Tabs. 9 to 11). These features allow to identify the 
presence of the complex after the synthetic procedure. 
Overall, complexation of the polyamine ligands leads to a marked weakening of the 
Raman bands at higher wavenumbers (above 1000 cm
-1
) relative to the very intense signals 
that appear below ca. 600 cm
-1
, which are due to strong vibrational modes involving the metal 
and its first coordination sphere. 
 These results are in accordance with the previously gathered data for cisplatin and its 
Pd(II) homologue [200,205,211,290], as well as for the similar polynuclear spermidine 
(M3Spd2) and spermine (M2Spm) chelates (M=Pt(II) or Pd(II)) [unpublished data]. Actually, 
comparison of the vibrational profile of the presently investigated cisplatin-like chelates, 
comprising two or three (MCl2(NH3)2) moieties, with cisplatin’s vibrational pattern [290] 
indicates that the deformation and stretching modes involving the metal centre, either Pt(II) or 
Pd(II), occur in defined spectral regions irrespective of the type of species – either the 
mononuclear cisplatin and its Pd(II) homologue, or the di- and trinuclear polyamine chelates – 
since they reflect a very similar metal coordination sphere (Table 9). 
 
 Evaluation of the Cellular Impact 
 Within the drug discovery field of cancer treatment, the study of the cellular impact of 
a potential anticancer agent by the use of methods that evaluate cell proliferation and cell 
cycle phase distribution, metabolic activity and cell death constitute important approaches. 
Since deregulation of cell proliferation is known to be a hallmark of cancer, the pathways 
involved are an essential source of new targets for cancer therapy [2]. 
 Taking this into account, the next step was to test the cytotoxic activity of these 
compounds against a wide range of breast cancer cell lines, using different biological assays 
in an attempt to fully evaluate their cellular effects. 
 The four breast cancer cell lines (JIMT-1, L56Br-C1, MCF-7 and MDA-MB-231) and 
the immortalised normal-like breast epithelial cell line (MCF-10A) were first used to 
investigate the cytotoxic effects of the spermidine analogue NSpd and its newly synthesised 
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trinuclear Pd(II) and Pt(II) complexes (Pd-NSpd and Pt-NSpd, respectively). In general, the 
results showed that the different cell lines reacted differently to the treatment with NSpd, Pd-
NSpd or Pt-NSpd, the normal-like MCF-10A line being the least sensitive. 
 As determined by the MTT assay, administration of NSpd, Pd-NSpd or Pt-NSpd 
resulted in decreased cell viability and an increased growth inhibition in a dose- and time-
dependent manner. MCF-10A was shown to be the least affected cell line while L56Br-C1 
was the most sensitive one. Interestingly, the polyamine analogue NSpd, which has not been 
tested before, presented a clear growth inhibitory effect. The effect obtained with the Pd(II) 
complex of NSpd was usually similar to that obtained with NSpd. However, a clear difference 
was seen between the two NSpd complexes. In fact, Pd-NSpd treatment resulted in much 
higher MTT reduction than Pt-NSpd treatment in all the cell lines tested, demonstrating it to 
be considerably more cytotoxic than the homologous Pt(II) complex.  
 Similar results were obtained in a cell proliferation assay in which the L56Br-C1 was 
the most sensitive cell line, whereas the MCF-10A cells were hardly affected by either of the 
drugs. In this assay, Pd-NSpd was shown to have a somewhat stronger antiproliferative effect 
on the breast cancer cell lines than NSpd. In addition, the Pd-NSpd effect was also stronger 
than that of the homologous Pt(II) complex. Results from repeated cycles of drug treatment 
and withdrawal demonstrated that the breast cancer cells did not easily recover from treatment 
with NSpd or Pd-NSpd. Again, the L56Br-C1 cells were the most sensitive ones, 
demonstrating an unchanged or decreased cell number after repeated cycles of treatment with 
NSpd or Pd-NSpd, respectively. Interestingly, the breast cancer cells appeared to recover 
quickly from the antiproliferative effect of Pt-NSpd. Only minor effects on cell proliferation 
were observed when treatment with Pt-NSpd was combined with withdrawal periods. The 
results are in accordance with those of published studies regarding other Pd or Pt-polyamine 
complexes, namely Pd(II)- and Pt(II)-spermine complexes [133,156,170,191,192], where the 
substitution of Pt(II) for Pd(II) increased the cytotoxicity of the drug [171]. Actually, this 
substitution was shown to significantly increase the anticancer effect against the human 
squamous carcinoma cell line (HSC-3) [156,170].  
 In most cell types, two classes of polyamine transport systems have been recognised: 
one that is sodium dependent with a preference for putrescine and one that is sodium 
independent with a preference for spermidine and spermine. The polyamine transport system 
is energy-, time-, temperature-, and concentration-dependent and saturable, suggesting it is a 
carrier-mediated transport. However, this system has a low specificity and, thus, can be 
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responsible for the transport of various molecules, like polyamine-based compounds, into the 
cell [53,85]. In general, and since the transporter is not specific for putrescine, spermidine or 
spermine, the affinity of the carrier increases to amines which have chain lengths resembling 
those of spermidine or spermine. It has also been shown that the primary nitrogen groups 
from the polyamines seem to be critical for uptake [87]. Primary amines are present in the 
linear NSpd, Pd-NSpd and Pt-NSpd (terminal amino groups), thus pointing to a possibility of 
these compounds being taken up by the polyamine transporter. In this study, it was shown that 
only NSpd competed efficiently with 
3
H-spermidine uptake in all four cell lines, indicating 
that NSpd uses the same polyamine transport system as spermidine to enter the cell. 
Regarding the complexes, Pd-NSpd inhibited 
3
H-spermidine uptake to a higher degree 
compared to Pt-NSpd, but still much less compared to NSpd. It is unclear how these chelates 
are transported into the cell but, since they share similarities with cisplatin, it is possible that 
they enter the cell in the same way. It was recently found that CTR1 and CTR2 modulate the 
uptake of Pt(II)-based anticancer drugs, such as cisplatin [137,143,149,151]. Currently, the 
CTR1 is known to act as a major Pt-drug transporter in several cell systems [143]. Therefore, 
the presently investigated complexes might also enter the cell using the CTR1 transporter or, 
since they are considerably more lipophilic than cisplatin (due to the presence of the 
alkylpolyamine ligands), by passive diffusion across the membrane to a larger extent. In 
addition they may partly use the polyamine transport system, as well. Again, minor structural 
differences can have important effects on activity, which was clearly shown through the 
substitution of a Pd by a Pt centre [170,171].  
 The differences in cytotoxicity observed between Pd-NSpd and Pt-NSpd complexes 
may be caused by differences in cellular uptake. Attempts to estimate the content of the 
complexes in L56Br-C1 and MCF-10A cells revealed a large difference between the two cell 
lines. The most sensitive cell line, L56Br-C1, contained more than 10-fold higher 
concentrations of Pd-NSpd or Pt-NSpd compared to the least sensitive cell line MCF-10A, 
after treatment with the complexes for 3 days. The reason for this difference is not known. No 
major differences were seen in the ability of the complexes to inhibit the 
3
H-spermidine 
uptake in the cells, indicating that the uptake of the complexes may be unrelated to the 
polyamine transport system. Interestingly, the data showed that in MCF-10A cells the content 
of Pt-NSpd was higher than of Pd-NSpd after treatment with the complexes, suggesting a 
more efficient uptake of Pt-NSpd than of Pd-NSpd. The same was not shown in L56BR-C1 
cells, which contained equal amounts of the complexes after treatment. Nevertheless, Pd-
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NSpd exhibited stronger cytotoxicity than Pt-NSpd in all of the breast cancer cell lines tested, 
making it a more efficient agent from a cancer treatment approach. 
 High expression of ODC characterises some cancers, including breast cancer. 
Consequently, there has been a great effort to search for new compounds that can inhibit ODC 
activity in tumour cells [303]. In the present study, the increase in ODC activity in all cell 
lines registered 24 h after seeding is correlated to cell proliferation. The reason for ODC 
activity remaining elevated for somewhat longer time in L56Br-C1 cells, compared to the 
other cell lines, is not known. However, this cell line has the slowest growth rate of the ones 
used in the present study and it is conceivable that the duration of the ODC peak is somewhat 
connected to the growth rate of the cells. NSpd or Pd-NSpd treatment resulted in ODC 
inhibition in all the cell lines, except for the JIMT-1 cells. In comparison, no significant 
inhibition was observed with Pt-NSpd treatment. Although the ODC activity was significantly 
suppressed by NSpd or Pd-NSpd treatment in all cell lines, it is not clear if it contributes to 
the compounds cytotoxicity. Overall, there did not seem to be a clear correlation between the 
effects of the drugs on ODC activity and their antiproliferative effects (i.e. compare growth 
inhibitory effects and ODC suppression in JIMT-1 and MCF-10A cells). However, polyamine 
analogues are known to also activate the polyamine catabolic pathway leading to the 
depletion of the biogenic polyamines, which may be part of the growth inhibitory mechanism. 
 The DNA distribution of a cell population evaluated by FCM gives information about 
cell cycle phase distribution and cell death. The most consistent changes in cell cycle phase 
distribution were found in L56Br-C1 and JIMT-1 cells. Treatment of L56Br-C1 cells with Pd-
NSpd or NSpd resulted in an increase in the percentage of cells in sub-G1 region. This 
increase of the sub-G1 fraction was substantially higher after 72 h of treatment, demonstrating 
that treatment with either Pd-NSpd or NSpd induced cell death in this cell line. Consequently, 
the whole cell cycle phase distribution was affected, resulting in a decrease in the percentage 
of cells in G1 phase along with an increase in both S and G2 phases. Since cell death was 
induced and no cell proliferation was observed, cell death presumably took place in G1 cells. 
There was no marked cell death observed in JIMT-1, MCF-7 and MCF-10A cells by 
treatment with either of the drugs. However, in JIMT-1 cells, the percentage of cells in G1 
phase was increased already after 24 h of treatment with Pd-NSpd, indicating a block in this 
phase. This is also obvious from the growth curve analysis where we detected a block in cell 
proliferation at the same time point. In accordance with the results from the other growth 
experiments, no clear differences in cell cycle phase distribution were observed in MCF-10A 
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and MCF-7 cells treated with NSpd, Pd-NSpd or Pt-NSpd. Nevertheless, as small effects on 
the cell cycle progression may be highly significant from a pharmacological point of view, it 
was important to fully evaluate the cell cycle progression, namely the length of S and G2+M 
phases, by the use of a DNA BrdUrd flow cytometric method. Compared to controls, NSpd 
and Pd-NSpd-treated cells showed a significant prolongation of the S phase as well as the 
G2+M phase in all cell lines. The prolongation of both phases was less evident in Pt-NSpd-
treated cells. Polyamines are known to stabilise DNA, so replacement of natural polyamines 
with analogues may result in DNA destabilisation that could have caused the S phase 
prolongation in NSpd-treated cells. On the other hand, the interaction of the chelates with 
DNA occurs by covalent linkage to the nitrogen atoms of the bases, mainly the N7 of guanine 
and adenine, therefore disrupting the base-paring. These complexes form long-range, intra- 
and interstrand DNA adducts that are responsible for a more severe and less reparable damage 
than their counterparts (for instance, cisplatin) [133,135,178-180,304]. Effects on cell cycle 
kinetics are often related to cell cycle regulatory proteins and polyamine levels. However, in 
this study we did not analyse any cell cycle regulatory protein nor polyamine pools and thus 
no further conclusions can be drawn.  
 The results are further emphasised by the CFE in soft agar. The ability of forming 
colonies in soft agar is characteristic of malignant cells and reproduces the invasiveness of the 
cancer, so only the breast cancer cell lines were analysed. This assay showed a decrease in 
colony formation in all treated cells compared to the control, after 72 h of treatment. Again, 
this reduction was higher in NSpd or Pd-NSpd-treated cultures. The largest effect was 
obtained in the L56Br-C1 cell line with a decrease in colony forming efficiency of over 50%. 
In the mammalian genotoxicity screen, NSpd and Pt-NSpd were found to be potential 
genotoxins at 50 µM and 100 µM concentrations. In contrast, Pd-NSpd did not show any 
genotoxicity at any of the concentrations tested in the mammalian genotoxicity screen, 
although we cannot rule out genotoxicity in other assays. SCGE assay did not shown any 
induction of DNA strand breaks with 25 µM NSpd, Pd-NSpd or Pt-NSpd treatment in any of 
the cell lines. However, taking these results together, we can expect that induction of DNA 
strand breaks could be detectable when using a higher concentration of the drug (50 µM for 
NSpd and 100 µM for Pt-NSpd). 
 It has been shown that high levels of AzI induce polyamine biosynthesis, thus leading 
to enhanced intracellular polyamine pools and, consequently, to promotion of cell 
proliferation and transformation [79,80,89,93]. In addition, AzI has been shown to be induced 
in growth-stimulated mouse fibroblasts, as well as in certain forms of human cancers, 
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suggesting a role for AzI in proliferation and cell cycle progression [90,305]. Therefore, it 
was of relevance to study how the treatments with the compounds affected the AzI levels in 
the various cell lines. However, although a strong AzI band was detected in all the cell lines 
analysed, no clear differences were observed between the different treatments. Therefore, the 
decrease in cell proliferation mainly observed in NSpd- and Pd-NSpd-treated cells cannot be 
explained by a decrease in AzI expression levels. 
Taking into consideration the results obtained with NSpd and its Pd(II) and Pt(II) 
complexes, we next analysed the cytotoxic effects of the polyamine analogues BENSpm and 
CPENSpm, together with the metal-based polyamine complexes, Pd-BENSpm, Pd-Spm and 
Pt-CPENSpm on JIMT-1, L56Br-C1, MCF-7 and MCF-10A human breast cell lines.  
Previous studies have shown that both BENSpm and CPENSpm effectively inhibit cell 
proliferation in breast cancer cell lines [107,112-114]. Interestingly, the platination of 
CPENSpm clearly induced a marked reduction in toxicity in all the cell lines analysed in the 
present study. In contrast, the palladination of BENSpm increased the cytotoxic effect of the 
compound. The reason for this difference in not known, but may be related to the cellular 
uptake, which was significantly higher for Pd-BENSpm than for Pt-CPENSpm. These results 
are in agreement with the data obtained for NSpd, Pd-NSpd and Pt-NSpd, where it was 
observed that platination of NSpd significantly reduced the cytotoxic effect of the compound, 
whereas palladination did not [306]. However, the difference in cytotoxicity between the 
Pd(II) and the Pt(II) complex of NSpd was not explained by a difference in uptake, thus 
indicating an alternative mechanism. Furthermore, the use of chelating ligands in this fashion 
may render a very stable Pt(II) compound with reduced lability compared to its parent 
compound cisplatin and its palladium counterparts and, therefore, less prone to react with the 
cellular targets. 
The Pd(II) complex of spermine was used for comparison and was demonstrated to 
exert cytotoxic activity against the breast cancer cells tested. However, the natural polyamine 
spermine normally does not exhibit any major cytotoxic effects, as opposed to BENSpm and 
CPENSpm. Interestingly, only minor effects were observed with Pd-Spm in the normal-like 
breast epithelial cell line (MCF-10A). Pd-Spm has previously been demonstrated to also be 
cytotoxic against the breast cancer cell lines MCF-7 and MDA-MB-231 [192], as well as the 
human oral squamous carcinoma cell line HSC-3 [171]. In those studies, the effect of Pd-Spm 
seemed to be irreversible. No recovery was observed after withdrawal of the drug. 
Nevertheless, as shown in the present study, the cytotoxic effect of Pd-Spm was, at least, 
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partly reversible in the cell lines JIMT-1 and MCF-10A. The cytotoxic effects of Pd-BENSpm 
as well as of BENSpm and CPENSpm, on the other hand, appeared to be irreversible in all 
cell lines tested.  
The cell line that presented an overall higher sensitivity to the compounds tested was 
the L56Br-C1 (in accordance with the previous results obtained with NSpd, Pd-NSpd and Pt-
NSpd). Pd-BENSpm, BENSpm and CPENSpm were all strongly cytotoxic against L56Br-C1 
cells, as revealed by growth inhibition, increased cell death, decreased colony forming 
efficiency, as well as induction of DNA strand breaks. The uptake of Pd-BENSpm was much 
more efficient in the L56Br-C1 cells than in the other cell lines tested, which may partly 
explain the sensitivity of this cell line for the Pd(II) complex. Another possible explanation 
for the difference in sensitivity may lie in different redox potentials in the cell lines. 
Determination of the GSH level showed that the GSH pool was about 50% lower in L56Br-
C1 cells compared to MCF-10A and JIMT-1 cells. 
Interestingly, we found that Pd-Spm lowered the GSH pool to an undetectable level in 
MCF-10A, JIMT-1 and L56Br-C1 cell lines, but this was not reflected in a similar decrease in 
cell number. The cell number was still high in MCF-10A and JIMT-1 cells and only reduced 
by 60% in L56Br-C1 cells. Pd-Spm was presumably inactivated by binding to GSH, thus 
resulting in a reduced cytotoxicity. The toxicity of cisplatin has been shown to be reduced by 
GSH [296]. GSH-binding to cisplatin is responsible for metabolic drug inactivation, thereby 
decreasing its bioavailability at the pharmacological target and hence its antitumour activity 
[307]. In addition, cisplatin resistance has sometimes been correlated with a rise in the levels 
of cellular GSH [307]. Moreover, Pd(II), which is more labile than Pt(II), is also more prone 
to bind to sulphur atoms than Pt(II), according to the soft and hard acid base theory [308]. The 
fact that the cell number did not decrease after 48 h of treatment with Pd-Spm may imply a 
very efficient synthesis of GSH, maintaining at least a low pool, although not detectable, of 
GSH sufficient for cell proliferation and survival. However, this notion has to be further 
investigated. BENSPM, Pd-BENSpm, and CPENSpm lowered the GSH pools but not to the 
same extent as Pd-Spm, implying that these compounds were not inactivated by GSH to the 
same extent as was Pd-Spm (even if these treatments all reduced the cell number to a larger 
extent than Pd-Spm treatment). The difference in effects on the GSH levels between Pd-
BENSpm and Pd-Spm is very interesting since the compounds are structurally very similar. 
However, this may be due to the extra –CH2CH3 arm making the metal centre less available 
for nucleophilic attack and thus less susceptible to inactivation by GSH. Regarding the GSH 
lowering activity of Pd-Spm, it may be exploited in the search for anticancer redox 
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chemotherapeutics [307,309]. Treatment of MCF-10A and L56Br-C1 cells with Pt-
CPENSpm, on the other hand, gave an increase in the GSH level at the same time as cell 
proliferation was reduced by about 10%. In JIMT-1 cells, Pt-CPENSpm treatment resulted in 
a reduced GSH level. Thus, we can conclude that there is no clear correlation between 
decrease in GSH levels and reduction of cell number in any of the cell lines. 
Biogenic polyamines are essential for a variety of cellular processes, including cell 
growth [53,76]. Depletion of cellular polyamines may potentiate the effect of the cytotoxic 
agents and, eventually, result in growth arrest. Under physiological conditions, the 
polyamines are positively charged and bind strongly to negatively charged macromolecules, 
like DNA and RNA [53,76]. The binding of polyamines to DNA is believed to stabilise the 
DNA. Thus, interference with the cellular polyamine homeostasis may render the cells more 
sensitive to cytotoxic drugs that interact with DNA. Polyamine analogues have been shown to 
decrease cellular polyamine levels by inhibiting their biosynthesis as well as inducing their 
catabolism [101,295,310]. As shown in the present study, Pd-BENSpm, BENSpm and 
CPENSpm besides being highly cytotoxic, all induced SSAT, which catalyses the rate-
limiting step in polyamine degradation, to very high levels in L56Br-C1 cells. High SSAT 
induction by BENSpm treatment was also previously found in L56Br-C1 cells [293]. The 
increase in SSAT was reflected in a concomitant decrease in cellular polyamine content. 
Moreover, platination of CPENSpm not only decreased the cytotoxic effect of the drug on 
L56Br-C1 cells, but also eliminated its effects on cellular SSAT activity and polyamine 
levels. Although there seems to be a strong correlation between the cytotoxic effects and 
polyamine depletion, the underlying mechanism is not known. However, it is also believed 
that the production of H2O2 and acetaldehyde formed in the polyamine oxidase-catalysed 
oxidation of the products of the SSAT reaction may also contribute to a cytotoxicity effect 
[293,311]. GSH is an essential metabolite in the molecular mechanisms involved in the 
detoxification of H2O2. The lower GSH pool in L56Br-C1 cells may thus also contribute to an 
increased sensitivity to the presence of H2O2 produced in polyamine catabolism.  
It has recently been suggested that spermine oxidase, and not the acetylpolyamine 
oxidase as previously was thought, is the exclusive source of H2O2, at least in breast cancer 
cell lines treated with polyamine analogues [311]. It was shown that the H2O2 formed upon 
induction of polyamine catabolism in MDA-MB-231 cells treated with BENSpm was found 
to be solely derived from spermine oxidase [311].  
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Stem cell markers are often used to evaluate the aggressiveness and invasiveness of 
cancer. It has been found that individual tumours contain highly heterogeneous cell 
populations identified by cell surface markers and also by intracellular markers. The cell 
surface markers CD44 and CD24 are adhesion molecules and the CD44
+
CD24
- 
cells were 
suggested to be CSCs in a breast cancer model [44]. We have shown that treatment with the 
polyamine analogue PG-11047 reduced the putative CD44
+
CD24
-
 CSC population in JIMT-1 
cells and decreased their CFE [283]. BENSpm, which is a polyamine analogue closely related 
to PG-11047, also reduced the CSC population evaluated by FCM and the CSC reducing 
effect was retained to a similar degree by Pd-BENSpm treatment (no significant difference 
was obtained between BENSpm and Pd-BENSpm). Although the antiproliferative effect of 
CPENSpm treatment was very much similar to that of BENSpm and Pd-BENSpm treatments, 
there was no effect on the putative CD44
+
CD24
-
 CSC population. Interestingly, all three 
compounds resulted in similar a decrease in CFE. Thus the CFE was markedly reduced, 
whereas the putative CD44
+
CD24
-
 CSC population was not, after treatment with CPENSpm. 
Moreover, Pt-CPENSpm treatment resulted in an increased putative CD44
+
CD24
-
 CSC 
population, in spite of a decrease in the CFE, compared to control. Thus, the data support the 
notion that other factors than only CD44 positivity and CD24 negativity define CSCs [312]. 
Also, we did the CFE in the presence of FCS which may support colony formation not only 
by CSCs but also by other progenitor cells, although this has not clearly been shown for 
breast cancer.  
The Anthem’s Genotox screen was used to determine if any of the compounds tested 
could be classified as potential genotoxins in the range of the concentrations analysed. This 
screen is highly sensitive and specific, when compared with currently available in vitro 
genotoxicity assays. By using this mammalian screen, BENSpm and Pd-BENSpm were found 
to induce p21 and p53 at 5 µM and 10 µM concentrations. Interestingly, Pd-BENSpm induced 
p21 to a higher degree than BENSpm which may contribute to the slight higher toxicity of Pd-
BENSpm compared to BENSpm. 
A close statistical comparison (not shown) between BENSpm and Pd-BENSpm 
showed that the latter was indeed somewhat more cytotoxic than the former. The cell number 
was significantly lower in Pd-BENSpm-treated cultures after 48 and 72 h of treatment than in 
BENSpm-treated cultures in all breast cancer cell lines. Pd-BENSpm treatment reduced the 
CFE significantly more than BENSpm treatment did. Pd-BENSpm treatment resulted in 
significantly more comets in SCGE than did BENSpm treatment in the two cancer cell lines 
JIMT-1 and L56Br-C1 but not in MCF-10A cells. Pd-BENSpm treatment also reduced the 
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GSH level significantly more than BENSpm treatment did in the two cancer cell lines. Thus, 
although the difference between BENSpm and Pd-BENSpm is small, Pd-BENSpm showed 
slightly higher toxicity against cancer cells and thus may be of some importance for further 
design of new metal-based polyamine analogues. 
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“Science knows no country, because knowledge belongs to humanity, and is the torch 
which illuminates the world.” 
Louis Pasteur 
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5.  Conclusions  
Interference with polyamine homeostasis through administration of modified analogues, 
or the use of metal complexes with a view to affect cell growth via DNA covalent binding, are 
promising therapeutic approaches against cancer. In order to follow this type of strategies, a 
thorough knowledge of the conformational preferences of both modified polyamines and their 
chelates is crucial for understanding the mechanisms through which they are metabolised after 
being transported into the cell (pharmacokinetics) and the molecular basis of their interaction 
with the pharmacological target (pharmacodynamics). 
 The reported results show the successful syntheses and purification of Pd(II) and Pt(II) 
chelates with modified biogenic polyamines (tri- and tetramines), presently modified and 
improved relative to previously published methods. Additionally, the theoretical approach 
used to simulate these systems was suitable, as expected in the light of previous data 
published within this research group on cisplatin and cisplatin-like complexes 
[170,200,205,211]. 
 As expected, and similarly to previously reported studies on biogenic polyamines, the 
all-trans geometry was found to be energetically favoured for the physiological, totally 
protonated, states of all the alkylated linear amines presently investigated. The polynuclear 
chelates display a stable geometry identical to that previously obtained for their analogues 
with spermine (M2Spm) and spermidine (M3Spd2), comprising two or three cisplatin-like 
(MCl2(NH3)2) moieties, respectively. Therefore, when interacting with DNA (their main 
biological target), they are able to bind to the purine/pirimidine bases through two or three 
different sites simultaneously, upon hydrolysis of the chloride leaving groups, via long-range 
intra- and interstrand interactions. This type of non-conventional interplay with the target, not 
available to mononuclear drugs such as cisplatin or carboplatin, greatly enhances their 
cytotoxicity while decreasing the success of repairing mechanisms. 
 This kind of conformational studies – both for the target and the potential 
chemotherapeutic agents – is the basis for a rational development of new anticancer drugs, 
coupling a higher (and hopefully selective) cytotoxic activity to an optimised therapeutic 
efficacy, as well as to the capacity of overcoming resistance to clinically used agents. 
 Concomitant biological studies – cytotoxicity and cell growth inhibition evaluation – 
were also performed for both the modified polyamines and their Pt(II) and Pd(II) chelates in 
human breast cancer cell lines, aiming at linking structural preferences to anticancer effect. 
 Tânia M. Silva 
___________________________________________________________________________ 
 
154 
 
The studies performed on the cellular effects of the tested compounds are important 
for future attempts to improve cancer treatment and also to increase our understanding 
regarding the polyamines and their effects in the cell. The results obtained in these studies 
show that a variety of responses are induced after treatment with various polyamine analogues 
and their Pd(II) and Pt(II) complexes, in several human breast cancer cells. Different 
behaviours of the drugs were shown in the various cell lines, with L56Br-C1 being the most 
sensitive and MCF-10A the least sensitive one.  
The overall data demonstrated that the Pd-NSpd complex displayed stronger 
antiproliferative effects on the human breast cancer cell lines tested, as compared to Pt-NSpd. 
Similar findings were observed when comparing the cytotoxic effects of trinuclear Pd(II) 
chelates of spermidine and spermine to those of their Pt(II) analogues [156,170,191,192]. The 
reason for this cytotoxicity enhancement is likely to be related to a more efficient interaction 
with DNA, yielding interstrand long-range adducts less prone to repair, and hence a more 
severe damage. Furthermore, this seems to be a selective effect, since the cytotoxicity activity 
of the Pd(II) and Pt(II) polyamine complexes varied depending on the cell line 
[156,170,191,192]. In general, cancer cells seemed more sensitive to the compounds than the 
non-neoplastic ones [156,169,192]. Overall, NSpd and Pd-NSpd were shown to have strong 
antiproliferative effects. 
BENSpm, Pd-BENSpm and CPENSpm were found to have the strongest 
antineoplastic effect on the breast cancer cells tested. The growth inhibition induced by the 
compounds affected polyamine homeostasis considerably, which points to the importance of 
finding biomarkers for sensitivity and resistance in the treatment of breast cancer. It was also 
verified that some of the compounds were responsible for a damaging interaction with DNA, 
although the exact nature of this interplay remains to be identified. Nevertheless, the 
differences observed between the complexes may be related to differences in uptake, 
metabolism and/or reaching the target. In addition, it is known that a simple chemical 
modification in the structure of a compound may alter its binding profile to DNA and, 
consequently, its cytotoxic activity.  
In conclusion, of the compounds studied, Pd-BENSpm may be regarded as a 
promising inorganic agent to be used for the development of new chemotherapy approaches 
against breast cancer, due to its slightly higher cancer cell toxicity coupled to lower side effect 
toxicity. 
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 Figure 56: Schematic representation of the main conclusions resulting from this study. 
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Pd(II) complexes display a stronger antiproliferative effect than their Pt(II) counterparts;
Breast cancer cell lines were more sensitive to the compounds than the non-malignant
MCF-10A cells. L56Br-C1 was the most sensitive cell line;
Pd-BENSpm was the most efficient compound  promising inorganic agent against breast
cancer  slightly higher cancer cell toxicity coupled to lower side effect toxicity.
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Future Perspectives 
 Although many of the questions initially asked in this study were already answered, 
thus contributing to an improvement of knowledge within this research field, some others 
arose: 
 
 How are these compounds transported into the cells? 
 
 What cellular mechanisms are responsible for the cytotoxicity induced by the 
polyamine analogues and the Pd(II) complexes in the breast cells? 
 
In order to address these questions, future work can be envisaged: 
 
 Synthesis and conformational characterisation of new Pd(II) and Pt(II) complexes 
with other modified polyamines (such as BESpm), as well as of Pt(II)-BENSpm and 
Pd(II)-CPENSpm chelates (in order to do comparison with Pd-BENSpm and Pt-
CPENSpm); 
 
 Analysis of cell cycle regulatory protein levels; 
 
 Study of SMO and PAO activity in breast cancer cells treated with these 
compounds; 
 
 Cytotoxicity assessment of the compounds in cisplatin-resistant breast cancer cell 
lines; 
 
 Biodistribution studies (namely by microRaman spectroscopy); 
 
 Study of the actual binding to DNA using ICP-MS; 
 
 Pretreatment (chemosensitisation) with DFMO, prior to drug administration; 
 
 Analysis of the general toxicity in cell culture systems to evaluate side effects; 
 
 Combination therapeutic schemes, aiming at a possible synergetic effect.  
__ 
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“A man's friendships are one of the best measures of his worth.” 
Charles Darwin 
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Annexe I – Symbols 
Au gold 
Bi bismuth 
Cu cooper 
Fe iron 
Ga gallium 
Pt platinum 
Pd palladium 
Re rhenium 
Ru ruthenium 
  
h Planck constant 
k Force constant  
m Atomic mass  
ν Frequency 
 µ Reduced mass  
  
 In-plane Angular Deformation (symmetric – s – or antisymmetric – 
as or longitudinal – long 
r rocking 
sciss scissoring 
t twisting 
 Stretching (symmetric – νs – or antisymmetric – νas) 
 wagging 
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Annexe II – Abbreviations 
3-AAP 3-Acetamidopropanal 
A Adenine base 
AdoMet S-Adenosylmethionine 
AdoMetDC S-Adenosylmethionine decarboxylase 
APAO Acetylpolyamine oxidase 
Az Antizyme 
AzI Antizyme inhibitor 
BESpm N
1
,N
12
-bis(ethyl)spermine 
BENSpm N
1
,N
11
-bis(ethyl)norspermine 
BrdUrd Bromodeoxyuridine 
CCD Charge coupled device 
CDKs Cyclin dependent kinases 
CDKIs Cyclin dependent kinase inhibitors 
CD44
+
/CD24
-
 Cell surface feature present essentially in stem-like cells 
CFE Colony Forming Efficiency 
Cisplatin Cis-Diamminedichloroplatinum (II) 
CPENSpm N
1
-cyclo-propylmethyl-N
11
-ethylnorspermine 
CSC Cancer stem cell 
CTR Cooper transporter 
dcAdoMet decarboxylated S-Adenosylmethionine 
DFMO α-Difluoromethylornithine 
DFT Density Functional Theory 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
ECL Enhanced chemiluminiscence 
EDTA Ethylenediaminetetraacetic acid 
ER Estrogen receptor 
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EtBr Ethidium bromide 
FCM Flow Cytometry 
FCS Fetal calf serum 
FDA Food and Drug Administration 
FITC Fluorescein isothiocyanate 
FT Fourier Transform 
FTIR Fourier Transform Infrared spectroscopy 
FT-Raman Fourier Transform Raman spectroscopy 
G Guanine base 
G0 Gap zero phase 
G1 Gap 1 phase 
G2 Gap 2 phase 
GSH Glutathione 
3
H-spermidine Radioactive-labelled spermidine 
H2O2 Hydrogen peroxide 
HER2 Human epidermal growth factor receptor 2 
HMG High mobility group 
HPLC High-Performance Liquid Chromatography 
ICP-MS Inductively Coupled Plasma Mass Spectrometry 
IgG Immunoglobulin 
IR Infrared 
LAM Longitudinal acoustic mode 
 laser Light amplification by stimulated emission of radiation 
M  Mitosis phase 
MGBG Methylglyoxal bis(guanylhydrazone) 
MTT 3-(4,5-Dimethyl-thiazolyl-2)-2,5 diphenyltetrazolium bromide 
NSpd Norspermidine 
ODC Ornithine decarboxylase 
PBS Phosphate-buffered saline 
PBS-T Phosphate-buffered saline with 0.05% Tween 20 
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Pd-BENSpm (PdCl2)2-N
1
,N
11
-bis(ethyl)norspermine 
Pd-NSpd (PdCl2)3-(norspermidine)2 
Pd-Spm (PdCl2)2-spermine 
PE Phycoerythrin 
PI Propidium iodide 
polyHEMA Poly(2-hydroxyethyl methacrylate 
PR Progesterone receptor 
Pt-CPENSpm (PtCl2)2-N
1
-cyclopropyl-methyl-N
11
-ethylnorspermine 
Pt-NSPd (PtCl2)3-(norspermidine)2 
PTS Polyamine transport system 
QFM–UC Molecular Physical-Chemistry research group, University of Coimbra 
RNA Ribonucleic acid 
RNase A Ribonuclease A 
RPMI Roswell ParK Memorial Institute medium 
S Synthesis phase 
SAR Structure-activity relationship 
SCGE Single Cell Gel Electrophoresis 
SD Standard deviation 
SEM Standard error of the mean 
SMO Spermine oxidase 
Spm Spermine 
SSAT Spermidine/spermine N
1
-acetyltransferase 
TAM Transverse acoustic mode 
 TMOM Tail moment 
  
(s) solid 
(aq) aqueous 
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Annexe III – Figures Index 
Figure 1: Schematic representation of the six hallmarks of cancer. 
Figure 2: Structural representation of the biogenic polyamines putrescine, spermidine 
and spermine under physiological conditions. 
Figure 3: Schematic representation of the polyamine metabolic pathways. 
Figure 4: Structural representation of the polyamine biosynthetic inhibitor DFMO. 
Figure 5: Structural representation of the polyamine analogues BESpm, BENSpm, 
CPENSpm and NSpd under physiological conditions. 
Figure 6: Schematic representation of the cell cycle in eukaryotic cells. 
Figure 7: Schematic representation of cisplatin. 
Figure 8: Schematic representation of carboplatin and oxaliplatin. 
Figure 9: Schematic representation of satraplatin and picoplatin. 
Figure 10: Schematic representation of BBR3464 and TriplatinNC. 
Figure 11: Structural representation of the Pd(II) and Pt(II) complexes Pd-NSpd, Pt-
NSpd, Pd-BENSpm and Pt-CPENSpm. 
Figure 12: Electromagnetic radiation spectrum. 
Figure 13: Schematic representation of a diatomic molecule AB. 
Figure 14: Schematic representation of stretching (A) and deformation (B) vibrational 
modes in a molecule (A represent heavy atoms). 
Figure 15: Schematic representation of the vibrational/electronic transitions characteristic 
of IR absorption, Raman and Rayleigh scattering, and fluorescence. 
Figure 16: Schematic representation of the Rayleigh, Stokes and anti-Stokes lines 
(adapted from [230]). 
Figure 17: Schematic representation of a Michelson interferometer. 
Figure 18: Schematic representation of the aims of the study. 
Figure 19: Phase contrast image of JIMT-1 cells, after 48 h of seeding. 
Figure 20: Phase contrast image of L56Br-C1 cells, after 48 h of seeding. 
 Tânia M. Silva 
___________________________________________________________________________ 
 
194 
 
Figure 21: Phase contrast image of MCF-7 cells, after 48 h of seeding. 
Figure 22: Phase contrast image of MDA-MB-231 cells, after 48 h of seeding. 
Figure 23: Phase contrast image of MCF-10A cells, after 48 h of seeding. 
Figure 24: Molecular structure of 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium 
bromide (MTT). 
Figure 25: Schematic representation of the radioactivity-based uptake assay. 
Figure 26: Molecular structure of propidium iodide (PI). 
Figure 27: Molecular structure of bromodeoxyuridine (BrdUrd). 
Figure 28: Schematic representation of an inductively-coupled plasma mass spectrometer 
for detection of Pd(II) and Pt(II). 
Figure 29: Schematic representation of the single cell gel electrophoresis (SCGE) assay.  
Figure 30: Experimental FTIR (A) and Raman (B) spectra for BESpm. 
Figure 31: Experimental (solid line) and calculated (dotted line) Raman spectra for 
BENSpm and CPENSpm. 
Figure 32: Experimental FTIR (A) and Raman (B) spectra for NSpd (pure liquid). 
Figure 33: Experimental FTIR (A) and Raman (B) spectra for BENSpm and Pd-
BENSpm. 
Figure 34: Experimental FTIR (A) and Raman (B) spectra for CPENSpm and Pt-
CPENSpm. 
Figure 35: Experimental FTIR (A) and Raman (B) spectra for NSpd, Pd-NSpd and Pt-
NSpd. 
Figure 36: Dose response effect of NSpd, Pd-NSpd or Pt-NSpd treatment. 
Figure 37: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on the proliferation of JIMT-
1, L56Br-C1, MCF-7, MCF-10A and MDA-MB-231 cells. 
Figure 38: Phase contrast images of JIMT-1, L56Br-C1, MCF-7 and MCF-10A cells 
treated with NSpd, Pd-NSpd or Pt-NSpd. 
Figure 39: Effect of NSpd, Pd-NSpd or Pt-NSpd on the uptake of 
3
H-spermidine in JIMT-
1, L56Br-C1, MCF-7 and MCF-10A cells. 
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Figure 40: ODC activity in JIMT-1, L56Br-C1, MCF-7 and MCF-10A cells treated with 
NSpd, Pd-NSpd or Pt-NSpd. 
Figure 41: Sub-G1 region and cell cycle phase distribution of JIMT-1, L56Br-C1, MCF-7 
and MCF-10A cells treated with NSpd, Pd-NSpd or Pt-NSpd. 
Figure 42: Intracellular accumulation of Pd-NSpd and Pt-NSpd in L56Br-C1 and MCF-
10A cells. 
Figure 43: Genotoxic effect of NSpd, Pd-NSpd or Pt-NSpd in genetically engineered 
reporter-based HCT-p21-GADD-p53 cells. 
Figure 44: SCGE assay for the evaluation of DNA damage in L56Br-C1 cells. 
Figure 45: Effect of NSpd or Pd-NSpd treatment on the AzI protein levels in JIMT-1, 
MCF-10A and MCF-7 cells. 
Figure 46: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on the AzI protein levels in 
L56Br-C1 cells. 
Figure 47: Dose response effect of BENSpm, Pd-BENSpm, CPENSpm or Pt-CPENSpm 
treatment. 
Figure 48: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm 
treatment on the cell proliferation. 
Figure 49: Intracellular concentration of Pd-BENSpm, Pd-Spm and Pt-CPENSpm in 
MCF-10A, JIMT-1 and L56Br-C1 cells. 
Figure 50: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm 
treatment on the polyamine content in L56Br-C1 cells. 
Figure 51: SSAT activity in L56Br-C1cells treated with BENSpm, Pd-BENSpm, Pd-
Spm, CPENSpm or Pt-CPENSpm. 
Figure 52: Sub-G1 region and cell cycle phase distribution of MCF-10A, JIMT-1 and 
L56Br-C1 cells treated with BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or 
Pt-CPENSpm. 
Figure 53: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm 
treatment on the CD44
+
CD24
-
 putative cancer stem cell population in JIMT-1 
cells. 
Figure 54: Genotoxic effect of BENSpm or Pd-BENSpm in genetically engineered 
reporter-based HCT-p21-GADD-p53 cells. 
Figure 55: Evaluation of DNA damage in L56Br-C1 cells by the SCGE assay. 
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Figure 56: Schematic representation of  the main conclusions resulting from this study. 
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Annexe IV – Tables Index 
Table 1: Main characteristics of the metabolic enzymes ODC, AdoMetDC and SSAT. 
Table 2: Main features of the polyamine analogues BES, BENSpm, CPENSpm and 
NSpd. 
Table 3: Main advantages and disadvantages of IR spectroscopy. 
Table 4: Main advantages and disadvantages of Raman spectroscopy. 
Table 5: List of the reagents used along the study. 
Table 6: List of the equipment used along the study. 
Table 7: Elemental analysis results for the complexes Pd-NSpd, Pt-NSpd, Pd-BENSpm 
and Pt-CPENSpm. 
Table 8: Experimental (solid state) and calculated Raman and FTIR wavenumbers (cm
1
) 
for BESpm. 
Table 9: Experimental and calculated Raman and FTIR wavenumbers (cm
-1
) for NSpd, 
Pt-NSpd and Pd-NSpd. 
Table 10: Experimental (solid state) and calculated Raman and FTIR wavenumbers (cm
-1
) 
for BENSpm and Pd-BENSpm. 
Table 11: Experimental (solid state) and calculated Raman and FTIR wavenumbers (cm
-1
) 
for CPENSpm and Pt-CPENSpm. 
Table 12: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on the length of the S and 
G2+M phases
1
. 
Table 13: Effect of NSpd, Pd-NSpd or Pt-NSpd treatment on colony forming efficiency in 
soft agar
1
. 
Table 14: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm 
treatment on colony forming efficiency in soft agar
1
. 
Table 15: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm 
treatment on the number of comets in MCF-10A, JIMT-1 and L56Br-C1 cell 
lines, evaluated by the SCGE assay
1
. 
Table 16: Effect of BENSpm, Pd-BENSpm, Pd-Spm, CPENSpm or Pt-CPENSpm 
treatment on the levels of GSH in MCF-10A, JIMT-1 and L56Br-C1 cell lines, 
evaluated by the GSH-Glo
™
 Glutathione Assay
1
. 
  
 Tânia M. Silva 
___________________________________________________________________________ 
 
198 
 
 
 
